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ABSTRACT 
 
Brunel University, Uxbridge 
School of Health Sciences and Social Care 
England, U.K. 
 
Maria Loizidou 
 
Genetic epidemiology of breast cancer in Cyprus: A case-control study of DNA 
repair genes 
 
Ph.D., 2009 
 
The occurrence of early-onset breast cancer (EOBC) has been associated with 
germline mutations in the BRCA1 and BRCA2 genes. The first aim of this thesis was 
to evaluate the frequency and distribution of mutations in these genes, in a group of 
Cypriot women diagnosed with EOBC. Pathogenic mutations were identified in 6 of 
the 26 unrelated patients. This study supports a strong correlation between the early 
onset breast cancer phenotype and the presence of pathogenic BRCA1/2 mutations. It 
is of interest that pathogenic mutations were detected in patients without a family 
history of the disease. Based on these results, we recommend that BRCA1/2 
screening should be offered to patients with a diagnosis of EOBC irrespective of 
their family history.  
 
The known breast cancer susceptibility genes explain only about 5% of breast cancer 
cases. Thus, it is likely that other breast cancer susceptibility genes exist. The second 
aim of the present thesis was to assess whether alterations in DNA repair genes 
modify breast cancer risk in the Cypriot population. Towards this objective, blood 
samples were collected and genomic DNA isolated from 1109 Cypriot female breast 
cancer patients diagnosed between 40-70 years old, and from 1177 age-matched 
healthy female controls. A total of 79 single nucleotide polymorphisms (SNPs) were 
genotyped in all samples. Significant associations with breast cancer risk were 
observed for eight of the SNPs studied. Five SNPs in the BRCA2, MRE11A, MUS81, 
PBOV1 and XRCC1 genes, were associated with an increased risk for breast cancer, 
while two SNPs in the NBS1 gene and one SNP in the MRE11A gene appeared to be 
associated with reduced risk for the disease. The data from this study support the 
hypothesis that genetic variants in DNA repair genes influence breast cancer risk and 
provides further evidence for the existence of a polygenic model for breast cancer.  
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Summary 
The aims of this study/project were two fold: (a) to carry out a mutational analysis of 
the BRCA1 and BRCA2 genes in Cypriot women diagnosed with early onset breast 
cancer (before the age of 40), who are unselected for a family history of this disease, 
and (b) to examine the association between common single nucleotide 
polymorphisms (SNPs) in DNA repair genes and breast cancer risk, in the Cypriot 
population. 
 
The thesis is divided into three parts, which comprise five chapters in all as outlined 
below. Part I provides a literature review on breast cancer incidence, mortality and 
epidemiology as well as the high-penetrance breast cancer genes, BRCA1 and 
BRCA2 (Chapter 1). This is followed by background information on lower 
penetrance breast cancer susceptibility alleles, the methods that are used to identify 
them, as well as a review of DNA repair mechanisms and the role that genes 
involved in these mechanisms play in breast cancer susceptibility (Chapter 2).   
 
Part II describes the experimental work performed and the two principal studies 
involved in the project; these comprise Chapters 3 and 4. Chapter 3 presents the 
first study, in which the contribution of BRCA1 and BRCA2 germline mutations to 
the incidence of early-onset breast cancer in Cyprus was investigated. For this study, 
twenty-six consecutive incident female breast cancer cases diagnosed before the age 
of 40, between the years 2003 and 2004, were recruited. The entire coding regions, 
including splice sites, of the BRCA1 and BRCA2 genes were sequenced using cycle 
sequencing. Four pathogenic mutations: two in BRCA1 and two in the BRCA2 gene, 
which confer high risks of breast and ovarian cancer, were identified in six of the 
twenty-six unrelated patients investigated. The BRCA2 Cypriot founder mutation 
c.8755delG (8984delG) was detected in three unrelated patients. Of the six BRCA1/2 
mutation carriers, only four had a family history. This was the first study evaluating 
the frequency and distribution of mutations in these genes in Cypriot women with 
early onset breast cancer who are unselected for a family history of the disease. The 
results of this study show that the prevalence of BRCA1 and BRCA2 mutations in 
this group of women is high. Hence, Cypriot women with early-onset breast cancer 
should be offered BRCA1/2 genetic testing, irrespective of their family history. 
Future clinical management of these early onset breast cancer patients will depend 
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on the result of this genetic testing. Furthermore, genetic counselling can help 
women at risk to make informed decisions about possible prevention strategies they 
may wish to pursue.  
 
The primary aim of the second study described in Chapter 4, was to investigate the 
association between SNPs in DNA repair genes and breast cancer risk in the Cypriot 
population. Towards this effort, blood samples were collected and genomic DNA 
was isolated from 1109 Cypriot female breast cancer patients diagnosed between 40-
70 years old and 1177 age-matched healthy female controls. A total of 79 SNPs were 
genotyped using three methods: PCR followed by restriction fragment length 
polymorphism analysis, real-time PCR with Taqman SNP genotyping assays, and 
SNP genotyping using the Sequenom MassARRAY iPLEX Gold assays and matrix 
assisted laser desorption / ionization-Time-of-Flight mass spectrometry (MALDI-
TOF MS) for detection. Significant associations with breast cancer risk were 
observed for eight of the SNPs studied. Five SNPs in the BRCA2, MRE11A, MUS81, 
PBOV1 and XRCC1 genes were associated with an increased risk for breast cancer, 
while two SNPs in the NBS1 gene and a SNP in the MRE11A gene appeared to be 
associated with reduced risk for the disease. This study provides support for the 
hypothesis that genetic variants in DNA repair genes influence breast cancer risk and 
provides further evidence for the current hypothesis that favours a polygenic model 
of breast cancer.  
 
In Part III, the results of the two studies are discussed (Chapter 5). In addition, 
directions for future research are presented, including the elucidation of the 
functional impact of the breast cancer associated SNPs, the expansion of the SNP 
study as well as the initiation of a genome-wide association study in the Cypriot 
population. 
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1.1 Breast Cancer 
Breast cancer is a major public health burden throughout the world. It is by far the 
most common type of cancer in women, comprising 23% of all female cancers. In 
year 2002, there were an estimated 1.15 million new cases of breast cancer and 
411,000 deaths resulting from this disease (Parkin et al., 2005). Despite the common 
occurrence, the exact aetiology of breast cancer is still unknown. It is believed that 
breast cancer is a multifactorial disease and it is a result of the interaction of genetic 
and environmental factors (Ponder, 2001). Over the past decade, significant progress 
has been made in defining risk factors determining susceptibility of individuals to 
developing breast cancer as well as the genetic factors that contribute to this risk. 
Despite this improved knowledge, the unravelling of the complex genetic and 
environmental influences on this disease is still at an early stage. An even better 
understanding of the genetic mechanisms underlying the development and 
progression of breast cancer would be a major advance for improved prevention, 
detection and treatment strategies.  
 
1.2 Incidence and mortality 
According to the latest cancer incidence and mortality estimates of the International 
Agency for Research on Cancer (IARC), available in the GLOBOCAN series, breast 
cancer is the second most frequent cancer in the world with 1.15 million cases in 
2002, and the most common malignancy in women, accounting for 23% of all new 
cases (Parkin et al., 2005).  
 
As described by Parkin (2004), incidence rates of breast cancer vary between 
different parts of the world with a significant difference observed between the low-
risk areas, which include the Far East and Africa, and the high-risk areas, mainly 
North America and Western Europe (Figure 1). The highest age-standardized 
incidence rates are in North America with 99.4 per 100,000 and the lowest are in 
Central Africa with 16.5 per 100,000. Together, the USA and Europe roughly 
account for 16% of the worldwide population and 60% of the worldwide incidence 
of breast cancer. Incidence rates of breast cancer are increasing in most countries, 
and the changes are usually greater where rates were previously low. Overall, there 
is an annual worldwide increase of breast cancer incidence rates of about 0.5%. 
However, cancer registries in Eastern Asia are recording annual increases in 
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incidence of up to 3% (China). Assuming a 3% growth in East Asia, there would be 
around 1.5 million new breast cancer cases in 2010 (Parkin, 2004; Parkin et al., 
2005). 
   
Breast cancer death rates have been decreasing steadily because of earlier detection 
and more effective treatments. Worldwide figures show that the ratio of mortality to 
incidence is about 0.35 and despite breast cancer being the second most common 
cancer overall, it ranks fifth as a cause of death (Parkin et al., 2005).  
 
In Cyprus, breast cancer is the most frequent type of cancer in women, with 
approximately 400 new cases diagnosed every year; about 20–30 of these occur in 
patients younger than 40 years of age (Bank of Cyprus Oncology Centre Database). 
Based on the Middle East Cancer Consortium (MECC) Monograph (Freedman et al. 
2006), the age standardized incidence rate for the years 1998-2001 was 57.7 per 
100,000. Although breast cancer incidence rates are increasing annually, mortality 
rates are stable, representing an improved survival rate. This improvement can be 
attributed to effective means of early detection, mainly mammography, as well as to 
significant improvement in treatment options with the availability of efficient 
hormonal and chemotherapeutic adjuvant and neoadjuvant therapy along with 
radiotherapy.  
 
Figure 1: Incidence of female breast cancer worldwide (per 100,000; all ages) 
(Taken from Parkin, 2004) 
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1.3 Breast morphology  
Breast development begins about 7-8 weeks after conception and at the later stages 
of gestation the nipples, areola and ducts are formed. Complete morphologic 
maturation of the breast tissue only occurs following pregnancy.  
 
In brief, as illustrated in Figure 2, the mammary gland consists of around twenty 
lobes, each of which has a branching duct system ending in terminal ducts. At the 
beginning of menarche, and with the influence of estrogen and progesterone, lobules 
are formed which replace pre-existing terminal ducts. Lobules are clusters of 
epithelial cells which radiate from the nipple and terminate in dozens of tiny bulbs 
that can produce milk (alveoli). They are bound together by fairly dense connective 
tissue septa. As a result of the replacement of terminal ducts by lobules, there is an 
increase in the volume and elasticity of the connective tissue as well as in the 
vascularity. The contour of the breast is filled out by fat tissue (Boron and Boulpaep, 
2003).  
Figure 2: Architecture of the human breast  
A. Schematic representation of the branching duct-to-lobule structure of the breast 
during lactation. B. Each breast lobule contains the alveoli, where the milk-secreting 
cells are located. C. The epidermal cells lining the alveoli secrete milk. Taken from 
(Boron and Boulpaep, 2003) 
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1.4 Breast carcinoma  
Breast carcinoma is a neoplastic condition that affects the breast tissue. In the past, it 
was believed that breast cancer is a result of a well-defined sequence of histological 
changes in the mammary epithelium. It was suggested that breast carcinogenesis is a 
multi-step process which starts with hyperplasia, progressing through atypical 
hyperplasia to in situ carcinoma and finally to invasive malignant carcinoma 
(Vogelstein and Kinzler 1998). The advancement of molecular biology and genetics 
has led to an abundance of data in relation to breast carcinogenesis. As a result of the 
new knowledge generated, it is nowadays believed that breast cancer is a complex, 
multi-factorial, polygenic and multi-step process (Beckmann et al., 1997; Ponder, 
2001; Antoniou and Easton, 2003). 
 
The most common breast cancers have an epithelial origin and are divided into two 
main categories: in situ carcinomas and invasive carcinomas, which account for 13-
30% and 70-85% of all cases respectively (Tavassoli and Devilee, 2003; Kumar et 
al., 2005). The majority of in situ (non-invasive) breast carcinomas are ductal 
carcinomas in situ (DCIS). The number of DCIS cases has increased significantly in 
the past two decades, because of the application of mammographic screening. It is 
noted that almost half of the mammographically detected cancers are DCIS. Invasive 
carcinomas are the most common breast carcinomas. The majority of invasive 
carcinomas (79%) are ductal carcinomas (Tavassoli and Devilee, 2003; Kumar et al., 
2005). 
   
1.5 Epidemiology and risk factors 
The epidemiology of breast cancer has been more extensively studied, than any other 
human disease. To date, several risk factors have been identified and table 1 
summarizes factors that increase breast cancer risk, as well as protective factors. 
 
Breast cancer incidence correlates with ethnic origin and shows age specific patterns. 
A substantial variation in breast cancer incidence and mortality is observed between 
different countries, with the difference between the Far East and Western countries 
being fivefold. Studies on breast cancer rates of immigrants, moving from low to 
high-risk countries, have shown that women assume the rate of their host countries 
within one or two generations, indicating that environmental factors are of greater 
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importance than genetic factors (McPherson et al., 2000). Breast cancer incidence 
increases with age and doubles almost every ten years until menopause, when the 
rate of increase slows dramatically, suggesting an important role of reproductive 
hormones in breast cancer aetiology (Collaborative Group on Hormonal Factors in 
Breast Cancer, 1996).    
 
One of the most established risk factors for breast cancer is lifetime exposure to 
hormones, both endogenous hormones that are related to menstrual cycle, as well as 
exogenous hormones which are derived from contraceptives, hormone replacement 
therapy (HRT) and diet (Dumitrescu and Cotarla, 2005). The hormone(s) that are 
responsible for breast cancer initiation remain unidentified as yet, but it is believed 
that estrogen plays a major role in modifying breast cancer risk. Two mechanisms 
have been proposed which correlate estrogens with breast carcinogenesis. The first 
mechanism suggests that estrogen metabolites, and in particular, the hydroxylated 
(catechol) estrogens, are genotoxic through induction of oxidative DNA damage, 
and long periods of exposure increase breast cancer risk (Cavalieri et al., 2000).  The 
second mechanism is the receptor-mediated hormonal activity, which is generally 
related to stimulation of cellular proliferation, resulting in more opportunities for 
accumulation of genetic damage leading to carcinogenesis (Russo et al., 2000).  
 
Women with early age at menarche or late menopause have an increased risk of 
developing breast cancer. A woman who began menstruating when she was younger 
than 12 years old has a 10-20% increased risk of breast cancer compared to one 
whose menstruation started when she was older than 14 years of age (Berkey et al., 
1999; Kelsey and Horn-Ross, 1993). In addition, women who experience a delayed 
natural menopause (after the age of 55) are twice as likely to develop breast cancer 
compared to women who experience menopause before the age of 45 (McPherson et 
al., 2000). The protective effect of menopause is also seen in women who undergo 
bilateral prophylactic oophorectomy (McPherson et al., 2000). There is a link 
between usage of exogenous hormones such as HRT and oral contraceptives and 
breast cancer. Women who take HRT, mainly estrogen combined with progestin, are 
more likely to develop breast cancer after four to five years of therapy compared to 
women who never used HRT (Rossouw et al., 2002). Some studies have shown an 
increased risk of breast cancer in women taking oral contraceptives. A small increase 
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in the relative risk of breast cancer has been reported among women taking oral 
contraceptives and for a period of 10 years after stopping them. However, after this 
period of 10 years, a woman’s risk of developing breast cancer returns to the same 
level as if she had never used oral contraceptives. Since most women take birth 
control at a young age, when breast cancer is rare, the increase in risk is thought to 
have little effect on overall incidence rates (Collaborative Group on Hormonal 
Factors in Breast Cancer, 1996).  
 
Pregnancy seems to have a dual effect on breast cancer risk. On the one hand, breast 
cancer risk is temporarily increased for a few years after a woman gives birth and on 
the other hand, this excess risk is reduced gradually and in the longer term, the effect 
of a birth is protective against the disease (Beral and Reeves, 1993). Furthermore, an 
early age of full-term pregnancy is protective for breast cancer, irrespective of the 
total number of pregnancies. In more detail, the younger a woman is when she has 
her first child, the lower her risk of developing breast cancer during her lifetime. A 
woman who gives birth to her first child after the age of 30, has approximately twice 
the risk of developing breast cancer, compared to a woman who has a child before 
the age of 20 (McPherson et al., 2000). Research also suggests that protection 
against breast cancer increases with the number of full term pregnancies; women 
with five or more children have about half the risk of nulliparous women (Ewertz et 
al., 1990; Layde et al., 1989). After pregnancy, breastfeeding for a long period of 
time (a year or longer) further reduces breast cancer risk by a small amount 
(Collaborative Group on Hormonal Factors in Breast Cancer, 2002).  
 
Breast density has also been related to breast cancer risk. Studies have shown that 
increased breast cancer density is associated with increased breast cancer risk in both 
premenopausal and postmenopausal women. Women with more than 75% increased 
breast density on mammography have an approximately five times increased risk of 
developing breast carcinoma compared to women with less than 5% increased breast 
density (Byrne et al., 1995; Boyd et al., 1995). In addition, there is evidence that 
nulliparity and high breast density act synergistically and breast cancer risk increases 
to sevenfold, in women who have never had a child and have dense breasts (van Gils 
et al., 2000). Studies have also indicated that there is a relationship between the 
presence of benign breast disease and breast cancer risk. Women diagnosed with 
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atypical hyperplasia, have a fourfold to fivefold increase in breast cancer risk. 
(McPherson et al., 2000).     
 
Obesity is another known risk factor for breast cancer. Obese women have an 
increased risk for postmenopausal but not premenopausal breast cancer. The 
association between obesity and breast cancer risk has been proposed to be largely 
due to increased estrogenic activity in overweight women. Increased body weight 
results in elevated circulating estrogens from peripheral aromatization of androgens 
in adipose tissue. Breasts, which are estrogen-sensitive tissues, are therefore exposed 
to more estrogen stimulation in obese women, leading to an increased risk for breast 
cancer. A second possible mechanism is that obesity, which is associated with 
metabolic syndrome, increases the levels of circulating insulin and insulin like 
growth factor (IGF–1) (Lorincz and Sukumar, 2006). Insulin and IGF1 have been 
implicated in breast tumorigenesis because of their ability to stimulate mitogenesis, 
and their key role in mammary gland cell proliferation and survival (Imagawa et al., 
2002; Deming et al., 2007).  
 
It has also been demonstrated that moderate physical activity in adolescence and 
young adulthood reduces the risk of breast cancer. This may be due to the fact that 
exercise can delay the age of menarche and modify the bio-available hormone levels 
(Monninkhof et al., 2007).  
 
Numerous epidemiological studies investigated the relationship between lifestyle 
factors such as diet, alcohol consumption and smoking and breast cancer risk. Data 
regarding the role of soy remains conflicting. A recent meta-analysis suggests that 
soy food intake in the amount consumed in Asian populations may have protective 
effects against breast cancer (Wu et al., 2008).  In addition, high fat diet seems to be 
weakly associated with breast cancer risk, whereas a diet rich in fruit and vegetables, 
that are good sources of natural antioxidants, seems to protect women from breast 
cancer (DeBruin and Josephy, 2002; Gerber et al., 2003).   
 
Contradictory results have been reported regarding cigarette smoking and breast 
cancer risk. Most studies found no or little association, between smoking and breast 
cancer risk (Terry and Rohan, 2002). However, more recent studies suggest that 
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smoking at young ages and particularly during the period between menarche and 
first childbirth may increase breast cancer risk. This sensitivity of the female breast 
to tobacco carcinogens decreases after the first childbirth when the breast tissue is 
terminally differentiated (Ha et al., 2007). The results of most studies indicate that 
there is a link between regular alcohol consumption and breast cancer risk 
(Singletary and Gapstur, 2001).  
 
Radiation exposure is another well-established risk factor for breast cancer. The best 
evidence that associates radiation with increased breast cancer risk comes from 
survivors of atomic bomb explosions in Japan, who have been shown to have a 
significant increase in the incidence of breast cancer compared to unexposed persons 
(Land et al., 2003). Furthermore, a significant increased risk for breast cancer is seen 
in patients with Hodgkin’s disease who have been treated with radiation therapy 
(Travis et al., 2003).  
 
Family history of breast cancer is one of the most important and well-established 
risk factors for breast cancer. The first reports documenting family history of breast 
cancer were written by two French surgeons, Le Dran in 1757 and Broca in 1866 
(Collaborative Group on Hormonal Factors in Breast Cancer, 2001; Eisinger et al., 
1998). Since then, many studies have addressed this issue and concluded that a 
woman’s risk is approximately doubled if she has a first-degree relative with breast 
cancer. The risk is elevated significantly by increasing number of affected relatives 
and is greater in women with relatives affected at a young age (Collaborative Group 
on Hormonal Factors in Breast Cancer, 2001; Thompson and Easton, 2004).   
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Table 1: Summary table of factors that influence breast cancer risk (modified from 
Dumitrescu and Cotarla 2005)  
FACTORS THAT MODIFY BREAST CANCER RISK MAGNITUDE OF RISK 
 
Factors that increase breast cancer risk 
Increasing age ++ 
Geographical region (USA & Western countries) ++ 
Family history of breast cancer ++ 
Mutations in BRCA1 and BRCA2 genes ++ 
Mutations in other high-penetrance genes  ++ 
Ionizing radiation exposure (in childhood) ++ 
History of benign breast disease ++ 
Late age of menopause (>54) ++ 
Early age of menarche (<12) ++ 
Nulliparity and older age at first birth ++ 
High mammographic breast density ++ 
Hormonal replacement therapy + 
Oral contraceptives recent use + 
Obesity in postmenopausal women + 
Tall stature + 
Alcohol consumption (~1 drink/day) + 
High insulin-like growth factor (IGF-I) levels ++ 
Well-confirmed 
factors 
High prolactin levels  + 
   
High-saturated fat and well-done meat intake + 
Polymorphisms in low-penetrance genes + Probable factors High socioeconomic status + 
   
Factors that decrease breast cancer risk 
Geographical region (Asia and Africa) -- 
Early age of full-term pregnancy -- 
Higher parity -- 
Breast feeding (longer duration) -- 
Obesity in premenopausal women  - 
Fruit and vegetables consumption - 
Physical activity - 
Well-confirmed 
factors 
Chemopreventive agents - 
   
Non-steroidal anti-inflammatory drugs - Probable 
factors Polymorphisms in low-penetrance genes - 
 
++ (moderate to high increase in risk) - odds ratios/relative risk: 1.5 - >3.0 (1.5 to greater than 3 times 
risk of disease) 
+  (low to moderate increase in risk) - odds ratios/relative risk: 1.1 - <1.5 (10% to 1.5 times greater 
risk of disease) 
-- (moderate to high decrease in risk) - odds ratios/relative risk: <0.4 (greater than 60% reduced risk 
of disease) 
-  (low to moderate decrease in risk) - odds ratios/relative risk: 0.4 - <0.9 (10% to 60% reduced risk 
of disease) 
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1.6 Inherited predisposition to cancer 
It is well established that most genetic alterations leading to cancer are somatic. 
However, a number of cancers (around 5-10%) are due to inherited cancer 
predisposition syndromes and arise from inherited germline mutations in a cancer-
susceptibility gene (Garber and Offit, 2005). Inherited cancer predisposition 
syndromes are characterized by multiple affected family members usually at an early 
age of cancer onset, multiple primary cancers and for some rare syndromes, 
congenital abnormalities (Fearon, 1997). To date, over 200 hereditary cancer 
susceptibility syndromes have been described, the majority of which are inherited in 
an autosomal dominant manner (Nagy et al., 2004). The lifetime risk of cancer for 
individuals carrying a mutation in a cancer predisposition gene is high and ranges 
between 50% and 80% (Ponder, 2001). The likelihood of developing cancer depends 
on the actual gene and the mutant allele as well as on other modifying risk factors, 
both genetic and non-genetic. Furthermore, it also depends on the complex gene-
environment interactions which are currently under intense investigation, but at the 
moment remain poorly understood (Ponder, 2001).   
 
Recently, a number of genome-wide association studies (GWAS) have identified 
common SNP-based variants conferring low to moderate risk for cancer. These 
findings have brought us a step closer to a polygenic model for cancer. However, 
these small effects of multiple genes only explain a small proportion of the observed 
familial clustering for cancer and an extended analysis with a more complete range 
of potential susceptibility variants is needed (McCarthy et al., 2008).   
 
1.7 Inherited predisposition to breast carcinoma 
Family history of breast cancer constitutes one of the most important risk factors for 
the disease. The Ancient Romans were the first who observed the presence of 
familial clustering of breast cancer (Steel et al., 1991) but, as already mentioned, it 
was not until the late 18th and mid 19th century, that the first formal reports were 
produced by two French surgeons, Le Dran and Broca, who noted an association 
between family history of breast cancer and disease (Collaborative Group on 
Hormonal Factors in Breast Cancer, 2001; Eisinger et al., 1998).  
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In the years that followed, epidemiological studies provided strong evidence that 
women who have breast cancer patients as first-degree relatives, have an elevated 
risk for the disease. This observation led to the suggestion, that there are genetic 
factors which are associated with breast cancer. In addition to epidemiological 
evidence, the existence of families prone to breast cancer that displayed multiple 
affected members with an early age of onset, stood as proof of the existence of 
genetic susceptibility to the disease (Thompson and Easton, 2004).   
 
The first evidence in favour of the existence of an autosomal dominant breast cancer 
susceptibility gene came in 1984, from a segregation analysis study of families with 
multiple cases of breast cancer (Williams and Anderson, 1984).  Two additional 
studies which followed a few years later provided further support for this (Claus et 
al., 1991; Newman et al., 1988).  
 
In 1990, Mary-Claire King and her group studied a large group of multiple-case 
early-onset families and by linkage analysis assigned, a chromosomal region (17q21) 
which appeared to be the locale of a gene responsible, for inherited susceptibility to 
breast cancer in families (Hall et al., 1990).  Three years later, the first breast-ovarian 
cancer-susceptibility gene BRCA1 (breast cancer 1) was identified by positional 
cloning (Miki et al., 1994). During the same year, the second breast cancer-
susceptibility locus, BRCA2 (breast cancer 2), was localized to chromosome 13q12–
q13 by linkage studies of families with multiple cases of early-onset breast cancer 
that were not linked to BRCA1 (Wooster et al., 1994). The BRCA2 gene was cloned 
in 1995 (Wooster et al., 1995) and its complete coding sequence and exonic structure 
were described in 1996 (Tavtigian et al., 1996).  
 
BRCA1 and BRCA2 are the most important breast cancer susceptibility genes in the 
context of large multiple case families, segregating both early onset breast cancer 
cases and ovarian cancer cases. It is estimated that mutations in these genes explain 
approximately 40% of familial breast cancer and account for 5% to 20% of the total 
breast and ovarian cancers respectively (Chen et al., 2006). Other more conservative 
estimates indicate that mutations in the high-risk breast cancer genes explain around 
20-25% of the overall excess familial risk and less than 5% of total breast cancer 
incidence (Oldenburg et al., 2007).  
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There are also a number of other inherited cancer predisposition syndromes which 
include breast cancer in their clinical presentation. These are Li-Fraumeni syndrome 
[TP53 (tumor protein p53) mutations], Cowden disease [PTEN (phosphatase and 
tensin homolog) mutations], Peutz-Jeghers syndrome [STK11/LKB1 
(serine/threonine kinase 11) mutations] and hereditary diffuse gastric cancer 
syndrome [CDH1 (cadherin 1) mutations]. Overall, hereditary breast cancer accounts 
for 5-10% of all cases but less than 25% of hereditary cases can be explained by 
germline mutations in the currently identified breast cancer susceptibility genes 
(Bradbury and Olopade, 2007; Stratton and Rahman, 2008).  
 
Recently, genome-wide linkage analyses were carried out using a large number of 
families with multiple cases of breast cancer which were not carrying mutations in 
the BRCA1 or BRCA2 genes. This approach has not mapped any additional breast 
cancer susceptibility loci (Smith et al., 2006). However, this does not entirely 
exclude the possibility of the existence of additional high-penetrance breast cancer 
susceptibility genes but it strongly suggests that if they exist, they account for only a 
small proportion of the excess familial risk (Stratton and Rahman, 2008).  
 
1.8 BRCA1 and BRCA2 genes 
1.8.1 BRCA1 and BRCA2 penetrance 
Germline mutations in the two breast cancer susceptibility genes confer strong 
lifetime risks of breast and ovarian cancer. BRCA1 germline mutations also confer 
increased risks of pancreatic and perhaps uterine and cervical cancer (Thompson and 
Easton, 2002b) and BRCA2 mutations may also predispose to prostate, pancreatic 
cancer and perhaps gallbladder, bile duct cancer and melanoma (Breast Cancer 
Linkage Consortium, 1999; van Asperen et al., 2005). 
 
BRCA1 mutations are strongly associated with families with ovarian cancer whereas 
BRCA2 mutations are strongly associated with families with male breast cancer 
cases. The calculated breast cancer risks for individuals’ harbouring a 
BRCA1/BRCA2 mutation depends on the method of ascertainment of the families 
studied. In high-risk families with multiple cases of breast and/or ovarian cancer, the 
cumulative risk of breast cancer at age 70 years was 85% for BRCA1 and 84% for 
BRCA2 mutation carriers. Furthermore, BRCA1 and BRCA2 mutations were 
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estimated to cause a cumulative lifetime risk of ovarian cancer at age 70 years of 
63% and 27% respectively. (Ford et al., 1998). However, the average estimates of 
breast cancer risks at age 70 of a more recent meta-analysis of 22 population-based 
and hospital-based studies between BRCA1 and BRCA2 mutation carriers were 65% 
and 45% respectively. In addition, the average cumulative risks for ovarian cancer 
by age 70 years were 39% for BRCA1 mutation carriers and 11% for BRCA2 
mutation carriers (Antoniou et al., 2003). Another observation made in studies 
focusing on BRCA1 mutation carriers, was that their relative risks for breast cancer 
declined significantly with age (Antoniou et al., 2003; Chen et al., 2006). The same 
trend was observed for BRCA2 mutation carriers by Chen et al. (2006) but not by 
Antoniou et al. (2003). 
 
From the above, it is quite evident that there is controversy regarding the penetrance 
of BRCA1 and BRCA2 mutations. Ever since the identification of the two genes 
more than a decade ago, the estimation of cancer risks in individuals who test 
positive for a mutation is still an area of intense research. Mutations in BRCA1 and 
BRCA2 genes are rare and therefore penetrance estimates from individual studies 
often lack precision. It should be noted that penetrance estimates are based on 
multiple-case families and vary between countries because of the influence of non-
genetic factors. Nevertheless, it is widely accepted that the lifetime breast cancer risk 
for BRCA1 mutation carriers ranges between 46% and 85% and for BRCA2 mutation 
carriers between 43% and 84%, depending on the population studied (Oldenburg et 
al., 2007).  
 
As interest in genetic testing increases and more women become aware that they are 
BRCA1/BRCA2 mutation carriers, the penetrance of these genes will decline because 
of preventive measures that will be undertaken such as prophylactic mastectomies 
and oophorectomies (Narod and Foulkes, 2004). Furthermore, it should be noted that 
risk estimates for BRCA1 and BRCA2 mutation carriers do not take into account the 
modifying effects of other genes on risk. One example is the presence of a SNP in 
the 5' untranslated region of RAD51 [RAD51 homolog (RecA homolog, E. coli) (S. 
cerevisiae] gene, 135G>C, which was proven that to modify breast cancer risk in 
BRCA2 mutation carriers by altering the expression of RAD51 (Antoniou et al., 
2007). Microarray studies in irradiated lymphoblastoid cell lines from breast cancer 
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patients have identified potential BRCA1/2 modifier genes which should be further 
investigated in the future (Walker et al., 2008).   
 
Cancer risks are also modified depending on the position of the mutation in the gene 
sequence. Carriers of a mutation within the central region of BRCA1 were found to 
have a lower breast cancer risk compared to carriers of mutations elsewhere in the 
gene. Furthermore, for BRCA2 mutations it was found that women with mutations in 
the central region of the gene (ovarian cancer cluster region), had a lower breast 
cancer risk than women with mutations outside this region (Thompson and Easton, 
2001; Thompson et al., 2002).  
 
1.8.2 BRCA1 and BRCA2 structure and expression 
The BRCA1 and BRCA2 genes do not share any obvious sequence homology but 
have common features. Both genes have an extremely large exon 11 which 
comprises 61% and 48% of the whole coding sequence of BRCA1 and BRCA2 
respectively. Furthermore, both genes have translational start sites at exon 2 and in 
humans, the highest levels of expression are observed in testis, thymus and ovaries 
(Miki et al., 1994; Tavtigian et al., 1996). BRCA1 and BRCA2 genes are relatively 
poorly conserved between species with the exception of a few small domains.  
 
1.8.2.1 BRCA1 structure 
The BRCA1 gene is located on chromosome 17q21 and spans approximately 100 kb 
of genomic DNA (Figure 3). It consists of 24 exons of which 22 are encoding a 1863 
amino acid protein. BRCA1 exon 1 is non-coding, and the region originally 
identified as exon 4 is an Alu repeat not generally included in the transcript (Miki et 
al., 1994; Smith et al., 1996). 
 
 
 
 
 
 
 
 
 31
  
 
 
 
 
 
 
 
 
Figure 3: Genomic structure of the BRCA1 gene which spans around 100 kb of 
genomic sequence and consists of 24 exons. Modified from Hakansson et al. 1997 
and  Genetics Home Reference website (http://ghr.nlm.nih.gov) 
 
1.8.2.1.1 BRCA1 protein 
BRCA1 is a 220 kDa protein which shows a predominantly nuclear localization and 
forms nuclear “dots,” or foci, during S phase of the cell cycle and following DNA 
damage (Chen et al., 1995; Scully et al., 1996; Scully et al., 1997). The BRCA1 
protein contains important functional domains that interact with a range of proteins. 
In summary, BRCA1 contains a zinc-binding RING finger motif in its amino 
terminal region (Miki et al., 1994), 2 nuclear export signals near its N terminus 
(Rodriguez and Henderson, 2000; Thompson et al., 2005), 2 nuclear localization 
signals (NLS) (Chen et al., 1996), a DNA binding domain in the central region of the 
protein (Paull et al., 2001), an SQ-cluster domain (SCD) between amino acids 1280 
and 1524 (Cortez et al., 1999) and two carboxy-terminal BRCT domains (Bork et al., 
1997; Callebaut and Mornon, 1997; Koonin et al., 1996) (Figure 4).  
 
The N-terminal RING domain is a zinc-binding domain that encompasses the first 
109 amino acids of the BRCA1 protein. The BRCA1 RING domain exhibits an 
ubiquitin ligase activity. It interacts with the BRCA1-associated RING domain 
protein (BARD1) which is required for ubiquitin-ligase activity (Brzovic et al., 
2001). Studies using BRCA1 and BARD1 mutant cell lines and knockout mice have 
shown that these two proteins have a shared functional role in vivo (Deng, 2002; 
McCarthy et al., 2003; Shen et al., 1998b). Indeed, the BRCA1 RING domain does 
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not bind directly to DNA; it forms an interaction surface which facilitates the 
formation of a heterodimer with the BARD1 RING domain (Brzovic et al., 2001).  
This interaction surface is targeted for mutations in the BRCA1 gene. Mutations in 
the BRCA1 RING domain predispose to cancer because they inactivate BRCA1 
ubiquitin ligase activity by reducing or abolishing heterodimerization in vivo 
(Ruffner et al., 2001). Studies have shown that the stability of the BRCA1 and 
BARD1 proteins is depended upon their heterodimerization in vivo (Brzovic et al., 
2003; Joukov et al., 2001). Overall, the formation of the BRCA1/BARD1 
heterodimer, along with the structural integrity of the BRCA1 RING domain, are of 
critical importance for the tumour-suppressor function of BRCA1. The RING finger 
of BRCA1 also interacts with BAP1 (BRCA1-associated protein 1) and has a role in 
BRCA1 homodimer formation (Brzovic et al., 1998; Jensen et al., 1998).  
  
BRCA1 contains two nuclear localization signals, a nuclear import and a nuclear 
export signal. This suggests that BRCA1 protein has the ability to shuttle between the 
nucleus and the cytoplasm and may have implications for the regulation and function 
of this tumour suppressor (Rodriguez and Henderson, 2000).  
 
The DNA binding domain of BRCA1 comprises amino acids 452-1079 and 
contributes to the DNA-repair-related  functions of the protein. A large number of 
DNA repair proteins including those making up the BRCA1-Associated Genome 
Surveillance Complex (BASC) bind to this region (Wang et al., 2000). This region 
also contains interaction sites for RAD51 (Scully et al., 1997), an important 
component of DNA repair by homologous recombination.  
 
The 244 amino acids between 1280 and 1524 contain 10 SQ/TQ sites [clusters of 
serines (S) and threonines (T) followed by glutamine (Q)] and comprise the BRCA1 
SCD domain. SQ or TQ sequences are the preferred sites of ATM phosphorylation. 
In response to DNA damage, BRCA1 is phosphorylated at multiple serine residues 
within the SCD domain by ATM (Cortez et al., 1999). 
 
The BRCT domain of the BRCA1 protein consists of two individual repeats, the N-
terminal BRCT and the C-terminal BRCT. The two motifs are about 110 residues 
long, are similar in structure and are packed together in a head-to-tail arrangement 
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(Williams et al., 2001). BRCA1 interacts with many proteins through its BRCT 
domain including CtIP (carboxy-terminal-binding-protein-interacting protein), BRIP 
(BRCA1-interacting protein), p300, RNA polymerase II, TP53 and RB 
(retinoblastoma). It is believed that this part of the protein functions as a 
multipurpose protein-protein interaction module (Cantor et al., 2001; Deng and 
Brodie, 2000). The BRCT motifs are also involved in phosphopeptide binding by 
either stabilizing or forming the phosphopeptide binding site (Clapperton et al., 
2004). Like the BRCA1 RING domain, the BRCT motifs of the protein are of critical 
importance for its tumour suppression function since truncating and missense 
mutations which predispose to breast and ovarian cancer were found in this domain.  
Mutations within the BRCT domain inhibit the interaction with partner DNA 
damage protein BRIP and as a result of this, damaged DNA escapes the checkpoints 
during the G2/M phase of the cell cycle (Yu et al., 2003).   
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Figure 4: BRCA1 functional domains and selected binding partners. Modified from 
Narod and Foulkes 2004  
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1.8.2.2 BRCA2 structure 
The BRCA2 gene is located on chromosome 13q12 and spans approximately 70 kb 
of genomic DNA (Figure 5). It consists of 27 exons of which 26 encode a 3418 
amino acid protein (Tavtigian et al., 1996; Wooster et al., 1995).  
 
 
Figure 5: Genomic structure of the BRCA2  gene which spans around 70 kb of 
genomic sequence consists of 27 exons. Modified from Hakansson et al. 1997 and  
Genetics Home Reference website (http://ghr.nlm.nih.gov) 
 
1.8.2.2.1 BRCA2 protein 
BRCA2 protein contains two known functional domains, the BRC-repeats motifs and 
the DBD binding domain. The middle region of the protein, which is encoded by 
exon 11, contains eight BRC-repeat motifs that are conserved among mammalian 
species suggesting an important function. The BRC repeats are essential for BRCA2 
function in DNA repair by mediating direct binding to the DNA recombinase 
RAD51, a protein that is essential for DNA repair and genetic recombination. It is 
currently believed that in human BRCA2, six of the eight motifs can bind directly to 
RAD51 (Chen et al., 1998; Wong et al., 1997). Mutations in BRCA2 BRC repeats are 
associated with cancer predisposition. Experiments in mice have demonstrated that 
deletions of all BRCA2 BRC domains are embryonically lethal whereas deletions of 
several BRC repeats lead to cancer (Donoho et al., 2003). 
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The BRCA2 C-terminal region contains the DBD binding domain, which interacts 
with DSS1 (deleted in split-hand/split-foot 1), a highly conserved 70 amino-acid 
protein. DSS1 binding protein is essential for BRCA2 function (Gudmundsdottir et 
al., 2004; Kojic et al., 2003; Li et al., 2006). Studies in mammalian cells have 
demonstrated that DSS1 is required for the formation of DNA damage-induced 
RAD51 foci suggesting that it has a role in BRCA2 and RAD51 dependent repair by 
homologous recombination (Gudmundsdottir et al., 2004; Li et al., 2006). 
Furthermore, studies implicate DSS1 in maintaining the correct conformation of the 
BRCA2 protein. The exact mechanism of how DSS1 depletion induces degradation 
of BRCA2 remains unclear but it was observed  that BRCA2 was largely insoluble in 
the absence of DSS1 (Yang et al., 2002). The carboxy-terminal region of BRCA2 
also includes two nuclear localization signals, which enable BRCA2 to enter the 
nucleus and also facilitate RAD51 transport into the nucleus (Davies et al., 2001; 
Spain et al., 1999) (Figure 6). 
  
A second RAD51 binding site also exists in the extreme C-terminus of the BRCA2 
protein (Mizuta et al., 1997; Sharan et al., 1997). This region is also phosphorylated 
at residue 3291 by cyclin-dependent kinases (Esashi et al., 2005). It is still unclear 
exactly how the two RAD51-binding regions of the BRCA2 work synergistically to 
control RAD51 function.  
 
 
 
 
 
 
DBD 
binding 
DSS1 RAD51 RAD51 
Figure 6: BRCA2 functional domains and selected binding partners. Modified from 
Narod and Foulkes 2004 
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1.8.3 BRCA1 and BRCA2 proteins and their proposed functions  
The BRCA1 and BRCA2 genes were discovered by positional cloning with no prior 
knowledge of their functional roles. Since their discovery, the elucidation of their 
biology has been the focus of intensive research. We now know that both genes are 
key players in DNA-repair pathways and are considered as “caretaker” genes (genes 
that act as sensors of DNA damage and participate in the repair process) (Kinzler 
and Vogelstein, 1997).  Until recently, it was believed that BRCA1 and BRCA2 
genes are classical tumour suppressor genes for which the Knudson two hit 
hypothesis holds true. Individuals who have a genetic predisposition to hereditary 
breast and ovarian cancer carry a deleterious germline mutation in the BRCA1 or the 
BRCA2 gene, in every one of their cells. According to Alfred Knudson’s two hit 
hypothesis of cancer causation (Knudson, 1971), a second hit in the wild-type 
BRCA1 or BRCA2 allele is required for the development of BRCA-associated cancer. 
A number of studies have documented loss of heterozygosity (LOH) in BRCA-
associated tumours with retention of the disease predisposing allele (Smith et al., 
1992; Neuhausen and Marshall, 1994; Collins et al., 1995; Gudmundsson et al., 
1995).  
 
Recently, there has been some controversy about this. A study by King et al. (2007) 
reported that breast cancer initiation in BRCA-mutation carriers might result from 
BRCA haploinsufficiency and not from loss of the wild-type allele. In contrast, data 
from the same group suggest that loss of the wild-type BRCA allele is required for 
ovarian carcinogenesis. An editorial in “Annals of Surgical Oncology” journal 
outlines a number of reasons, which can explain the variability of these findings 
compared to previous studies (Meric-Bernstam, 2007). Meric-Bernstam suggests 
that the variability may be due to differences in methodology or sampling as well as 
to studying only two genotypes: 185delAG in BRCA1 and 617delT in BRCA2. 
Furthermore, King et al. have not evaluated changes in methylation, which could 
cause epigenetic silencing of the wild-type allele. Additional studies using larger 
numbers of samples with different genotypes are warranted in order confirm or 
refute the hypothesis that LOH affecting the wild-type BRCA allele is not obligatory 
for breast tumorigenesis in BRCA1/2 mutation carriers.  
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Despite the progress that has been made in understanding the functions of the 
BRCA1 and BRCA2 genes, a complete picture has not yet been attained and there is 
still much more to learn. Based on the current information, we know that BRCA1 has 
multiple biological functions and is involved in DNA damage repair, transcriptional 
regulation, cell cycle checkpoint control, protein ubiquitylation and chromatin 
remodelling (Narod and Foulkes, 2004). On the other hand, BRCA2 plays an 
important role in homologous recombination, both in meiosis and repair of double-
strand breaks. It also has a role in centrosome regulation and maintenance of 
chromosomal stability (Narod and Foulkes, 2004).  
 
BRCA1 and BRCA2 participate in the biological response to DNA damage that 
includes the activation of cell cycle checkpoints and the recruitment of the DNA 
damage repair machinery. Both BRCA1 and BRCA2 are implicated in DNA repair by 
homologous recombination, a repair mechanism in which a homologous chromatid 
serves as a template to guide repair of the damaged strand. BRCA1 and BRCA2 
proteins have distinct roles in double-strand break repair (Narod and Foulkes, 2004).  
 
1.8.3.1 BRCA1 protein functions 
BRCA1 plays a key role in DNA double strand break repair and in the maintenance 
of genomic integrity. It has been demonstrated that BRCA1 facilitates DNA repair 
through its involvement in homologous recombination (HR), non-homologous end 
joining (NHEJ) and nucleotide excision repair (NER). An overview of these DNA 
repair mechanisms will be presented in section 2.2 of this thesis. BRCA1 protein 
serves as a scaffold that organizes and coordinates a number of proteins that are 
involved in maintaining genomic integrity (Deng and Brodie, 2000). 
 
The most deleterious form of DNA damage is double strand breaks. There are two 
main pathways that are used for repairing these breaks: HR and NHEJ. There is 
evidence that BRCA1 is implicated in both these pathways. It is believed that BRCA1 
protein is involved in NHEJ via its interaction with the MRN [MRE11A [meiotic 
recombination 11 homolog A (S. cerevisiae)] - RAD50 [RAD50 homolog (S. 
cerevisiae)]- NBS1 [Nijmegen breakage syndrome 1 (nibrin)] complex. The MRN 
complex plays an important role in both HR and NHEJ.  The exact mechanism of 
BRCA1 interaction with the MRN complex and its involvement in NHEJ is not yet 
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fully known. There is conflicting evidence on the role of BRCA1 in NHEJ, which is 
summarized, in a recent review by Bau et al. (2006). Many studies have provided 
evidence that BRCA1 deficient cells have decreased NHEJ fidelity. Moreover, 
BRCA1-deficient mouse embryonic fibroblasts were found to have significantly 
reduced NHEJ activity. On the other hand, other studies have demonstrated that 
BRCA1 can promote only specific subtypes of NHEJ and has no effect on others. 
This may be a reflection of the different roles of BRCA1 in sub-pathways of NHEJ 
(Bau et al., 2006).  
 
BRCA1 is also involved in DNA repair by homologous recombination. The first 
indication that BRCA1 participates in DNA repair was the observation that it 
associates and co localizes with RAD51 in subnuclear clusters (Scully et al., 1997). 
RAD51 is the major component of the HR pathway. The nature of interaction 
between BRCA1 and RAD51 is unknown but it is believed that the association is 
likely to be indirect and possibly mediated by BRCA2. In the event of DNA damage, 
both RAD51 and BRCA1 localize to the region of damage and BRCA1 also 
undergoes phosphorylation. The subnuclear localization and the phosphorylation of 
BRCA1 protein, suggest that it is involved in DNA-damage dependent replication 
checkpoint response (Scully et al., 1997b; Thomas et al., 1997). Further evidence 
that BRCA1 is involved in DNA repair by homologous recombination comes from 
the observation that BRCA1 deficiency results in decreased RAD51 foci formation in 
cultured cells after γ-irradiation (Huber et al., 2001). Based on the fact that BRCA2 
also interacts with RAD51, it was suggested that a complex consisting of BRCA1, 
BRCA2 and RAD51 is formed and functions to repair damaged DNA (Chen et al., 
1999). There is an indication that this complex functions during or after DNA 
replication, since the levels of BRCA1, BRCA2 and RAD51 expression increase in 
cells when they enter the S phase of the cell cycle (Venkitaraman, 2002).  
 
BRCA1 has also been linked to a number of other DNA repair processes due to its 
interaction with other proteins that are involved in response to and in the repair of 
DNA damage. BRCA1 together with BRCA2, RAD51, BARD1 and other proteins is 
part of the BRCC (BRCA1-BRCA2-Containing Complex) that constitutes an E3 
ubiquitin ligase that enhances cellular survival following DNA damage (Dong et al., 
2003). Furthermore, BRCA1 forms part of the BASC (BRCA1-Associated Genome 
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Surveillance Complex) super complex. The BASC complex includes the DNA 
mismatch repair proteins MLH1 [mutL homolog 1, colon cancer, nonpolyposis type 
2 (E. coli)], MSH2 [mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)]  
and MSH6 [mutS homolog 6 (E. coli)], the MRN complex proteins MRE11A-
RAD50-NBS1, the Bloom syndrome helicase BLM, ATM (ataxia telangiectasia 
mutated) kinase, DNA replication factor C, RFC (replication factor C) and PCNA 
(proliferating cell nuclear antigen). It is believed that this complex acts as a sensor 
for DNA damage and is also directly involved in repairing DNA damage by DNA-
replication associated repair (Wang et al., 2000). The involvement of BRCA1 in 
repairing double strand breaks is supported by its participation in the BASC complex 
and its interaction with the MRN complex. The MRN complex plays a critical role in 
DNA damage sensing, signalling and repair mechanism, as well as in the 
maintenance of chromosomal integrity of the cell (Assenmacher and Hopfner, 2004).  
 
BRCA1 also functions in signalling the response to DNA damage. Following DNA 
damage, ATM and ATR (ataxia telangiectasia and Rad3 related) protein kinases 
phosphorylate BRCA1 in response to different stimuli (Cortez et al., 1999; Gatei et 
al., 2000; Okada and Ouchi, 2003; Tibbetts et al., 2000). Furthermore, in response to 
γ-irradiation ATM phosphorylates and activates CHEK2 [CHEK2 checkpoint 
homolog (S. pombe)], which in turn phosphorylates BRCA1 (Lee et al., 2000). 
Hence, ATM, ATR and CHEK2 kinases regulate BRCA1 function and in turn cell 
cycle regulation and DNA repair by phosphorylation.   
 
Recently there has been progress in elucidating the mechanism by which BRCA1 
recognizes double-strand breaks. BRCA1, through its C-terminal domains forms 
three distinct complexes with Abraxas, BACH1 and CtIP proteins. RAP80 (receptor 
associated protein 80) recruits BRCA1-Abraxas and BRCA1-CtIP complexes to 
damaged DNA. (Kim et al., 2007; Sobhian et al., 2007; Wang et al., 2007). In 
addition, the BRCA1-CtIP complex interacts with the MRN complex to facilitate 
double-strand break resection and to activate homologous recombination mediated 
repair of DNA (Chen et al., 2008; Sartori et al., 2007).   
 
BRCA1 also plays a role in DNA repair by NER and is involved in both transcription 
coupled repair and global genome repair. In detail, it was reported that BRCA1 
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deficiency leads to blockage of RNA polymerase II transcription machinery at the 
site of repair of oxidative 8-oxoguanine residues (Le Page et al., 2000). Moreover, 
BRCA1 has been reported to be involved in global genomic repair and more 
specifically in the transcriptional activation of genes that are involved in recognition 
of damaged DNA. In detail, BRCA1 induces expression of XPC (xeroderma 
pigmentosum, complementation group C), DDB2 (damage-specific DNA binding 
protein 2) and GADD45 (growth arrest and DNA-damage-inducible) genes in the 
absence of TP53 (Hartman and Ford, 2002). Another link between BRCA1 and the 
NER pathway comes from its association with MSH2 and MSH6 (as part of the 
BASC complex) which are required for transcription-coupled repair (Wang et al., 
2000).  
 
Recently BRCA1 has been found to have an enzymatic function as a ubiquitin ligase 
together with its interacting protein BARD1, via the formation of a RING/RING 
heterodimer. Ubiquitylation is the process during which proteins are tagged for 
degradation by the proteasome. The BRCA1/BARD1 heterodimer targets proteins 
involved in cell cycle regulation and DNA repair, for degradation (Irminger-Finger 
and Jefford, 2006). 
  
Another important function that is associated with the BRCA1 protein is chromatin 
remodelling. BRCA1 is involved in chromatin remodelling around the sites of DNA 
damage via its direct interaction with a protein complex that contains the chromatin 
remodelling proteins SW1/SNF.  As a result of this interaction, a number of other 
proteins that are implicated in response to DNA damage, namely KU70 (Ku 
autoantigen, 70kDa) and GADD45, are activated (Bochar et al., 2000). Also, BRCA1 
via its C-terminal BRCT repeat directly interacts with BACH1 (also known as 
FANCJ or BRIP1), a DNA helicase that plays a critical role in maintenance of 
genome stability (Cantor et al., 2001) . Another indication that BRCA1 is involved in 
chromatin remodelling comes from its participation in the BASC complex, which is 
known to be involved in the chromatin remodelling process that facilitates DNA 
repair (Wang et al., 2000). 
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1.8.3.2 BRCA2 protein functions 
The exact role of the BRCA2 protein still remains elusive. It has been demonstrated 
that BRCA2 plays an important role in homologous recombination, both in meiosis 
and in the repair of double-strand breaks. The major role of the BRCA2 protein is to 
assist in organizing RAD51 function and facilitate homologous recombination. 
BRCA2 binds RAD51 recombinase directly and regulates recombination-mediated 
double strand break repair. BRCA2 is required for the efficient nuclear localization 
of RAD51 and mediates the recruitment of RAD51 to the sites of double strand 
breaks. Hence it is essential for the cellular function of RAD51 (Davies et al., 2001; 
Sharan et al., 1997; Yuan et al., 1999).  BRCA2-deficient cell lines are very sensitive 
to DNA damaging agents and exhibit a genomic instability phenotype that includes 
accumulation of double-strand breaks and in turn chromosomal breaks (Kraakman-
van der Zwet et al., 2002; Moynahan et al., 2001). In addition, BRCA2 has been 
identified as the FANCD1 (Fanconi Anemia complementation group D1) gene. 
When both BRCA2 alleles are inactivated, a Fanconi anemia phenotype can occur 
(Howlett et al., 2002; Offit et al., 2003).  
 
Not long ago, a nuclear partner of BRCA2, namely PALB2 was identified. PALB2 
(partner and localizer of BRCA2) provides stability to the BRCA2 protein to perform 
its cellular functions namely DNA repair by homologous recombination and 
checkpoint control. PALB2 is also required for BRCA2 intranuclear localization (Xia 
et al., 2006).  
 
Recently, it has been demonstrated that BRCA2 plays a critical role in meiotic 
recombination through its direct interaction with DMC1 recombinase (Thorslund et 
al., 2007). Moreover, BRCA2 controls mitotic checkpoint activity (Tutt et al., 1999; 
Yu et al., 2000), maintains normal centrosome number and function  and has been 
implicated in regulation of cytokinesis in the final stages of cell division (Daniels et 
al., 2004). Finally, BRCA2 has been shown to contribute to activation of 
transcription (Milner et al., 1997; Shin and Verma, 2003), G2/M checkpoint control 
(Yuan et al., 1999), suppression of tumour development by inhibition of cancer cell 
proliferation (Wang et al., 2002) and mammalian gametogenesis (Sharan et al., 
2004).  
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1.8.3.3 BRCA1 and BRCA2 protein functions and targeted therapy 
Since the identification of BRCA1 and BRCA2 genes, extensive research has been 
carried out to elucidate their functions and identify the pathways in which they are 
involved. Recently, the knowledge gained on BRCA1 and BRCA2 function in DNA 
repair has been exploited to therapeutic advantage.   
 
As it was discussed extensively in this chapter, heterozygous germline mutations in 
the BRCA1 and BRCA2 genes predispose their carriers to breast and ovarian cancers 
(Wooster and Weber, 2003). These individuals have a wild type allele, which 
expresses the BRCA1/2 protein and therefore their cells have relatively normal 
BRCA1/2 function. However, at some point in their lifetime, somatic loss of 
heterozygosity of the wild-type BRCA1/2 allele occurs which is believed to foster 
cancer progression by promoting genomic instability and mutation. As a result of 
this, the wild type allele is lost in tumours and only the mutant protein is expressed 
(Gudmundsdottir and Ashworth, 2006).  
 
BRCA1 and BRCA2 proteins play an important role in repairing DSBs by HR. 
BRCA1/2 mutation carriers are deficient in the homologous recombination repair 
pathway and cells are forced to use alternative repair pathways which are error prone 
and lead to genomic instability and eventually cell death (Moynahan et al., 1999; 
Moynahan et al., 2001b; Tutt et al., 2001).  
 
A novel therapeutic approach, which is based on the concept of “synthetic lethality” 
(Hartwell et al., 1997) and is targeted towards women who carry BRCA1 or BRCA2 
mutations is currently being evaluated. The principle of this therapy is to kill tumour 
cells, which are BRCA1/2 – deficient, but not harm cells with normal BRCA1/2 
function. Scientists hypothesized that loss of an additional DNA repair pathway 
(BER pathway) in BRCA1/2 mutant cells would result in synthetic lethality whereas 
cells with functional BRCA1/2 alleles would be unaffected and able to survive 
(Bryant et al., 2005; Farmer et al., 2005). The base excision repair (BER) pathway 
was targeted, by reducing the activity Poly (ADP-ribose) Polymerase (PARP) 
enzyme which is critical for BER (Boulton, 2006). Experiments using small 
molecule inhibitors of PARP1 have demonstrated that BRCA1 or BRCA2 deficient 
cells were selectively killed whereas cells with functional BRCA1 or BRCA2  had 
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remained unaffected (Farmer et al., 2005; Tutt et al., 2005).  
 
The efficacy of PARP inhibitors led to a phase I clinical trial aiming to assess the use 
of PARP inhibitors in the treatment of cancer in BRCA1 or BRCA2 mutation carriers. 
The preliminary results of phase I trial showed significant efficacy and modest 
toxicity and phase II trials are currently underway (Ratnam and Low, 2007). A 
considerable amount of testing is still required before PARP inhibitors are used in a 
clinical setting for the treatment of BRCA1- or BRCA2-associated cancers.  
 
This approach represents a good example of how basic research into the biology of 
BRCA1 and BRCA2 can lead to novel therapeutic strategies and new tailored 
therapies. It is anticipated that in the future, the expansion of our knowledge on the 
functions of BRCA1 and BRCA2 will enhance our ability to treat BRCA1- and 
BRCA2-associated cancers.  
 
1.8.4 BRCA1 and BRCA2 mutation spectrum 
Genetic testing to identify the presence of BRCA1 and BRCA2 mutations has become 
an integral part of contemporary clinical practice in many countries. Mutation 
screening of the two breast cancer predisposition genes is also carried out all over 
the world for research purposes, and more specifically for estimating the prevalence 
of these genes in different ethnic groups.  
 
More than 3000 distinct sequence variants have been described in the BRCA1 and 
BRCA2 genes to-date. The Breast Cancer Information Core (BIC) database had 
recorded (as of December 2008) more than 1600 distinct germline BRCA1 mutations 
and more than 1800 BRCA2 mutations. It is interesting that there are no hot spots in 
these two genes and mutations are evenly distributed across their entire coding 
sequences (Figure 7). This makes mutation screening of BRCA1 and BRCA2 
technically challenging and requires that each gene is screened in its entirety. 
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Figure 7: Mutation spectrum of BRCA1 and BRCA2 genes spanning across their 
exons in a condensed map modified from the BIC database 
(http://research.nhgri.nih.gov/bic/). The three most common mutations in the BRCA1 
(185 delAG, 5382 insC) and BRCA2 (6174delT) genes are pointed out with arrows.  
 
Initial reports on disease-associated BRCA1 and BRCA2 mutations documented 
genetic alterations that resulted in protein truncations, mainly small deletions and 
insertions as well as nonsense mutations leading to premature stop codons (Castilla 
et al., 1994; Friedman et al., 1994; Miki et al., 1994; Simard et al., 1994; Wooster et 
al., 1995; Couch et al., 1996; Neuhausen et al., 1996; Tavtigian et al., 1996). 
Deleterious mutations generate truncated non-functional BRCA1 or BRCA2 proteins.  
Nowadays, the most common types of deleterious BRCA1 and BRCA2 mutations 
identified remain small frameshift insertions and deletions as well as nonsense 
mutations and splice-site mutations.  
 
With the advancement of technology and the development of sensitive quantitative 
techniques, it is now possible to screen both genes for the presence of genomic 
rearrangements i.e. large exonic deletions or insertions. Studies on homogeneous 
ethnic populations have revealed that the frequency of BRCA1 genomic 
 45
rearrangements in high-risk breast cancer families ranges between 1.3% and 4.4%, 
depending on the ethnicity as well as on the study eligibility criteria. The frequency 
of BRCA2 genomic rearrangements is lower than BRCA1 and ranges between 0% 
and 2.4%, depending again on the population studied and the study eligibility 
criteria. Overall, large BRCA1 rearrangements account for between 8% and 19% of 
the total number of BRCA1 mutations whereas large BRCA2 deletions/duplications 
contribute between 0% and 11%, of all BRCA2 mutations (Palma et al., 2008). Based 
on these data, it can be concluded that genomic rearrangements contribute 
significantly to the spectrum of identifiable mutations of the BRCA1 and BRCA2 
genes and screening for genomic rearrangements should become an integral part of 
the routine mutational analysis of BRCA1/2 genes (Palma et al., 2008).  
 
In addition to protein truncating mutations, splice site mutations and genomic 
rearrangements, large numbers of missense mutations have been identified in both 
BRCA1 and BRCA2 (BIC Database). These mutations cause single amino acid 
changes. In some cases, depending on the location of the mutation and the actual 
amino acid substitution missense mutations can disrupt protein function, whereas in 
others they are neutral polymorphic variants. The classification of missense 
mutations as disease-associated or neutral is difficult and given that the status of the 
majority of missense mutations identified so far is uncertain, they are reported as 
variants of uncertain significance or unclassified variants (BIC Database).  
 
Geneticists are currently using a number of approaches to classify variants of 
uncertain significance in the BRCA1 and BRCA2 genes and to assess their 
contribution to breast cancer risk.  These include analysis of segregation of 
mutations with disease in families (Thompson et al., 2003), evaluation of the 
frequency of variants in unaffected controls (Deffenbaugh et al., 2002) , analysis of 
clinical and histopathological data (Gomez-Garcia et al., 2005), loss of 
heterozygosity analysis (Osorio et al., 2002), bioinformatics analysis to predict effect 
of the amino acid change on protein structure (Mirkovic et al., 2004) and cross-
species sequence variation analysis (Abkevich et al., 2004; Tavtigian et al., 2006). 
Recently, integrated models which combine several approaches for classification of 
DNA sequence variants of unknown clinical significance, into deleterious or neutral, 
have been proposed (Chenevix-Trench et al., 2006; Easton et al., 2007; Goldgar et 
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al., 2004; Lovelock et al., 2007; Osorio et al., 2007; Phelan et al., 2005; Spurdle et 
al., 2008). The application of these methods has resulted into the classification of a 
number of BRCA1 and BRCA2 unclassified variants. These methods have the 
disadvantage that they use high-risk mutations as reference. For this reason, the 
possibility that some missense mutations classified as being of low clinical 
significance, are in fact associated with moderate risk of cancer cannot be excluded 
(Waddell et al., 2008).   
 
The most reliable method for the classification of BRCA1 and BRCA2 alterations is 
via the development of specific functional assays that take advantage of 
biochemistry and cell biology in order to assess the influence of unclassified variants 
on protein function.  It is expected that these assays will be adapted in the future in 
conjunction with other sources of information for clinical purposes and more 
specifically for the development of validated likelihood models which will provide 
reliable risk assessment to individuals at high risk (Carvalho et al., 2007).  
 
1.8.5 Ethnic differences in BRCA1 and BRCA2 mutation spectra 
Germline disease-causing BRCA1 and BRCA2 mutations have been identified in 
individuals from all over the world, originating from different races and ethnic 
groups. Many studies have demonstrated that certain BRCA1 and BRCA2 mutations 
are restricted to certain ethnic populations and geographical areas. This observation 
is partly the result of the presence of founder mutations within these genes 
(Neuhausen, 1999; Szabo and King, 1997).  
 
The most common and well-characterized mutations are those detected in 
individuals of Ashkenazic Jewish descent. It is estimated that around 2.5% of 
Ashkenazi Jews carry one of the three founder mutations (185delAG and 5382insC 
in BRCA1 and 6174delT in BRCA2) (Fodor et al., 1998; Roa et al., 1996; Struewing 
et al., 1997). Another population, whose BRCA1 and BRCA2 mutational spectrum is 
well characterized due to the availability of samples, is the Icelanders. Around 0.4-
0.6% of  the Icelandic population carry a single BRCA2 founder mutation 
(999delTCAAA) (Johannesdottir et al., 1996; Thorlacius et al., 1997).  
 
 47
Several other recurrent mutations have been described in a number of ethnic groups 
and populations and are summarized in a recent review by Fackenthal and Olopade 
(2007). Briefly, the small number of detected BRCA1 and BRCA2 pathogenic 
mutations characterizes some populations, whereas others have a broader and more 
diverse mutational spectrum (Figure 8). It should be noted that some of the recurrent 
mutations were found in a number of different populations and ethnic groups. The 
number of distinct recurrent mutations in a population depends on the population 
history and more specifically on influences of migration, population structure, 
geographical and cultural isolation (Szabo and King, 1997). 
 
 
8984delG 
Figure 8: Position of several founder mutations within BRCA1 and BRCA2 genes. 
BRCA1 185delAG and 5382insC and BRCA2 6174delT are founder mutations for 
Ashkenazi Jews, BRCA1 1135insA and 1675delA are founder mutations for the 
Norwegian population and BRCA1 3171ins5 and 4153delA are founder mutations 
for the Swedish and Polish population respectively. Furthermore BRCA2 9254del5 is 
a founder mutation of the Spanish population and 8984delG is a founder mutation of 
the Cypriot population  [modified from Fackenthal and Olopade (2007)]. 
 
 
In Cyprus, 10 distinct disease-causing BRCA1 and BRCA2 mutations were identified 
in 150 Cypriot breast/ovarian cancer families subjected to genetic testing 
(Hadjisavvas et al., 2001; Hadjisavvas et al., 2003; Hadjisavvas et al., 2004; 
unpublished data). Two out of the ten mutations, 8984delG in BRCA2 gene and 
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5429delG in BRCA1 gene, have been detected in more than one Cypriot family. 
These two mutations account for the majority of BRCA1 and BRCA2 mutation-
positive families identified so far in Cyprus. Furthermore, four of the truncating 
mutations that have been identified are novel and characterise the Cypriot 
population. It seems that the BRCA2 gene plays a more important role in familial 
breast cancer than BRCA1 in the Cypriot population. It is noted that frameshift 
mutation 8984 delG in the BRCA2 gene is the most frequent mutation identified in 
the Cypriot population and was detected in nine unrelated families. Haplotype 
analysis revealed that this is a founder mutation for the Cypriot population 
(Hadjisavvas et al., 2004).  
 
1.8.6 BRCA1 and BRCA2 in early onset breast cancer 
Early age of diagnosis is a useful marker of genetic susceptibility to breast cancer. 
Familial breast cancer occurs at a considerably younger age compared to the typical 
age of onset in the general population (Claus et al., 1991). The occurrence of early-
onset breast cancer has been associated with mutations in the BRCA1 and BRCA2 
genes (Langston et al., 1996; Krainer et al., 1997).  
 
In the general population, women with an early age of breast cancer diagnosis are 
more likely than others, to have genetic predisposition to the disease. Studies on the 
contribution of BRCA1 and BRCA2 mutations to the incidence of breast cancer have 
primarily focused on individuals coming from high-risk families and large founder 
effect populations. In contrast to the plethora of family based studies, few population 
based studies examining the prevalence of BRCA1 and BRCA2 mutations in women 
who were diagnosed with breast cancer at a young age, have been carried out.  
 
Chronologically, the first population-based studies that were performed had 
concentrated on selected populations with highly recurrent founder mutations i.e. the 
Icelanders and the Ashkenazi Jews. Data from these studies revealed that the 
prevalence rates of BRCA1 and BRCA2 mutations amongst early onset breast cancer 
patients can be as high as 30% for Ashkenazi Jews (Abeliovich et al., 1997) and 
around 25% for Icelanders (Johannesdottir et al., 1996; Thorlacius et al., 1997). This 
high percentage is a result of the presence of founder mutations in these two ethnic 
populations. In detail, 25% of women in Iceland diagnosed with breast cancer below 
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the age of 40 carried a single BRCA2 mutation (999delTCAAA) while among 
unselected Jewish breast cancer cases diagnosed below the age of 40, 30% were 
found to carry one of the three founder BRCA1/2 mutations (BRCA1 185delAG, 
5382insC and BRCA2 6174delT).   
 
In addition to Icelanders and Ashkenazi Jews, the contribution of BRCA1 and 
BRCA2 mutations to the population incidence of early-onset breast cancer has been 
examined in various other geographical regions and ethnic groups. In detail, studies 
were carried out in North America, United Kingdom, Spain, the Netherlands, 
Sweden, Germany, Philippines, Korea and Australia (Langston et al., 1996; Krainer 
et al., 1997; Peto et al., 1999; Southey et al., 1999; Anglian Breast Cancer Study 
Group, 2000; Loman et al., 2001; Malone et al., 2000; Papelard et al., 2000; Loman 
et al., 2001; De Leon Matsuda et al., 2002; Antoniou et al., 2003; de Sanjose et al., 
2003; Hamann et al., 2003; Choi et al., 2004). In these geographical regions, the 
prevalence of BRCA1 and BRCA2 mutations among early onset breast cancer 
patients’ ranges between 5% and 10%. Mutations in the two cancer predisposition 
genes make approximately equal contributions to the incidence of early onset breast 
cancer, with the exception of the Philippines, where BRCA2 plays a more significant 
role compared to BRCA1 (De Leon Matsuda et al., 2002). The differences observed 
in the mutation frequencies between various populations may be explained by the 
different study selection criteria as well as by differences in the sensitivity of the 
genotyping methods. However, it is also possible that these are real differences since 
the patient groups that were studied, come from different ethnic and racial 
backgrounds. 
 
In these population-based studies it was observed that the chances of finding a 
pathogenic mutation in either BRCA1 or BRCA2 genes increased by increasing 
numbers of first degree affected relatives. Thus the frequency of deleterious 
mutations in patients with a strong family history was greater compared to patients 
without a family history. A family history was observed in more than 80% of 
patients from the Icelandic population and 40% to 90% in other populations.  
 
However, studies from Korea and Australia (Southey et al., 1999; Choi et al., 2004) 
challenged this paradigm. In these studies it was found that the majority of women 
 50
with deleterious BRCA1/2 mutations did not have a family history of breast or 
ovarian cancer. Therefore, it is possible in the clinical setting that the proportion of 
early onset breast cancer patients with family history is smaller compared to patients 
without family history. Hence, the majority of early onset breast cancer cases that 
are BRCA1/2 mutation carriers in these countries are not “hereditary” but “sporadic” 
since they occur in individuals without a family history of breast cancer. This 
highlights the importance of a population-based perspective for breast cancer 
genetics which not only focuses on families with multiple cases of breast cancer but 
also on women with early onset breast cancer irrespective of their family history.  
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Chapter 2  
Genetic susceptibility to breast cancer and  
the role of DNA repair genes 
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2.1 Genetic susceptibility to breast cancer 
2.1.1 Moderate risk breast cancer genes 
Breast cancer susceptibility genes can be split into 2 main categories: “high-risk” 
genes and “moderate risk” genes. As discussed extensively in Chapter 1, BRCA1 and 
BRCA2 are the main breast cancer susceptibility genes and together with PTEN, 
TP53, CDH1 and LKB1/STK11 comprise the high-risk susceptibility group. These 
highly penetrant genes were first identified in the 1990s by genetic linkage studies 
(Oldenburg et al., 2007). Nowadays, it is widely accepted that among all 
populations, around 5% to 10% of all breast cancer cases, arise in individuals who 
inherit a highly penetrant mutation in a breast cancer susceptibility gene such as the 
BRCA1 and BRCA2 (Thompson and Easton, 2004).  
 
Over the past five years a number of genes conferring a moderate increase in breast 
cancer risk have been discovered. These genes were identified through candidate 
gene resequencing of genes whose encoded proteins are involved in biological 
pathways that include BRCA1 and BRCA2. Rare coding variants in the ATM, 
CHEK2, BRIP1 and PALB2 genes confer a two to three times higher breast cancer 
risk to their carriers (Foulkes, 2008). It is estimated that the contribution of this class 
of genetic variants to familial risk is less than 3%. This estimation is based on their 
relatively low frequency and the modest increases in risk that they cause (Pharoah et 
al., 2008).  
 
2.1.1.1 ATM 
The ATM gene encodes a checkpoint kinase which plays a central role in sensing and 
signalling in the presence of DNA double-strand breaks. Mutations in the ATM gene 
(OMIM number 607585) are known to cause Ataxia telangiectasia, a rare recessive 
disorder characterized by neurologic deterioration, telangiectasias, 
immunodeficiency states, and hypersensitivity to ionizing radiation. Initially there 
was controversy regarding the role of heterozygous ATM mutations in breast cancer 
predisposition. A number of studies provided conflicting results with estimated 
relative risk ratios ranging from 1.3 to 12.7 (Angele and Hall, 2000; Ahmed and 
Rahman, 2006; Renwick et al., 2006).  ATM is currently classified as a moderate risk 
breast cancer gene based on the results of a large epidemiological study, which has 
demonstrated that heterozygous ATM mutation carriers have an estimated relative 
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risk for breast cancer of 2.37 (Renwick et al., 2006). 
  
 2.1.1.2 CHEK2 
CHEK2 is a checkpoint kinase which plays an important role in the DNA damage 
repair response pathway. A number of CHEK2 mutations were studied in relation to 
breast cancer risk but no clear relationship was found (Bell et al., 2007). CHEK2 
1100delC mutation appears to be the only mutation associated with an increase in 
breast cancer risk. Heterozygous 1100delC mutation carriers have a two fold 
increased risk for breast cancer (CHEK2 Breast Cancer Case-Control Consortium, 
2004). In addition, a recent meta-analysis has reported a 4.8 relative risk of 
developing breast cancer for heterozygous CHEK2 1100delC mutation carriers, who 
have a family history of breast cancer (Weischer et al., 2008). The clinical 
applicability of this finding still remains uncertain because of population-specific 
differences in mutation frequency. Offit and Garber (2008) suggested that it is not 
justified to test for the CHEK2 1100delC mutation because of the low mutation 
frequency. In contrast, Weischer et al. (2008) proposed that CHEK2 1100delC 
should be considered together with BRCA1 and BRCA2 mutation screening in 
women with a family history of breast cancer. 
 
2.1.1.3 BRIP1 
BRIP1, also known as BACH1 directly interacts with BRCA1 and has a role in DNA 
repair and cell cycle checkpoint.  Monoallelic BRIP1 gene mutations are associated 
with an increased risk of breast cancer whereas biallelic BRIP1 mutations cause 
Fanconi Anemia (Levran et al., 2005; Seal et al., 2006).  In a recent study, Seal et al. 
(2006) screened 1212 individuals with breast cancer from BRCA1/BRCA2 mutation 
free families and 2081 controls and calculated that the relative risk of breast cancer 
for heterozygous BRIP1 mutation carriers is 2.0. It is noteworthy that incomplete 
segregation of BRIP1 mutations with breast cancer was observed in this study, which 
is consistent with a low penetrance allele.  
 
2.1.1.3 PALB2 
PALB2 is a gene that directly interacts with BRCA2 and plays a role in homologous 
recombination and DNA double strand break repair. Biallelic PALB2 mutations 
cause Fanconi Anemia and predispose to childhood cancer (Reid et al., 2007). 
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Monoallelic PALB2 mutations confer a 2.3-fold higher risk of breast cancer. As in 
the case of BRIP1, incomplete segregation of PALB2 mutations in families with 
hereditary breast cancer was observed making predictive screening of unaffected 
women difficult (Rahman et al., 2007).  
 
In general, the moderate-penetrance breast cancer susceptibility genes make a 
relatively small contribution to the overall familial risk of breast cancer. Current 
estimates suggest that carriers of moderate-penetrant mutant alleles in one of the four 
genes have approximately 6-10% risk of developing breast cancer by age 60, 
compared to around 3% in the general population (Stratton and Rahman, 2008).  
 
2.1.2 Association studies for discovering low penetrance breast cancer genes  
As mentioned above, it is estimated that around 5-10% of all breast cancers and less 
than 25% of the inherited component of breast cancer can be explained by germline 
mutations in the known breast cancer susceptibility genes (Easton, 1999; Oldenburg 
et al., 2007). However, despite the large body of evidence which supports the fact  
that breast cancer has a strong genetic component, most genes underlying the disease 
remain unknown. Attempts to localize additional highly penetrant breast cancer 
susceptibility genes have failed and it was concluded that if any additional high 
penetrance genes exist, they account for only a small proportion of the excess 
familial risk (Smith et al., 2006). This led to the suggestion that the remaining breast 
cancer susceptibility is polygenic in nature and that a number of low penetrance 
alleles, each conferring a small risk, are involved (Antoniou et al., 2002; Pharoah et 
al., 2002).  
 
Linkage studies have been very successful in mapping disease genes for monogenic 
disorders but have limited power to detect low to moderate risk alleles that 
predispose to polygenic diseases such as breast cancer (Pharoah et al., 2004). An 
alternative method for mapping disease genes are association studies. Association 
studies are based on the “common disease-common variant” hypothesis which 
proposed that common variants possibly in association with environmental factors, 
underlie most common diseases (Chakravarti, 1999; Reich and Lander, 2001). In 
association studies the frequency of a genetic variant is compared between a group 
of cases (affected individuals) and a group of controls (unaffected individuals) 
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(Cardon and Bell, 2001; Risch, 2000). Allelic association is present when the 
distribution of the genetic marker differs between the two groups i.e. a variant is 
associated with disease susceptibility if it is over-represented in the cases group and 
vice-versa; it is protective for the disease if it is under-represented in the cases 
group. All the currently known low-penetrance breast cancer susceptibility alleles 
have been discovered through association studies. 
 
At present, mostly due to technical ease, the most commonly studied form of genetic 
variation are single nucleotide polymorphisms; SNPs. Single nucleotide 
polymorphisms (from the Greek meaning "having multiple forms") are classified as 
commonly occurring (>1%) single base pair genetic substitutions in at least one 
population. It has been estimated that around 90% of the sequence variants in the 
human genome are SNPs (Collins et al., 1998). Using the classic neutral theory of 
population genetics is was inferred that there are about 11 million SNPs in the 
human genome (Kruglyak and Nickerson, 2001).  
 
Over the last 10 years, considerable research effort has been expended into searching 
for low penetrance breast cancer susceptibility alleles, via the conduction of 
association studies. The majority of the initial association studies for breast cancer 
had concentrated on testing functional SNPs in candidate genes, involved in 
important biological pathways such as DNA repair, carcinogen metabolism, cell- 
cycle control and hormone synthesis and metabolism. Recently, studies have shifted 
towards studying minimal sets of tagging SNPs which can capture common genetic 
variation in the region / gene of interest (Pharoah et al., 2004).   
 
Numerous individual studies evaluating candidate genes have reported associations 
which failed to replicate across studies. The failure to replicate these associations has 
led to scepticism and the majority of these results are nowadays considered to be 
false-positive findings (Hirschhorn et al., 2002; Ioannidis et al., 2001; Ioannidis et 
al., 2006; Lohmueller et al., 2003; Wacholder et al., 2004). The lack of replication is 
mainly due to two factors: insufficient power of individual studies to detect small 
contributions to risk and low prior probability of a disease association for a given 
variant. All genetic associations demand a high level of proof and thus replication of 
findings in large independent data sets is of paramount importance and is regarded as 
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a prerequisite for convincing evidence of association (Chanock et al., 2007). 
Recently, scientists from all over the world have joined forces by forming 
multigroup collaborations and combining data from thousands of breast cancer cases 
and controls from different ethnics groups, in order to overcome limitations of 
individual studies and  have sufficient power to detect small effects on breast cancer 
risk (Breast Cancer Association Consortium, 2006).   
 
This collaboration proved to be successful and the Breast Cancer Association 
Consortium has identified, the only well-validated breast cancer susceptibility locus 
to emerge so far, using the candidate gene approach. In detail, they identified a SNP 
in the CASP8 gene D302H (rs1045485) which is associated with a reduction in 
breast cancer risk (Ptrend = 1.1 × 10-7) in this large multiethnic cohort (Cox et al., 
2007).  
 
Thus far, candidate gene studies on breast cancer have examined only a small 
fraction of the more than 25000 genes across the human genome.  However, the 
majority of these studies performed only limited evaluations of genetic variation in a 
proportion of these genes. It is therefore possible that additional breast cancer 
susceptibility loci can be identified by the candidate gene approach, in large highly 
powered studies, involving more comprehensive evaluations of genetic variation. 
Furthermore, it is believed that this approach will assist scientists in identifying rare 
variants in candidate genes which are associated with disease risk (Garcia-Closas 
and Chanock, 2008). 
    
Recently, a new approach which involves the study of genetic variation across the 
entire human genome by rapid genotyping of hundreds of thousands of SNPs, in 
many samples aiming to identify genetic associations with a particular disease has 
emerged. Scientists are taking advantage of the new genotyping platforms, which 
allow simultaneous genotyping of more than 1.8 million markers for genetic 
variation and enable high-performance, high-powered and low-cost genotyping to 
carry out genome-wide association studies (GWAS). With GWAS it is possible to 
scan the human genome for associations without prior knowledge of gene function 
or position.   
 
 57
Over the past 2 years, four GWAS for breast cancer have been published. These 
studies have reported a small number of well-validated, statistically unimpeachable, 
low penetrance breast cancer susceptibility alleles. Easton et al (2007b) identified 
five SNPs that were associated with breast cancer risk. The largest effect was 
observed with a SNP in intron 2 of the FGFR2 gene (rs2981582) with a per allele 
relative risk of 1.26 as compared with the low-risk allele. In addition, loci within or 
near the TNRC9 (recently renamed TOX3), MAP3K1 and LSP1 genes as well as a 
locus in 8q24 that does not contain any known protein-coding genes were associated 
with disease risk at the genome wide level of association. Subsequent GWAS from 
the Nurses Health study, an Icelandic study and a familial Ashkenazi Jewish cohort 
study have replicated the associations observed with the FGFR2 and TNRC9 loci 
and have also identified additional novel susceptibility loci at chromosomal 
locations 2q35, 5p12 and 6q22.33 (Hunter et al., 2007; Stacey et al., 2007; Gold et 
al., 2008; Stacey et al., 2008).  
 
The population prevalence of the low risk breast cancer alleles is high and ranges 
from 28% to 87% (Stratton and Rahman, 2008). It is of interest that for some of 
these newly identified loci the higher risk allele is the more common. Based on their 
high frequency and despite the low risks that these predisposition alleles confer, it 
was estimated that they account for a substantial proportion of familial breast cancer 
(Stratton and Rahman, 2008).  
 
GWAS for breast cancer are still at an early stage. It is likely that many more breast 
cancer susceptibility loci, which exhibit weaker effects than the ones identified so 
far, exist (Easton and Eeles, 2008). It is expected that the next generation of GWAS 
studies, that will be larger in size and will combine analysis across multiple scans, 
will identify these additional susceptibility loci (Easton and Eeles, 2008). As more 
risk alleles are identified, our knowledge on the biological pathways involved in 
carcinogenesis will improve. It is anticipated that by increasing the number of 
susceptibility loci identified, the ability to predict risk will improve and single 
common low penetrance genes may become clinically useful (Easton and Eeles, 
2008).  
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2.1.3 Summary of the three classes of known breast cancer susceptibility alleles 
In the last twenty years major advances have been made in understanding 
susceptibility to breast cancer. Current knowledge supports the existence of three 
classes of breast cancer susceptibility alleles as outlined below. It is now well 
accepted that BRCA1 and BRCA2 genes are possibly the only highly penetrant breast 
cancer susceptibility genes. Mutations in these two breast cancer susceptibility genes 
are rare (population carrier frequency ≤0.1%) and confer a 10-20 fold increased risk 
for breast cancer. The BRCA1 and BRCA2 genes account for a substantial proportion 
of the familial risk for breast cancer. The second class of breast cancer susceptibility 
genes consists of genes that confer moderate increases in breast cancer risk. These 
genes are ATM, BRIP1, CHEK2 and PALB2 which are all involved in BRCA1- and 
BRCA2-related biological pathways. Heterozygous mutations in these genes are rare 
(population carrier frequency ≤0.6%) and their carriers have a two to three fold 
relative risk for breast cancer. The possibility that other moderate-penetrance breast 
cancer susceptibility alleles exist cannot be excluded since mutations in these genes 
are quite uncommon. Resequencing studies which will include large families may 
help towards this direction. The third class of genetic risk alleles for breast cancer 
has emerged more recently and consists of low penetrance susceptibility alleles, 
mainly SNPs which confer risks of 1.3-fold or less. These SNPs were identified by 
GWAS and are very common (population carrier frequency 5-50%). It is very likely 
that a number of additional low penetrance breast cancer susceptibility alleles exist. 
It is anticipated that these additional susceptibility alleles will be identified within 
the next few years by large scale GWAS (Stratton and Rahman, 2008). Figure 9 
summarizes the genetic landscape of breast cancer susceptibility. 
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Figure 9: Summary of genes predisposing to breast cancer (taken from Olopade et 
al., 2008) 
 
2.2 DNA repair  
Mammalian cells are under constant mutagenic attacks from both endogenous 
reactive metabolites as well as a plethora of exogenous agents, including chemical 
carcinogens, ionizing radiation, ultraviolet rays and chemotherapeutic drugs that 
impact its integrity. Consequently, multiple mechanisms for repairing DNA damage 
and maintaining genomic integrity have evolved. DNA repair is essential for 
survival of mammalian cells. Deficiencies in the cell’s DNA repair system can cause 
hypersensitivity to DNA damaging agents, accumulation of mutations and 
chromosomal aberrations which in turn lead to cell malfunctioning, cell death and 
tumorigenesis (van Gent et al., 2001).  
 
Inherited deficiencies in the DNA repair mechanism are responsible for a number of 
highly penetrant genomic instability syndromes that have cancer as a predominant 
phenotype. Examples include Bloom and Werner’s syndromes, Fanconi Anemia and 
Xeroderma Pigmentosum. These syndromes are characterized by hypersensitivity to 
DNA damaging agents leading to mutation accumulation and in turn to tumour 
formation. (Hamosh et al., 2005). The link between inherited DNA repair 
deficiencies and susceptibility to cancer highlights the importance of safeguarding 
genomic integrity via efficient DNA repair processes. 
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The human genome has about 150 genes that are associated with DNA repair. The 
DNA repair genes can be split into two main categories: those which are associated 
with signalling and regulation of DNA repair and those which are associated with 
distinct repair mechanisms such as base excision repair (BER), nucleotide excision 
repair (NER) and DNA double-strand break (DSB) repair (Wood et al., 2005).  
  
The evolutionary process has endowed us, with a sophisticated DNA repair system. 
In mammals there are at least five main repair pathways that protect us against DNA 
damaging agents - BER, NER, homologous recombination (HR), non homologous 
end joining (NHEJ) and mismatch repair (MMR) which are illustrated in Figure 10. 
The pathway choice is dependant on the type of damage (Friedberg et al.,1995; 
Lindahl and Wood, 1999). 
 
 
Figure 10: Common DNA damaging agents, examples of DNA lesions induced by 
agents, and most relevant DNA repair mechanism responsible for removal of lesion. 
Taken from Hoeijmakers (2001). 
 
 
 
 61
2.2.1 Base excision repair 
BER is the main mechanism that repairs oxidized DNA bases arising either 
spontaneously within the cell, due to reactive oxygen radicals, methylation, 
deamination and hydroxylation or from attack by exogenous agents including 
ionizing radiation and long-wave UV light.  Hence, BER is mostly responsible for 
recognizing and repairing minor damages to DNA bases and sugars Christmann et 
al. (2003).  
 
There are at least 12 different DNA damage specific glycosylases as well as about 20 
other proteins which participate in the BER process (Christmann et al., 2003) . The 
first step of BER is carried out by specific DNA glycosylases that recognize the 
specific base modification and excise the lesion by hydrolysis of the N-glycosylic 
bond, which connects the base to the sugar-phosphate backbone, forming an AP site 
(Scharer and Jiricny, 2001). The abasic site is subsequently recognized by APE1 
endonuclease protein, which cleaves the phosphodiester bond 5' to the abasic sugar 
site, leaving behind a nick with a normal 3' hydroxyl group and an abnormal 5' 
abasic terminus (Wilson and Barsky, 2001). "Short-patch" BER that is the dominant 
mode in mammals, proceeds with DNA polymerase β removing the 5'-abasic residue 
and filling in the single nucleotide gap (Wiebauer and Jiricny, 1990; Dianov et al., 
1992; Sobol et al. 1996). Next, the nick is sealed by either the XRCC1/Ligase III 
complex or DNA ligase I (Kubota et al., 1996). An alternative BER sub pathway 
referred to as “long-patch” BER exists. “Long-patch” BER repair mode occurs by 
the excision of at least 2 nucleotides by FEN1 (flap structure-specific endonuclease 
1) protein (Klungland and Lindahl, 1997). DNA synthesis is catalyzed by either a 
PCNA-stimulated, Pol β-directed pathway or a PCNA-dependent, Pol δ/ε -directed 
pathway (Stucki et al., 1998). Finally, DNA ligase I seals the nick to complete the 
repairing process (Tomkinson et al., 2001). A summary of the BER mechanism is 
depicted in Figure 11.   
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Figure 11: Mechanism of base excision repair. Taken from Christmann et al. (2003) 
 
2.2.2 Nucleotide excision repair 
Enzymes involved in NER recognize and repair chemical modifications to DNA 
bases which cause bulky distortions in the shape of the DNA double helix. 
Consequently this pathway is critical for protecting against agents that cause 
structural distortion in DNA including pyrimidine dimers, photodimers resulting 
from UV irradiation and DNA intra-strand cross-links. There are about 30 proteins 
which are involved in the NER pathway (Christmann et al. 2003). 
 
NER consists of 2 distinct sub-pathways termed global genomic repair (GGR) and 
transcription coupled repair (TCR). GGR is responsible for the removal of lesions 
from the non-transcribed domains of the genome. In GGR, several sensing proteins 
including the DDB and XPC-RAD23B [RAD23 homolog B (S. cerevisiae)] 
complexes screen the genome and recognize DNA helix distortions (reviewed in 
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Balajee and Bohr, 2000; Hanawalt, 2002; Mullenders and Berneburg, 2001). TCR 
focuses on repairing the damage that blocks elongating RNA-polymerases in the 
transcribed strand of active genes (Bohr et al., 1985; Mellon et al., 1987). In 
response to damage, RNA polymerases are displaced by the action of TCR-specific 
factors CSA and CSB as well as NER proteins XPB, XPD and XPG in order to make 
the area accessible for repair (Schaeffer et al., 1993; Le Page et al., 2000). The 
subsequent steps of GGR and TCR are identical. Upon identification of the DNA 
damage site more than 25 NER proteins are recruited to the site of the lesion to 
excise the damaged DNA surrounding the lesion and synthesize and ligate the 
resulting gap (Hoeijmakers, 2001; Christmann et al. 2003). In detail, XPD and XPB 
helicases of the TFIIH transcription factor open around 30 bases of DNA in the area 
surrounding the damage and RPA binds to the undamaged strand (Schaeffer et 
al.1993 ; Schaeffer et al., 1994; Yokoi et al., 2000). Next, ERCC1/XPF endonuclease 
cuts the damaged strand 5’ of the damaged base while XPG endonuclease performs 
the same action 3’ of the damaged base (Habraken et al., 1994 ; O'Donovan et al., 
1994 ; Sijbers et al., 1996). The cleaved nucleotides, which contain the damage, are 
then removed and the regular DNA replication machinery is recruited to fill in the 
gap (Hoeijmakers, 2001).  A summary of the NER mechanisms is shown in Figure 
12.   
 
In section 1.8.3.1 of this thesis, the role of BRCA1 in NER mechanisms was 
discussed. BRCA1 is implicated in both transcription-coupled repair and global 
genomic repair (Le Page et al., 2000; Wang et al. 2000; Hartman and Ford; 2002).  
 
There are at least three syndromes, which are associated with defects in NER 
pathway: Xeroderma Pigmentosum, Cockayne syndrome and Trichothiodystrophy. 
All three syndromes are characterized by extreme ultraviolet sensitivity and an 
increased risk of sun-induced skin cancer (Christmann et al., 2003; Hoeijmakers, 
2001; Mohrenweiser et al., 2003). 
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Figure 12: Mechanisms of nucleotide excision repair. Taken from Christmann et al. 
(2003). BRCA1 is implicated in both GGR and TCR. BRCA1 enhances GGR repair 
by inducing expression of XPC, DDB2 and GADD45 (not pictured) genes which are 
involved in recognition of damaged DNA (Hartman and Ford, 2002). BRCA1 is also 
implicated in TCR via the activation of the RNA polymerase II transcription 
machinery. It is essential for the repair of the 8-oxoguanine oxidative damage, 
located on the transcribed strand in human cells. (Le Page et al., 2000).  
 
2.2.3 Double strand break repair 
DNA double-strand breaks are potentially harmful damages that can arise either 
directly from exposure to DNA-damaging agents such as ionizing radiation, X-rays, 
free radicals and chemicals or may spontaneously arise due to replication failure 
(Hoeijmakers, 2001). It is noted that only one non-repaired DSB in an essential gene 
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is sufficient for inducing cell death via apoptosis. This highlights the importance of 
the existence of efficient DSB repair mechanisms (Rich et al., 2000).  
 
There are two different pathways involved in DSB repair: HR and NHEJ. In 
mammals the predominant DSB repair pathway is NHEJ whereas in simple 
eukaryotes, HR is the main pathway (Cromie et al., 2001; Haber, 2000). Moreover, 
the occurrence of HR or NHEJ also depends on the cell cycle phase. HR takes place 
during late S and G2 phases whereas NHEJ takes place mainly in G0/G1 phases  
(Takata et al., 1998; Johnson and Jasin, 2000). 
 
2.2.3.1 Homologous Recombination 
HR uses nucleotide sequence complementarity between the intact and the damaged 
chromatid, as a basis for properly repairing DSB. HR is an error-free pathway since 
it entails copying the missing information from an undamaged homologous 
chromosome (Sonoda et al., 2001).  
 
Briefly, in HR the DSB is first resected in the 5’ to 3’ direction by the MRN 
complex (MRE11-RAD50-NBS1). The resulting 3’ single-stranded tails are bound by 
a heptameric ring complex formed by the RAD52 proteins in order to be protected 
against exonucleolytic digestion (Stasiak et al., 2000). The resulting 3’ single-
stranded tails then invade the DNA double helix of a homologous, undamaged 
partner molecule. These strand-exchange events are catalyzed by RAD51 that has the 
ability to bind single-stranded DNA and promote ATP-dependent and RPA-
stimulated interactions, with homologous regions on undamaged DNA molecules. In 
detail, RAD51 forms filaments along the unwound DNA strand to facilitate strand 
invasion. RAD51 nucleoprotein filament includes five RAD51-related proteins: 
XRCC2, XRCC3, RAD51B, RAD51C and RAD51D. Following DSB recognition and 
identification of the homologous undamaged sequence, the broken ends are extended 
by the action of DNA polymerase, which copies information from the intact double-
stranded copy. Finally the ends are ligated by DNA ligase I and the interwound 
DNA strands, known as Holliday junctions, are resolved by resolvases according to 
the classical model of Holliday (Haber, 2000; Khanna and Jackson, 2001; van Gent 
et al., 2001). The mechanism of DNA repair by HR is summarized in Figure 13. 
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As it was already mentioned in section 1.8.3 of this thesis, the proteins encoded by 
the breast cancer susceptibility genes, BRCA1 and BRCA2, are integral components 
of the HR pathway due to their interactions with RAD51 protein. BRCA2, via its 
BRC repeats and a C-terminal domain interacts directly RAD51 and plays a major 
role in the control, localization and function of this key recombinase, whereas 
BRCA1 has an indirect association with RAD51 which is possibly mediated by 
BRCA2. Furthermore, HR is mediated by the BASC complex. BRCA1 is part of this 
complex (Narod and Foulkes, 2004). Studies have shown that BRCA2 deficiency 
leads to impaired DSB repair by HR (Moynahan et al., 2001; Tutt et al., 2001; Xia et 
al., 2001). In addition, BRCA1 mutant cells have an impaired ability to repair DNA 
damage by HR (Deng and Wang, 2003; Moynahan et al., 2001; Snouwaert et al., 
1999). 
 
Deficiencies in HR have been strongly linked to carcinogenesis. Malfunctioning 
copies of helicase genes involved in HR regulation cause a number of cancer-related 
syndromes including Bloom’s, Werner’s and Rothmund-Thomson (Kitao et al., 
1999). 
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Figure 13: Mechanism of homologous recombination repair. Taken from Christmann 
et al. (2003). HR is initiated by single-stranded DNA (ssDNA) generation. This 
process is promoted by a number of proteins including the MRN complex (MRE11-
RAD50-NBS1). Next, ssDNA invades the undamaged template, in events catalyzed 
by RAD51, BRCA1 and BRCA2. Following the actions of specific polymerases, 
helicases and other essential components, DNA ligation and substrate resolution 
occur.  
 
2.2.3.2 Non-homologous End Joining  
In humans, the predominant mechanism of DSB is NHEJ. In contrast to HR, the 
NHEJ system does not require sequence homology between the DNA ends. DSB are 
repaired by directly ligating the two DSB ends (Critchlow and Jackson, 1998). 
NHEJ mechanism involves 5 steps: detection of DSB, molecular bridging of broken 
DNA ends, processing of the DNA ends to make them compatible and ligatable, gap 
filling and ligation (Figure 14). The processing of broken DNA ends in most cases, 
results in loss of a few nucleotides at the broken ends, making NHEJ pathway error-
prone (Christmann et al. 2003). 
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There is growing evidence suggesting that there are multiple pathways for NHEJ. 
The best understood pathway involves Ku proteins, DNA-dependent protein kinase, 
and the DNA ligase IV-XRCC4 complex (Jazayeri and Jackson, 2002). However, it 
was demonstrated that cell extracts lacking DNA-PKcs, as well as Ku-depleted 
extracts could still perform efficient end joining. This indicates the existence of 
additional Ku-independent pathways of NHEJ (Wang et al., 2003). Moreover, cell 
extracts from Fanconi Anemia fibroblasts, have a deficiency in NHEJ process that 
appears to be independent of DNA-PKcs and Ku (Lundberg et al., 2001).  
 
The first step of Ku-dependent NHEJ pathway involves the recognition and binding 
of the DNA ends by the Ku70 and Ku80 heterodimer. This step protects DNA from 
exonuclease digestion. Next, the Ku heterodimer recruits and activates the catalytic 
subunit of DNA-dependent protein kinase (DNA-PKcs) together forming the DNA-
PK holoenzyme. Ku proteins and DNA-PKcs are both capable of attaching to the 
DNA ends. Ku translocates internally upon binding of the DNA-PKcs to the DNA 
end. The DNA ends need to be processed and trimmed for proper annealing. A 
fraction of DSB ends are processed by Artemis nuclease and DNA-PKcs. Artemis 
forms a complex with DNA-PKcs, which acts as an endonuclease at both 5’and 3’ 
overhangs degrading single-strand overhangs and hairpins. Processing of DSB is 
also performed by the MRN complex that removes excess DNA at 3’ flaps as well as 
by FEN1, which removes 5’ flaps. Polymerases Pol μ and Pol λ possibly fill in all 
the gaps. Finally, ligation to form a single DNA molecule is performed by XRCC4 - 
DNA ligase IV complex. This complex is recruited by and interacts with Ku and 
DNA-PKcs. It binds to the ends of DNA molecules and links together duplex DNA 
molecules with complementary but not ligatable ends (Khanna and Jackson, 2001; 
van Gent et al., 2001; Christmann et al., 2003; Schulte-Uentrop et al., 2008). 
 
As it was already mentioned in section 1.8.3.1 of this thesis, BRCA1 is involved 
DNA repair by NHEJ. BRCA1 binds in vivo and in vitro to the MRN complex which 
is an important component of the NHEJ pathway (Bau et al. 2006).  
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Figure 14: Mechanism of non-homologous end joining. Taken from Christmann et 
al. (2003). NHEJ pathway is initiated by the binding of Ku70/Ku80 heterodimer to 
the broken DNA ends. The DSB-bound Ku then recruits the catalytic subunit DNA-
PKcs, which forms a complex with Artemis nuclease. The DNA ends are rejoined by 
XRCC4/ DNA ligase IV complex. Recently, XLF (XRCC4-like factor; also called 
Cernunnos), a new factor of the NHEJ pathway has been identified (Ahnesorg et al., 
2006; Buck et al., 2006). XLF has at least 2 distinct functions NHEJ. The major role 
of XLF protein in NHEJ is the stimulation of the ligase activity of the XRCC4/ DNA 
ligase IV complex (Hentges et al., 2006). XLF also has a function to the early 
process of NHEJ. It responds to DSB induction and accumulates at the damaged site 
within a few seconds  (Yano and Chen, 2008).    
BRCA1 is implicated in the NHEJ pathway via its interaction with the MRN 
complex. The exact mechanism of interaction and its involvement in NHEJ is not yet 
fully know. MRN complex proteins are involved in processing broken DNA ends, 
making them available for ligation by the XRCC4/ DNA ligase IV complex. 
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2.3 Genetic polymorphisms, DNA repair capacity and breast cancer risk 
 
2.3.1 Genetic polymorphisms 
As it was mentioned in section 2.2, mammalian cells are equipped with various 
DNA repair mechanisms, to preserve genomic integrity. However, from an 
evolutionary perspective, genetic variation is the raw material of evolution. A certain 
level of continuous mutagenesis may be deemed necessary to allow individuals to 
cope with environmental or lifestyle shifts and challenges. Sequence changes take 
place throughout the human genome. The vast majority of these alterations are non-
coding changes which have no or little effect on cellular function (Shastry, 2007).  
 
Humans share more than 99.9% of their genome sequence. Single nucleotide 
polymorphisms explain around 90% of all sequence variants in the human genome 
(Collins et al., 1998). It is estimated that approximately 11 million SNPs exist in the 
human genome with a minor allele frequency (MAF) of 1% and approximately 5 
million SNPs with a MAF of 10% (Ladiges et al., 2004). However, only a small 
number (50,000–250,000) of these SNPs are functionally important, resulting in 
small/moderate alterations on phenotypes that are related to disease risk (Chanock, 
2001). The National Center for Biotechnology Information (NCBI) has established 
the Single Nucleotide Polymorphism Database (dbSNP) in response to a need for a 
general catalog of genome variation (Sherry et al., 2001). According to data obtained 
from the dbSNP database on December 2008, there are 19,125,432 registered SNPs 
in the database  which are distributed throughout the 3.2 billion bases of the human 
genome.  
 
2.3.2 Reduced DNA repair capacity and breast cancer risk 
There is growing evidence that human cancer can be initiated by DNA damage 
caused by endogenous and exogenous mutagens. It was estimated that in normal 
human cells approximately 1% of single-strand lesions are converted to 
approximately 50 endogenous double-strand breaks per cell per cell cycle (Vilenchik 
and Knudson, 2003). These double strand breaks are usually repaired with a high 
fidelity. Unrepaired DNA double-strand breaks, due to either a decrease in HR 
accuracy or to shunting repair events in NHEJ pathway that are inherently 
mutagenic, contribute significantly to the rate of cancer. A series of additional 
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mutations and epigenetic changes are needed in order to lead to tumour formation. 
Disruption of the caretaker functions of DNA repair genes leads to the inactivation 
of gatekeeper genes that regulate growth or promote cell death. These events result 
in acceleration of the multi-step process of carcinogenesis and give rise to early 
onset cancer. Consequently, women with a reduced DSB repair capacity are thought, 
to be at an increased risk of breast cancer (Ralhan et al., 2007).  
 
It is evident that the DNA repair process has a critical role in protecting the genome 
against mutations that lead to cancer. Research focusing on genetic variation in DNA 
repair genes is driven by the hypothesis that SNPs in DNA repair genes can reduce 
their capacity to repair DNA damage and thereby lead to increased cancer 
susceptibility. This idea has been fuelled by skin, colorectal and breast cancers since 
a number of cases are attributed to hereditary defects in NER, mismatch repair and 
the BRCA1/2 genes, respectively (Foulkes, 2008).  
 
It has been suggested that inter-individual differences in DNA repair capacity 
modify cancer risk (Berwick and Vineis, 2000). Evidence supporting this comes 
from epidemiological studies, focusing primarily on lung and skin cancer, which 
have reported that deficiencies in DNA repair capacity lead to accumulation of DNA 
damage and accelerate the carcinogenesis process. (Berwick and Vineis, 2000; 
Michiels et al., 2007). To test the hypothesis that reduced DNA repair capacity 
underlies breast carcinogenesis, many studies have examined lymphocytes that were 
treated in vitro with DNA-damaging agents. DNA damage was evaluated using a 
number of phenotypic assays for cancer risk including Comet assay for measuring 
DNA strand breaks and mutagen sensitivity assay (Berwick and Vineis, 2000; 
Rajeswari et al., 2000; Ramos et al., 2004; Shi et al., 2004; Smith et al., 2003b). All 
studies have reported an increased risk of breast cancer in individuals with greater 
sensitivity to mutagens or poorer DNA repair capacity. Characteristically, a Puerto 
Rican study by Ramos et al. (2004) reported that the DNA repair capacity of breast 
cancer patients was severely reduced (36%) compared to healthy controls. The study 
concluded that a 1% decrease in the DNA repair capacity corresponded to a 22% 
increase in breast cancer risk. In summary, the findings of these studies support the 
hypothesis that reduced DNA repair capacity is associated with an increased risk of 
breast cancer.  
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Recent studies have adopted a family based design in order to assess the relationship 
between DNA repair capacity and breast cancer risk. Sister sets discordant for breast 
cancer were used in order to reduce potential confounding due to population 
admixture, differences in genetic susceptibility as well as lifestyle factors that cluster 
within families. Large differences in DNA repair capacity were observed between 
these sisters’ sets, which had other breast cancer risk factors in common. This 
observation further supports and strengthens the hypothesis that deficient DNA 
repair capacity is associated with susceptibility to breast cancer (Kennedy et al., 
2005; Machella et al., 2008).  
 
It has also been suggested that deficient DNA repair capacity predisposes to familial 
and sporadic breast cancer. Ionizing radiation that is an established risk factor for 
breast cancer as well as other suspected risk factors such as chemical carcinogens, 
alcohol and diet result in reactive oxygen species, bulky DNA adducts and DNA 
strand breaks (Ron, 1998; Johnson-Thompson and Guthrie, 2000). As a result of 
this, women may acquire modifications in critical oncogenes and tumour suppressor 
genes leading to cellular transformation and carcinogenesis (Gonzalez et al., 1999; 
Katsama et al., 2000).  A number of studies have reported that breast cancer patients 
as well as healthy women with a family history of breast cancer, are hypersensitive 
to IR and may have deficient DNA repair capacity compared to healthy women 
without a family history. Hence, a combination of exposure to genotoxic agents with 
genetic factors may elevate breast cancer risk (Helzlsouer et al., 1996; Parshad et al., 
1996; Patel et al., 1997; Scott et al., 1999; Hu et al., 2002).  
 
The importance of DNA repair mechanisms in carcinogenesis is emphasized by 
familial cancer syndromes, which are linked to aberrant DNA repair activity. The 
two major breast cancer susceptibility genes, BRCA1 and BRCA2 play an important 
role in the HR pathway for repairing DSB. This further supports the hypothesis that 
DNA repair mechanisms are of particular etiological importance during breast 
carcinogenesis.  Consequently, genes involved in DNA repair pathways, are possible 
breast cancer susceptibility candidates. Notably, the 10 established breast cancer 
susceptibility genes, which are implicated in inherited predisposition to breast 
cancer, are all involved in pathways critical to genomic integrity (Walsh and King, 
2007).  
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In addition to familial breast cancer, genes involved in the DNA repair pathway also 
play a role in sporadic breast cancers.  A number of studies have shown that there 
was reduced or absent expression of BRCA1, in 30-40% of breast cancers, indicating 
a more general role of BRCA1 in breast carcinogenesis (Thompson et al., 1995; 
Wilson et al., 1999). Additionally, there is evidence that low or absent expression of 
ATM, CHEK2 and TP53 occurs in sporadic breast cancers (Angele and Hall, 2000; 
Sullivan et al., 2002). Loss of heterozygosity (LOH) of TP53, BRCA1, BRCA2, and 
ATM genes has been demonstrated to occur early in sporadic breast tumorigenesis 
and to contribute to genetic heterogeneity during tumour development (Meng et al., 
2004). The study of sporadic breast tumours has also revealed loss of heterozygosity 
in a number of additional genes that are involved in DNA repair. LOH was found in 
the RAD51, RAD52 and RAD54 regions in 32%, 16% and 20% respectively, of the 
breast specimens investigated, suggesting that LOH in these regions, could be 
related to breast cancer and poor tumour prognosis (Gonzalez et al., 1999).  
 
Taken together, these data support the hypothesis that common variation in genes 
involved in DNA repair pathways may influence breast cancer risk. A large number 
of such common variants have been identified by resequencing DNA repair genes, in 
samples from unrelated individuals (Shen et al., 1998a; Kuschel et al., 2002; 
Mohrenweiser et al., 2002). Novel SNPs are being identified continuously by large-
scale genotyping efforts such as the National Institute of Environmental Health 
Sciences (NIEHS) SNPs Program. Candidate genes are continuously being 
sequenced to identify common sequence variation for functional analysis and 
population-based studies.  
 
2.3.2.1 DNA repair SNPs and association with breast cancer risk  
The reporting of SNPs that are associated with breast cancer risk has increased 
exponentially in recent years. Consequently, the number of genetic epidemiology 
studies examining associations between DNA repair SNPs and breast cancer risk has 
also increased rapidly. In the last seven years, several studies have identified variant 
alleles, which are associated with breast cancer risk. In this section, some of these 
studies, which have found associations between SNPs in DNA repair genes and 
breast cancer risk will be outlined. It is not the intention in this section, to provide a 
complete review of the related literature as the list of SNPs studied to date in relation 
 74
to breast cancer risk is exhaustive, and is increasing rapidly.   
 
One of the first large-scale studies analysing SNPs in DNA repair genes  in relation 
to breast cancer risk, was conducted in the U.K by Kuschel et al. (2002). The study 
consisted of 2205 breast cancer cases and 1826 healthy controls. Associations were 
found for two SNPs in the XRCC3 gene, namely T241M and IVS5 A>G at 
nucleotide 17893. Homozygous carriers of the 241M allele had an increased risk for 
breast cancer. In addition, the rare allele of IVS5 A>G was associated with a 
dominant protective effect. A marginally significant association was also observed 
for the rare variant in R188H of the XRCC2 gene. Furthermore, a SNP in the LIG4 
gene (T>C at nucleotide 1977) was associated with a decrease in breast cancer risk. 
In brief, this study provided evidence that SNPs in LIG4, XRCC2 and XRCC3 genes 
alter breast cancer risk and that variation in genes involved in DNA repair pathways, 
plays a role in breast carcinogenesis. 
 
Recently, a collaborative study has evaluated the association of 19 SNPs in 7 genes 
involved in DSB DNA repair and breast cancer risk. The basis of this study were 2 
population-based case-control studies in the USA (3,368 cases and 2,880 controls) 
and Poland (1,995 cases and 2,296 controls). Weak associations with breast cancer 
were found for XRCC3 T241M and IVS7-14A>G variants (pooled odds ratio (95% 
CI): 1.18 (1.04-1.34) and 0.85 (0.73-0.98) for homozygous variant vs. wild-type 
genotypes, respectively), as well as for a rare variant in ZNF350 S472P [1.24 (1.05-
1.48)], with no evidence for study heterogeneity. A meta-analysis of studies in the 
Caucasian population which provided support that BRCA2 N372H variant is also 
weakly associated with breast cancer risk (1.13 (1.10-1.28); total of 13,032 cases and 
13,314 controls) was also conducted (Garcia-Closas et al., 2006).  
 
One of the bigger studies on the contribution of genetic variation in DNA repair 
genes in relation to breast cancer risk, is the one carried out by Haiman et al. (2008). 
The study examined common genetic variation across 60 genes in a multiethnic 
cohort consisting of five different racial/ethnic populations. Over 2600 SNPs were 
genotyped in each population and LD patterns at each candidate locus were 
identified. A total of 2093 cases and 2303 controls participated in that study. 
Validations of the top allelic associations were performed in additional 6483 cases 
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and 7309 controls. A SNP in the FANCA gene (rs1061646) was associated with an 
increased risk for breast cancer in both the initial as well as in the replication studies. 
This SNP yielded an 8% increase in risk per allele. No other statistically significant 
associations were observed. The study concluded that common variation in the 
examined DNA repair genes is not strongly associated with breast cancer risk. 
Johnson et al. (2007) have reported that combinations of rare coding variants in the 
BRCA1, BRCA2, ATM, TP53 and CHEK2 genes are significantly associated with 
breast cancer risk among women with bilateral breast cancer. The study analyzed 
1037 potentially functional SNPs in 473 women with bilateral breast cancer and 
2463 controls. For 21 SNPs, with a MAF of less than 10%, a significant trend in risk 
was observed with increasing numbers of variant alleles (Ptrend = 0.00004, odds ratio 
for 3 or more SNPs = 2.90, 95% CI 1.69–4.97). The study suggested that the 
combined effects of functional variants in the BRCA1, BRCA2, ATM, TP53, CHEK2 
genes as well as a few other candidate genes such as PALB2 and BRIP1 may account 
for a substantial proportion of breast cancer.  
 
In January 2009, a field synopsis on low-penetrance variants in DNA repair genes 
and cancer susceptibility was published (Vineis et al., 2009). The aim of this study 
was to identify all articles published between 1985 and August 2007 reporting 
frequencies of DNA repair gene variants in cancer patients and healthy cancer-free 
controls. A summary of these articles is available on the DNA repair web site of the 
Institute for Scientific Interchange foundation (http://www.episat.org). The 
systematic searches identified 82 studies that referred to breast cancer risk and DNA 
repair gene variants. The meta-analysis of these studies failed to identify many 
signals with strong credibility. In detail, statistically significant associations were 
found for 7 SNPs in the BRCA2, ERCC4, PARP1, TP53 and XRCC3 genes. 
However, all SNPs lost their statistical significance after excluding studies in which 
the requirement for HWE was not met or after excluding the first published studies 
on the respective association. From this study it was concluded that the genetic 
effects, if any, of the DNA repair gene SNPs that were part of the analyses in breast 
cancer, are small in magnitude. Additional variants in DNA repair genes should be 
studied in order to help us improve our understanding, on the role and effects of 
DNA repair genes in the aetiology of breast cancer. For this reason Chapter 4 of this 
thesis involves the study of genetic variation in selected DNA repair genes in 
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relation to breast cancer risk. 
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Chapter 3  
Early onset breast cancer study 
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3.1 Materials and Methods 
 
3.1.1 Subjects 
Twenty-six consecutive incident female breast cancer cases diagnosed before the age 
of 40, between the years 2003 and 2004, participated in this study. These Cypriot 
patients were selected on the basis of a diagnosis of early-onset breast cancer, under 
age 40, irrespective of their family history. All patients had a histological diagnosis 
of breast cancer and were clinically managed by the Bank of Cyprus Oncology 
centre, which operates as a referral centre and offers treatment and follow-up for 80-
90% of all breast cancer cases diagnosed in Cyprus. Patients received genetic 
counselling and were informed about the aims of the study. All 26 women agreed to 
undergo genetic testing, gave an informed consent and provided blood samples. 
Information on family history of cancer, with emphasis on breast or ovarian cancer 
incidence, was obtained and pedigrees were constructed. Cancer diagnoses for 
patients and their affected relatives were verified by reviewing histological reports.  
 
3.1.2 Control Samples 
A control group that consisted of 50 DNA samples from 50, age-matched, unrelated 
healthy Cypriot women, with no family history of breast or ovarian cancer, was 
recruited. This was used to estimate the frequency of the detected BRCA1 and 
BRCA2 variants in the general population and to assess whether nucleotide variants 
were likely polymorphisms.  
 
3.1.3 Preparation of total genomic DNA 
Genomic DNA was isolated from peripheral-blood lymphocytes using a standard 
extraction protocol (phenol-chloroform method). Briefly, red blood cells were lysed 
using RBC lysis buffer (Sambrook et al., 1989). White blood cells were separated 
from the lysed red blood cells by centrifugation. An extraction buffer containing 
SDS was used together with proteinase K to lyse the white blood cells by overnight 
incubation at 370C.  This was followed by a phenol-chloroform extraction step and 
the DNA was precipitated using ethanol. DNA samples were resuspended in 400 μl 
of HPLC grade water. 
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3.1.4 Polymerase chain reaction (PCR)  
Polymerase chain reaction was used to amplify the entire coding sequence and 
intron- exon junctions of the BRCA1 and BRCA2 genes. Briefly, preparation of the 
PCR included 30 ng of genomic DNA in total volume of 25 μl with 0.25 mM of each 
appropriate primer, in the presence of Tris-Cl, KCl, (NH4)2SO4, 15 mM MgCl2 ; at 
pH 8.7 (Qiagen 10X PCR buffer), 0.25 mM of dATP, dCTP, dGTP, dTTP 
(Invitrogen) and 1 unit of Taq DNA polymerase (Qiagen). Amplification was carried 
out on an Applied Biosystems 9700 thermocycler. The thermocycling profile 
involved an initial denaturing step at 940C 5 min followed by 35 cycles of a 
denaturing step for 20 sec at 940C, an annealing step for 20 sec at 550C, and an 
extension step for 20 sec at 720C, with a final extension for 7 min at 720C. The 
primers used for amplification were designed in the department of Electron 
Microscopy / Molecular Pathology of the Cyprus Institute of Neurology and 
Genetics using Primer 3 software. A total of 31 primer pairs for BRCA1 and 41 
primer pairs for BRCA2 were used for mutation screening (Hadjisavvas et al., 2004).  
 
Following PCR amplification, the DNA products were electrophoresed on a 2% 
agarose gel as described by Sambrook et al. (1989).  Following gel electrophoresis,  
DNA was visualized under short wavelength UV light and a digitalized photograph 
was taken for reference.  
 
Next, the PCR products were purified through a Montage™ PCRm96 plate 
(Millipore) according to manufacturer’s recommendations. The purification protocol 
included a filtration step followed by resuspension and recovery of the samples in a 
final volume of 40 μl. 
 
3.1.5 Cycle Sequencing 
Three μl of the purified PCR products were used for cycle sequencing. The reactions 
were carried out according to manufacturer’s recommendations using the BigDye 
Terminator Cycle Sequencing kit (Applied Biosystems). PCR products were 
sequenced using the same primers used for PCR amplification. On completion of the 
reaction, dye terminators were removed using Montage SEQ96 Sequencing Reaction 
Cleanup plates (Millipore). Samples were placed on an ABI 310 Genetic Analyzer 
(Applied Biosystems) and were electrophoresed according to manufacturer’s 
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instructions. When a mutation was identified, a new PCR product using a second 
DNA sample, obtained from the same patient, was sequenced in order to confirm the 
result.  
 
3.1.6 Multiplex ligation-dependent probe amplification (MLPA) 
In order to detect large genomic rearrangements in the BRCA1 and BRCA2 genes, 
MLPA (MRC Holland) using the P087 and P045 kits was carried out, following the 
manufacturer’s protocols. Fragment analysis was carried out on an ABI 310 Genetic 
Analyzer using ROX-500 as a size standard. Peak profiles were analyzed using 
Coffalyser software (MRC Holland).  
  
3.1.7 In silico sequence analysis tools 
To evaluate potential alternative splicing effects, three in silico sequence analysis 
tools, namely NNSPLICE (http://www.fruitfly.org/seq_tools/splice.html), 
SpliceSiteFinder (http://violin.genet.sickkids.on.ca/ali/splicesitefinder.html) and 
NetGene (http://www.cbs.dtu.dk/services/NetGene2/) were used. In order to classify 
missense variants, the Polyphen algorithm (http://coot.embl.de/PolyPhen.) was used.  
 
3.2 Results 
 
3.2.1 BRCA1 and BRCA2 mutation analysis 
Mutation analysis revealed the presence of six pathogenic mutations (two in BRCA1 
and four in BRCA2) in 6 out of the 26 women diagnosed with early-onset breast 
cancer (Figure 15). In total, mutational analysis of the two genes revealed the 
presence of 20 variants in the BRCA1 gene and 26 variants in the BRCA2 gene. In 
describing individual variants, mutation nomenclature guidelines of the HGVS 
(Human Genome Variation Society) (http://www.hgvs.org/rec.html) and the 
nomenclature used in the BIC database (http://research.nhgri.nih.gov/bic/), which 
appears in brackets, were used. 
  
The 20 variants identified in the BRCA1 gene include two truncating mutations, six 
missense mutations, five polymorphisms and seven intronic variants (Table 2). The 
two truncating mutations are a nonsense mutation c.1840A>T (1959A>T), at codon 
614 in exon 11, a lysine to a STOP (K614X) and a frameshift mutation at position 
c.5310delG (5429delG) at codon 1770 in exon 21, which introduces a STOP 22 
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amino acids downstream (p.Phe1772Serfsx21). These mutations were detected in 
two unrelated patients. The six missense mutations which were detected are 
c.1067A>G (Q356R), c.1984C>T (H662Y), c.2612C>T (P871L), c.3113A>G 
(E1038G), c.3348A>G (L1183K) and c.4837A>G (S1613G). Finally, of the 20 
variants identified, 7 occur within intronic sites of the BRCA1 gene, namely in 
introns 5, 8, 9, 12, 17 and 18. It is noted that missense mutation c.1984C>T 
(H662Y), polymorphism c.1482A>G (Q494Q) and intronic variants c.126-23C>A 
(IVS5-23C>A) and c.4185+3A>G (IVS12+3A>G) are novel while the remaining 
variants have been reported by others in the BIC database.  
 
Table 2: Details of the 20 variants detected in BRCA1 in the patient and the control 
group 
Exon Sequence variant Amino acid variant Mutation   
type 
Mutation 
effect 
Frequency 
in the 
patient 
group (%) 
Frequency 
in the 
control 
group (%) 
Truncating Mutations 
11 c.1840A>T (1959A>T) p.Lys614X N N 2 0 
21 c.5310delG (5429delG) p.Phe1772Serfsx21 F F 2 0 
Missense Mutations 
11 c.1067A>G (1186A>G) p.Glu356Arg (Q356R) M P 15 5 
11 c.1984C>T (2103C>T) p.His662Tyr (H662Y) M UV 2 0 
11 c.2612C>T (2731C>T) p.Pro871Leu (P871L) M P 29 50 
11 c.3113A>G (3232A>G) p.Glu1038Gly (E1038G) M P 37 41 
11 c.3348A>G (3467A>G) p.Leu1183Lys (L1183K) M P 31 42 
16 c.4837A>G (4956A>G) p.Ser1613Gly (S1613G) M P 37 41 
Polymorphisms 
9 c.591C>T (710C>T) p.Cys197Cys (C197C) P P 2 0 
11 c.1482A>G (1601A>G) p.Gln494Gln (Q494Q) P P 2 0 
11 c.2082C>T (2201C>T) p.Ser694Ser (S694S) P P 37 39 
11 c.2311 T>C (2430T>C) p.Leu771Leu (L771L) P P 37 34 
13 c.4308T>C  (4427T>C) p.Ser1436Ser (S1436S) P P 37 47 
Intronic Variants 
5 c.126-23C>A (IVS5-23C>A)  UV UV 2 0 
8 c.302-34T>C (IVS7-34T>C)  UV P 60 100 
9 c.442-57delT (IVS8-57delT)  UV P 31 29 
12 c.4185+3A>G (IVS12+3A>G)  UV UV 2 0 
17 c.4676-68A>G (IVS16-68A>G)  UV P 31 31 
17 c.4676-94A>G (IVS16-94A>G)  UV P 31 31 
18 c.5152+66G>A (IVS18+66G>A)  UV P 37 29 
 
F = Frameshift; N = nonsense; UV = unclassified variant; 
M = missense; P = polymorphism; Boldface = novel variants 
 
Mutation nomenclature is according to GenBank accession number U14680 (BRCA1) with numbering starting at 
the A of the first ATG. The nomenclature as used in the BIC database is shown in parentheses. 
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The 26 BRCA2 variants identified in the Cypriot early onset breast cancer cases 
include two truncating mutations, seven missense mutations, six polymorphisms and 
11 intronic variants (Table 3). The first truncating mutation which was detected is a 
novel frameshift, c.3531-3534 delCAGC (p.Asp1177Glufsx19) in exon 11, which 
introduces a STOP codon (1196X). This mutation was detected in one patient. The 
second frameshift mutation detected is c.8755delG (8984delG) in exon 22 which 
introduces a STOP codon 7 amino acids downstream (p.Gly2919Valfsx8). This 
mutation was detected in three unrelated patients. The seven missense mutations are 
c.865A>C (N289H), c.1114C>A (H372N), c.1889C>T (T630I), c.2971A>G 
(N991D), c.4258 G>T (D1420Y), c.5744 C>T (T1915M) and c.7544C>T (T2515I). 
Finally of the 26 variants identified, 11 occur within intronic sites of the BRCA2 
gene, namely in introns 2, 4, 8, 10, 11, 14, 17, 25 and 27. It is noted that 
polymorphism c.7140T>C (H2380H) and intronic variant c.681+43A>G 
(IVS8+43A>G) are novel while the remaining variants have been reported by others 
in the BIC database.  
 
The MLPA analysis of BRCA1 and BRCA2 genes was negative for all 26 DNA 
samples evaluated in this study indicating that large deletions or duplications were 
not present in the study cohort.  
 
Three different theoretical splicing and skipping prediction methods were applied in 
an attempt to predict aberrant splicing based on the DNA sequence of the 
unclassified variant BRCA1 c.4185+3A>G (IVS12+3A>G). All three software 
applications used predicted that this intron variant might result in deleterious 
alterations at the mRNA level. Furthermore, the Polyphen algorithm predicted that 
the missense mutation BRCA1 c.1984C>T (H662Y) is “probably damaging”. 
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Table 3: Details of the 26 variants detected in BRCA2 in the patient and the control 
group 
Exon Sequence variant Amino acid variant Mutation 
type 
Mutation 
effect 
Frequency 
in the 
patient 
group (%) 
Frequency 
in the 
control 
group (%) 
Truncating Mutations 
11 c.3531_3534del4 (3758del4) p.Asp1177Glufsx19 F F 2 0 
22 c.8755delG (8984delG) p.Gly2919Valfsx8 F F 6 0 
Missense Mutations 
10 c.865A>C (1093A>C) p.Asn289His (N289H) M P 12 11 
10 c.1114A>C (1342A>C) p.His372Asn (H372N) M P 21 22 
10 c.1889C>T (2117C>T) p.Thr630Ile (T630I) M UV 2 0 
11 c.2971 A>G (3199A>G) p.Asn991Asp (N991D) M P 12 7 
11 c.4258G >T (4486G>T) p.Asp1420Thr (D1420Y) M P 2 2 
11 c.5744 C>T (5972C>T) p.Thr1915Met (T1915M) M P 2 0 
15 c.7544C>T (7772C>T) p.Thr2515Ile (T2515I) M P 2 0 
Polymorphisms 
10 c.1365A >G (1593A>G) p. Ser455Ser (S455S) P P 12 10 
11 c.2229T.C (2457T>C) p.His743His (H743H) P P 8 10 
11 c.3396A>G (3624A>G) p.Lys1132Lys (L1132L) P P 27 26 
11 c.3807jC>T (4035C>T) p.Val1269Val (V1269V) P P 54 57 
14 c.7130T>C (7358T>C ) p.His2380His (H2380H) P P 2 1 
14 c.7242A>G (7470A>G) p.Ser2414Ser (S2414S) P P 23 20 
Intronic Variants 
2 c.1-203G>A (203G>A)  P P 23 25 
4 c.425+36A>G (IVS4+36A>G)  UV UV 2 0 
8 c.681+43A>G  (IVS8+43A>G)  UV UV 2 0 
8 c.681+56C>T  (IVS8+56C>T)  UV P 12 17 
10 c.1909+12delT (IVS10+12delT)  UV P 100 100 
11 c.1910-51G>T (IVS11-51G>T)  UV P 2 11 
11 c.6841+80del4 (IVS11+80del4)  UV P 29 51 
14 c.7435+53C>T (IVS14+53C>T)  UV P 2 11 
17 c.7618-14T>C (IVS16-14T>C)  UV P 46 51 
25 c.9118-16T>C (IVS24-16T>C)  UV UV 2 1 
27 c.10333A>G (IVS27+76A>G)  UV UV 2 1 
 
F = Frameshift; N = nonsense; UV = unclassified variant; 
M = missense; P = polymorphism; Boldface = novel variants 
 
Mutation nomenclature is according to GenBank accession number U43746 (BRCA2) with numbering starting at 
the A of the first ATG. The nomenclature as used in the BIC database is shown in parentheses. 
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Out of the 26 patients recruited, 15 women reported a family history of at least one 
breast or ovarian cancer, whereas 11 women had a negative history. Furthermore, of 
the six BRCA1/2 mutation carriers detected, two had a negative family history (two 
of 11, approximately 20%). A summary of the family history of breast and ovarian 
cancer for the six carriers of the pathogenic mutations, as well for the one case 
carrying the variant c.4185+3A>G (IVS12+3A>G) is presented in Table 4. The 
family history of women who were not found to carry a pathogenic BRCA1/2 
mutation ranged from one first degree relative with breast cancer, to a maximum of 
four breast cancer cases in the family.  
 
Table 4: Details of the BRCA1 and BRCA2 pathogenic mutation carriers 
Gene Exon Mutation Amino acid 
variant 
Age at 
Diagnosis 
BC/OV 
Family 
History 
BRCA1 11 c.1840A>T (1959A>T) p.Lys614X 40 1 MBC 
BRCA1 21 c.5310delG (5429delG) p.Phe1772Serfsx21 33 - 
BRCA1 12 c.4185+3A>G (IVS12+3A>G)  27 - 
BRCA2 11 c.3531-3534delCAGC (3758del4) p.Asp1177Glufsx19 32 3 BC, 1 OC 
BRCA2 22 c.8755delG (8984delG) p.Gly2919Valfsx8 33 - 
BRCA2 22 c.8755delG (8984delG) p.Gly2919Valfsx8 34 3 BC 
BRCA2 22 c.8755delG (8984delG) p.Gly2919Valfsx8 30 9 BC 
 
BC=breast cancer; M=male; OC=ovarian cancer 
 
3.2.2 Results of BRCA1 and BRCA2 gene analysis in the control group  
In order to evaluate the significance of BRCA1 and BRCA2 sequence variants 
detected in the patient group, general population frequency analysis was conducted 
using a group of 50 unrelated age-matched healthy women (section 3.1.2).  Details 
of the results from analyzing the 20 BRCA1 and the 26 BRCA2 variants in the 
healthy group and frequencies of these variants in the patient group are displayed in 
Tables 2 and 3.   
 
Figure 15: Summary of the pathogenic mutations as well as the unclassified variants detected in the Cypriot early onset breast cancer group. 
Frameshift mutations are represented by red circles, nonsense mutations appear in black and unclassified variants appear in green. Black circles 
represent the number of early onset breast cancer patients carrying each mutation.   
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3.3 Discussion 
In Cyprus, molecular studies of germline BRCA1 and BRCA2 mutations to date, had 
focused on women from high-risk families with multiple cases of breast or ovarian 
cancer. Results of the molecular analysis of these high-risk Greek Cypriot families 
revealed a different spectrum of BRCA1/2 mutations compared to other 
Mediterranean countries. In addition, a founder Cypriot mutation in the BRCA2 gene 
has been identified (Hadjisavvas et al., 2004).  
 
Family studies have proved invaluable for understanding the significance and 
contribution of BRCA1 and BRCA2 genes in breast cancer among Greek Cypriot 
women. However, observations in such families regarding the nature and penetrance 
of BRCA1 and BRCA2 mutations may not reflect the full spectrum of alterations 
present in the general population. It is currently accepted that a variable proportion 
of early-onset breast cancer is associated with mutations in highly penetrant 
dominant genes such as BRCA1 and BRCA2 and that the proportion may be higher in 
populations harbouring founder mutations (Robson et al., 1998). 
 
In Cyprus, the prevalence of BRCA1 and BRCA2 mutations in patients with breast 
cancer who were unselected for a family history of this disease, has not been 
determined. The aim of this study was to evaluate the frequency and distribution of 
mutations in the BRCA1 and BRCA2 genes, in a cohort of Greek Cypriot women 
with early-onset breast cancer.  
 
Breast cancer is the most common cancer among women in Cyprus, with about 400 
new cases diagnosed annually. About 20–30 of these newly diagnosed cases occur in 
patients younger than 40 years of age. As described in section 3.1.1, the cases 
investigated in this study were consecutive cases diagnosed with early-onset breast 
cancer, by age 40, between the years 2003 and 2004. This number represents the 
annual expected incidence of this category of cases, as indicated by the accumulated 
data from the Cyprus Cancer Registry.  
 
A total of 26 DNA samples from women who were given a diagnosis of early onset 
breast cancer, before the age of 40, and who were not selected on the basis of family 
history, were screened for BRCA1/2 mutations. In the 26 breast cancer cases 
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investigated, two pathogenic mutations in BRCA1 affecting two patients and two 
pathogenic mutations in BRCA2 affecting four patients were detected. All 
characterized disease-associated mutations were truncating mutations causing 
premature stop codons and were detected in six unrelated patients. 
 
Of the 26 recruited patients, 15 reported a positive family history of at least one 
incidence of breast or ovarian cancer. In this group, four patients were found to carry 
pathogenic BRCA1/2 mutations. The remaining 11 patients had no relevant family 
history, but it is of interest that two of these were found to carry pathogenic 
BRCA1/2 mutations. In addition, in this group of 11 patients, a possible splice-site 
variant c.4185+3A>G (IVS12+3A>G) was detected in one patient raising the 
number of pathogenic mutation carriers to a possible three (3 of 11, approximately 
30%). 
 
A total of six missense mutations in the BRCA1 gene and seven missense mutations 
in the BRCA2 gene have been detected in the study population. It is noted that five 
out of the six missense mutations identified in the BRCA1 gene are polymorphisms, 
since they were also present in more than 5% of the control group. Similarly, three 
out of the seven missense mutations identified in the BRCA2 are polymorphisms. In 
addition, missense mutations c.4258G>T (D1420Y), c.5744C>T (T1915M) and 
c.7544C>T (T2515I) have been previously reported as polymorphisms (Deffenbaugh 
et al., 2002; Sigurdson et al., 2004; Wu et al., 2005).   
 
The unclassified variant c.4185+3A>G (IVS12+3A>G) in the BRCA1 gene is of 
particular interest. This specific variant involves nucleotide +3 in the consensus 
sequence of the donor splice site of exon 12. It is well characterized that mutations 
in the regions required for correct RNA splicing can result in exon skipping or in 
activation of cryptic splice-sites, which in turn lead to deletion of exon sequences or 
retention of intronic sequences (Shapiro and Senapathy, 1987). Hence, intronic 
alterations that are located within or near intron-exon boundaries of the BRCA1 and 
BRCA2 may have a potential impact on mRNA splicing fidelity. A number of splice-
site prediction programs, that use highly conserved sequences as a basis of 
predicting the effects of mutations on RNA splicing have been developed.   
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Three different theoretical splicing and skipping prediction software applications 
were applied in an attempt to predict the effect of the BRCA1 c.4185+3A>G variant 
on RNA splicing. All three software applications, predicted that this intronic variant 
might result in deleterious alterations at the mRNA level. Unfortunately, an RNA 
sample from this patient, which would allow the assessment of the transcript that is 
produced by this variant allele, was not available.  
 
The novel missense mutation c.1984C>T (H662Y) in the BRCA1 gene may also be 
pathogenic. Amino acid 662 is located in the DNA-binding region of the BRCA1 
gene, and contributes to the DNA repair- related functions of BRCA1 (Narod and 
Foulkes, 2004). Mutation c.1984C>T (H662Y) alters the amino acid histidine from a 
basic polar, positively charged molecule, to the aromatic, non-polar amino acid 
tyrosine. It is well known that the stoichiometry and the charges of the amino acids 
play a role in the conformation and the function of proteins. The Polyphen algorithm 
predicted that this variant is “probably damaging”. Polyphen is an algorithm that 
classifies the functional effect of each missense variant into three categories 
(probably damaging, possibly damaging, and benign). This classification is based on 
comparing homologous sequences for conservation and examination of the structural 
and physicochemical aspects of the substitution. Polyphen has been reported to have 
the smallest false positive rate among the various online algorithms (Ng and 
Henikoff, 2006). In silico analysis of missense mutations provides a useful first line 
analysis method for newly observed substitutions. Based on Polyphen algorithm, 
missense mutation c.1984C>T (H662Y) in the BRCA1 gene may lead to the 
synthesis of a dysfunctional BRCA1 protein which in turn predisposes to the breast 
cancer phenotype. Although bioinformatics methods can predict the impact of 
missense mutations, the predictions cannot be applicable in the clinical setting unless 
they are complemented by functional studies. Hence, in the case of H662Y missense 
mutation in the BRCA1 gene, it would be interesting to carry out functional studies 
in order to determine the pathogenicity of this variant. This is part of future work, 
and it is our intention to study the effect of this variant further by expressing it in 
vivo and investigating its influence on protein function. The experimental plan 
involves subcloning the BRCA1 H662Y unclassified variant in a mammalian 
expression vector followed by transiently transfecting the expression construct in 
mammalian cell lines and studying both the functional activity of the protein as well 
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as its biological effects on the cell. The BRCA1 C61G variant that is known to be 
pathogenic (Brzovic et al., 1998) will be used as a positive control in our 
experimental plan.   
 
Little is known about the contribution of large BRCA1 and BRCA2 rearrangements 
to early onset breast cancer. So far, very few studies have examined this. In a recent 
study from Germany, large rearrangements were detected in 3 out of the 103 (2.9%) 
early-onset breast cancer patients screened. All three gross alterations were detected 
in the BRCA1 gene (Engert et al., 2008). In an Indonesian series of early-onset breast 
cancer cases, BRCA1 large rearrangements accounted for 1% (1/102) of these cases 
(Purnomosari et al., 2007). Furthermore, when screening 59 Singapore-Asian early 
onset breast and ovarian cancer patients, 2 genomic rearrangements were detected in 
2 unrelated breast cancer patients, 1 in each gene (Lim et al., 2007). Based on the 
published results of these studies, it can be concluded that large BRCA1/2 
rearrangements account for only a small fraction of early onset breast cancer.  
 
It is interesting that no large genomic rearrangements were detected in the Cypriot 
early-onset breast cancer cohort. This could be attributed to the small number of 
samples screened but the most likely explanation is ethnic background differences. 
The percentage of large genomic rearrangements in the BRCA1 and BRCA2 genes 
has been reported to vary significantly between different populations (Palma et al., 
2008). At this point it should be noted that studies performed in high-risk Cypriot 
families, have also not detected any large BRCA1 or BRCA2 rearrangements 
(unpublished data). However, due to the small number of individuals included in this 
investigation, no conclusive recommendations for large-rearrangements testing in 
Cypriot early onset breast cancer cases can be drawn. 
 
The histopathology of BRCA1-mutation carriers’ breast tumours is distinct from 
sporadic cases. Most BRCA1-associated tumours are infiltrating ductal carcinomas 
(Narod and Foulkes, 2004). Medullary breast carcinomas are more common among 
BRCA1-mutation carriers compared to controls. In addition, carriers of BRCA1 
mutations show low rates of carcinoma in situ (Breast Cancer Linkage Consortium, 
1997). Over-representation of the “triple-negative” phenotype [(negative for 
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estrogen-receptor, progesterone-receptor and epidermal growth factor receptor 2 
(HER2)] is another feature of  BRCA1-associated tumours (Lakhani et al., 2002). In 
contrast, the histopathology of BRCA2 mutation carriers is more heterogeneous and 
similar to non-carriers (Breast Cancer Linkage Consortium, 1997). In the present 
study, infiltrating ductal carcinoma was the predominant tumour type in both 
BRCA1/2 mutation carriers and non-carriers. It is noted that two of the infiltrating 
ductal carcinomas were comedo type and were diagnosed in women with truncating 
BRCA1/2 mutations. 
 
Previous population-specific studies revealed that the contribution of BRCA1 and 
BRCA2 mutations to the incidence of early-onset breast cancer ranges between 5% 
and 10% (Langston et al., 1996; Peto et al., 1999; Malone et al., 2000; Anglian 
Breast Cancer Study Group, 2000; Hamann et al., 2003). In contrast, the findings of 
the present study show that 23% (6 of 26) of Cypriot early-onset breast cancer cases 
are associated with a germline mutation in either the BRCA1 or the BRCA2 genes. 
This figure of 23% is higher than most studies but compares favourably with data 
from two other ethnic populations, for which a higher proportion of BRCA-
associated early-onset breast cancers has been reported. Data show that the 
prevalence rates can be as high as 30% for Ashkenazi Jews (Abeliovich et al., 1997) 
and around 25% for Icelanders (Johannesdottir et al., 1996; Thorlacius et al., 1997). 
This high percentage is a result of the presence of founder mutations in these ethnic 
populations. More specifically, three ancestral mutations [BRCA1 c.68_69delAG 
(185delAG), c.5266insC (5382insC) and BRCA2 c.5946delT (6174delT)] appear in 
about 2% of Ashkenazi Jews (Struewing et al., 1997), while about 0.5% of 
Icelanders carry the c.771delTCAAA (999del5) mutation in the BRCA2 gene 
(Johannesdottir et al., 1996; Thorlacius et al., 1997). The high prevalence rates of 
BRCA1 and BRCA2 mutations in the Cypriot cohort of patients may also be 
explained by the presence of the Cypriot founder mutation c.8755delG (8984delG) 
in the BRCA2 gene (Hadjisavvas et al., 2004). Although the effect of this founder 
mutation is not as striking as the case of the Icelanders or Ashkenazi Jews, the 
results show that it makes a substantial contribution to the incidence of early-onset 
breast cancer in the Cypriot population. In addition, it is likely that the contribution 
of these genes to early-onset breast cancer might be even higher given that certain 
unclassified variants might also be causative. 
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In the group of patients studied, the highest proportion of mutations was reported in 
the BRCA2 gene, 15% (4 of 26 positive) vs. 7.7% (2 of 26 positive), in the BRCA1 
gene. Evidently, BRCA2 accounts for a considerably larger proportion of early-onset 
breast cancer in Cyprus than does BRCA1. This is in agreement with previous data 
on familial breast/ovarian cancer studies in Cypriot families (Hadjisavvas et al., 
2001; Hadjisavvas et al., 2004). It appears that in most other populations studied, 
mutations in the two genes make approximately equal contributions to early-onset 
breast cancer (Langston et al., 1996; Peto et al., 1999; Anglian Breast Cancer Study 
Group, 2000; Hamann et al., 2003) with the exception of Iceland where BRCA2 
accounts for most of the early-onset breast cancer cases, and the Ashkenazi Jews 
where BRCA1 accounts for the majority of cases. 
 
In the majority of western world countries, single cases of breast cancer are not 
generally accepted for genetic testing for hereditary breast cancer genes. Given the 
current constraints on health care resources, BRCA1 and BRCA2 screening in these 
countries is limited to women with a strong family history of breast cancer. 
International guidelines have as a prerequisite for breast cancer genetic screening 
before the age of 50, the presence of at least one first-degree relative diagnosed with 
breast cancer under the age of 40 (Blamey, 1998; Eccles et al., 2000) or 50 (Hoskins 
et al., 1995). Hereditary breast ovarian cancer syndrome is characterized by an 
autosomal dominant pattern of inheritance and as a result of this, half of BRCA gene 
mutation carriers are expected to be men. Sometimes, it is very difficult to recognize 
this inheritance pattern, due to the very low penetrance (<6%) of BRCA-associated 
breast cancer in men, especially in families with limited numbers of women old 
enough to develop breast and ovarian cancer. This is also the case for small families, 
families which lack paternal aunts or families with premature mortality (Weitzel et 
al., 2007).  
 
Overall, the current study data indicate that BRCA screening policies based on 
family history would miss a substantial proportion of early onset mutation carriers in 
Cyprus. BRCA1/2 pathogenic mutations were detected in 4 of 15 patients with a 
family history, as well as in 2 of 11 patients without a family history. These findings 
support a strong correlation between the early onset breast cancer phenotype and 
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BRCA1/2 gene analysis, since the prevalence of BRCA1/2 mutations in young 
Cypriot patients is relatively high.  
 
Although no definitive recommendations can be made from this study regarding 
genetic testing of Cypriot women with early onset breast cancer, it is clear that the 
prevalence of BRCA1/2 mutations in this population of young women is high. The 
analysis of early-onset breast cancer in the Cypriot population suggests that young 
age of diagnosis alone, could be a sufficient predictor of finding a pathogenic 
BRCA1/2 mutation. Based on these results, it is recommended that BRCA1/2 
screening should be offered to Cypriot patients, with a diagnosis of early-onset 
breast cancer irrespective of their family history. 
 
3.4 Publications resulting from work described in this Chapter 
 
 Loizidou, M., Marcou, Y., Anastasiadou, V., Newbold, R., Hadjisavvas, A., 
and Kyriacou, K. (2007). Contribution of BRCA1 and BRCA2 germline 
mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 
71, 165-170. 
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Chapter 4 
Case-control study of DNA repair genes 
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4.1 Materials and Methods  
4.1.1 Study population 
To investigate the associations between genetic factors and breast cancer risk in the 
Cypriot population, we conducted a population-based case-control study, with the 
acronym MASTOS (Greek word for breast). The study population for this PhD 
project were women participating in the MASTOS study. Blood samples were 
collected between 2004-2006 from 1109 female breast cancer patients diagnosed 
between 40-70 years old and 1177 aged-matched healthy controls. Cases 
participating in the study were women who were previously diagnosed with breast 
cancer between January 1999 and December 2006. The majority of cases were 
ascertained from the Bank of Cyprus Oncology Centre, which operates as a referral 
centre and offers treatment and follow-up for 80-90% of all breast cancer cases 
diagnosed in Cyprus. The rest of the patients, were recruited at the Oncology 
Departments of the Nicosia, Limassol, Larnaca and Paphos district hospitals. The 
control group consisted of healthy women who were participating in the National 
program for breast cancer screening with the use of mammography. Volunteers were 
enrolled in the study during the same calendar period as the cases, from the 4-district 
mammography screening centres that operate in Cyprus. Eligible controls were 
women with no previous history of breast cancer who had a negative mammography 
result. All study participants, both cases and controls, were of Greek Cypriot 
Caucasian origin, thus reducing any potential bias due to population stratification. In 
addition, the study population was representative of the whole island population and 
thus consisted of women who resided in all five districts of the country, minimizing 
potential selection bias. The participation rate of cases and controls was very high 
covering around 98% of eligible cases and controls. In addition to blood samples, a 
risk factor questionnaire, which included extensive demographic, epidemiological 
and pathological data, was obtained from each participant through a standardized 
interview. Breast cancer cases were verified by reviewing histological reports. The 
study was reviewed and approved by the National Bioethics Committee of Cyprus. 
All participants provided written informed consent. 
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4.1.2 Gene and SNP selection 
The study concentrated on genes that are important components of the DNA repair 
pathway. One of the most extensively studied group of genes in relation to breast 
cancer risk, are the XRCC (X-Ray Cross-Complementing) genes. These genes were 
initially discovered through their role in DNA damage response caused by ionizing 
radiation. XRCC genes are important components of various DNA repair pathways 
contributing to DNA-damage processing and genetic stability (Thacker and 
Zdzienicka, 2004). In summary, XRCC1 gene is an important component of the BER 
pathway acting as a scaffold for other BER enzymes (Caldecott, 2003). XRCC2 and 
XRCC3 genes are necessary for HR repair and are required for RAD51 focus 
formation (Bishop et al., 1998; O'Regan et al., 2001). 
 
This section of the thesis had two primary aims as explained below. The first aim of 
this study, was to test the hypothesis that common variants in the XRCC genes 
modify susceptibility to breast cancer. The investigation focused on evaluating five 
potentially functional SNPs in the XRCC1, XRCC2 and XRCC3 genes. The five 
SNPs that were studied are: XRCC1 R194W (rs1799782), XRCC1 R280H (rs25489), 
XRCC1 R399Q (rs25487), XRCC2 R188H (rs3218536) and XRCC3 T241M 
(rs861539).  
 
The second and primarily aim of this study was to investigate the association 
between SNPs in genes that interact with BRCA1 and BRCA2 and breast cancer risk 
in the Cypriot population. Genetic variation in 72 SNPs in 35 genes (see Table 5 for 
a list of DNA repair genes in which SNP(s) were studied), which interact with 
BRCA1 and/or BRCA2 genes and their association with breast cancer, was assessed 
in a case-control study of Cypriot women. Furthermore, the role of 2 additional 
SNPs in the PBOV1 (UROC28) and DBC2 genes which are both upregulated in 
breast cancer was assessed (An et al., 2000; Hamaguchi et al., 2002).  
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Table 5:: Details of the genes studied and their DNA repair activity (Wood et al., 
2005) 
 
 
 
 
Gene Activity 
Base Excision Repair (BER)  
XRCC1 Ligase accessory factor 
OGG1 8-oxoG opposite C 
Mismatch excision repair (MMR)  
MLH1 MutL homologs, forming heterodimer 
MSH2 Mismatch and loop recognition 
MSH6 Mismatch and loop recognition 
Nucleotide excision repair (NER)  
DDB2 Complex defective in XP group E 
ERCC2 5' to 3' DNA helicase 
XPC Binds damaged DNA as complex 
Homologous recombination (HR)  
BRCA2 Cooperation with RAD51, essential function 
MRE11A 3' exonuclease 
DMC1 Rad51 homolog, meiosis 
EME1 Structure-specific DNA nuclease 
MUS81 Structure-specific DNA nuclease 
NBS1 Mutated in Nijmegen breakage syndrome 
RAD50 ATPase in complex with MRE11A, NBS1 
RAD51 Homologous pairing 
XRCC2 DNA break and crosslink repair 
XRCC3 DNA break and crosslink repair 
DNA polymerases (catalytic subunits)  
PCNA Sliding clamp for pol δ and pol ε 
Genes defective in diseases associated with sensitivity to DNA damaging agents 
ATM ataxia telangiectasia  
BLM Bloom syndrome helicase 
BRIP1 BRCA1-associated DNA helicase 
FANCA Involved in tolerance or repair of DNA crosslinks 
FANCC Involved in tolerance or repair of DNA crosslinks 
FANCD2 Involved in tolerance or repair of DNA crosslinks 
FANCE Involved in tolerance or repair of DNA crosslinks 
PALB2 Involved in tolerance or repair of DNA crosslinks 
Other conserved DNA damage response genes  
ATR ATM- and PI-3K-like essential kinase 
CHEK1 Effector kinase 
CHEK2 Effector kinase 
TP53 Regulation of the cell cycle 
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The genetic variants were selected based on three main criteria: (1): all SNPs chosen 
belong to genes which interact with either BRCA1 and/or BRCA2; (2) the SNPs 
chosen are either functional SNPs (based on potential protein changes, evolutionary 
conservation and location in putative functional regions (Nakken et al., 2007; Rudd 
et al., 2005; Savas et al., 2004) or (3) SNPs which were reported by other groups to 
modify cancer risk (Barroso et al., 2006; Beiner et al., 2006; Gaudet et al., 2008; 
Johnson et al., 2007; Justenhoven et al., 2004; Kilpivaara et al., 2004; Landi et al., 
2006; Lu et al., 2007; Poplawski et al., 2005; Rahman et al., 2006; Sigurdson et al., 
2004; Webb et al., 2005). For MRE11A and RAD50, the tagging SNPs in (Allen-
Brady and Camp, 2005) were genotyped and for NBS1, the tagging SNPs in Lu et al. 
(2006) were genotyped. SNPs in the PBOV1 and DBC2 genes were selected based 
on their minor allele frequency (MAF) >0.05.  
 
In total, a panel of 79 SNPs, which are summarized in Table 6, were genotyped and 
analyzed in the Cypriot case-control population. 
 
4.1.3 Preparation of total genomic DNA 
Blood samples were collected from all 2286 study participants in 10 ml EDTA 
tubes. Genomic DNA was isolated from peripheral-blood lymphocytes using the 
phenol chloroform method (as described in section 3.1.3).  
 
4.1.4 SNP genotyping   
SNPs were genotyped using one of the following three methods:  
1) PCR followed by restriction fragment length polymorphism (RFLP) analysis, with 
genotypes being determined by agarose gel electrophoresis 
2) real-time PCR with Taqman SNP genotyping assays and allelic discrimination 
using an ABI PRISM 7900HT instrument (Applied Biosystems) and  
3) SNP genotyping using the Sequenom MassARRAY iPLEX Gold assays and 
matrix assisted laser desorption / ionization-Time-of-Flight mass spectrometry 
(MALDI-TOF MS) for detection (Sequenom). 
 
At the start of this study, the Department of Electron Microscopy/ Molecular 
Pathology of the Cyprus Institute of Neurology and Genetics was not equipped with 
a high-throughput genotyping technology. Consequently, the only SNP genotyping 
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method which could be used, based on available equipment, was PCR-RFLP 
analysis. PCR-RFLP is a poor choice for high throughput analysis since it is a 
relatively slow and expensive genotyping method. Not a long time after the 
commencement of this study, the Department purchased a real time PCR instrument. 
Taqman SNP genotyping is a PCR-based method which is relatively easy to 
implement and provides high-confidence results. It does not require post-PCR 
processing and can be used for high throughput genotyping (Syvanen, 2001). Hence, 
based on the clear advantages of Taqman SNP genotyping over PCR-RFLP 
genotyping, in terms of higher-throughput and lower cost, it was decided to 
genotype the rest of the SNPs under investigation, using this technology. SNP 
genotyping technology is progressing rapidly and novel, faster and cheaper methods 
are emerging. In order to keep up with the latest developments, the Cyprus Institute 
of Neurology and Genetics purchased a Sequenom MassArray MALDI-TOF MS 
system. This methodology is one of the cheapest and most error free technologies for 
high throughput SNP typing. It uses samples arrayed in 384 well plates and allows 
multiplexing with simultaneous genotyping of up to 40 SNPs (Sequenom). The 
accuracy of this method, combined with the high data acquisition speed and the 
capability of multiplexing led to the abandonment of Taqman technology and the 
application of Sequenom MassARRAY iPLEX Gold assays for genotyping the rest 
of the SNPs under investigation. 
 
 
 
 
 
 
Table 6: Details of the single nucleotide polymorphisms investigated 
Gene rs number Base  change 
Amino acid  
change 
Genotyping  
method Gene rs number 
Base  
change 
Amino acid 
change 
Genotyping 
method 
ATF1 rs2230674 G>C P191A iPLEX FANCE rs9462088 G>A A502T iPLEX 
ATM rs1800057 C>G P1054R iPLEX MLH1 rs1799977 A>G I219V TAQMAN 
 rs2234997 T>A D126E iPLEX  rs1800149 C>G L729V iPLEX 
 rs2235000 G>A G514D iPLEX  rs2020872 A>G I32V iPLEX 
 rs3218688 C>T L942F iPLEX  rs2308317 G>A V213M iPLEX 
 rs3218695 C>A D814E iPLEX  rs1800734 G>A - iPLEX 
 rs3218708 C>T T935M iPLEX MRE11A rs1009456 G>T - iPLEX 
 rs4987945 C>G L546V iPLEX  rs10831234 C>T - iPLEX 
ATR rs2227928 T>C T211M iPLEX  rs556477 G>A - iPLEX 
 rs2229032 A>G R2425Q iPLEX  rs601341 G>A - TAQMAN 
BARD1 rs2070094 G>A V507M iPLEX MSH2 rs2059520 A>G - TAQMAN 
 rs2229571 G>C R378S iPLEX  rs2303428 T>C - iPLEX 
 rs3738888 C>T R658C iPLEX MSH6 rs1042821 C>T G39E iPLEX 
 rs1048108 C>T P24S TAQMAN  rs1800935 T>C D180D iPLEX 
BLM rs11852361 C>T P868L iPLEX MUS81 rs545500 C>G P180R iPLEX 
 rs7167216 G>A I1321V iPLEX NBS1 rs1805787 C>G - iPLEX 
BRCA2 rs1799944 A>G N991D TAQMAN  rs1805794 C>G E185Q iPLEX 
BRIP1 rs4986764 T>C S919P iPLEX  rs6413508 C>T P672L iPLEX 
CHEK1 rs506504 T>C I471V iPLEX  rs769416 G>T Q216K iPLEX 
CHEK2 rs17879961 T>C I157T iPLEX  rs769420 G>A P266L iPLEX 
DBC2 rs2241261 C>T - iPLEX  rs12677527 C>T - iPLEX 
DDB2 rs830083 G>C - iPLEX  rs13312840 T>C - iPLEX 
DMC1 rs2227914 A>G M200V iPLEX OGG1 rs1052134 C>G S326C TAQMAN 
EME1 rs12450550 T>C I350T iPLEX PALB2 rs45494092 T>C L337S iPLEX 
ERCC2 rs13181 A>C K751Q TAQMAN  rs45532440 G>C E672Q iPLEX 
FANCA rs1800282 T>A V6D iPLEX  rs45478192 T>G L939W iPLEX 
 rs2239359 C>T G501S TAQMAN  rs45551636 G>A G998E iPLEX 
 rs7190823 T>C T266A iPLEX PBOV1 rs6927706 A>G I73Y iPLEX 
 rs9282681 A>G T1328A iPLEX PCNA rs3626 G>C - iPLEX 
FANCC rs1800364 A>T D195V iPLEX RAD50 rs2299015 A>C - iPLEX 
FANCD2 rs2272125 A>C L1366L iPLEX  rs2522406 G>A - iPLEX 
 101
 102
Gene rs number Base  change 
Amino acid  
change 
Genotyping  
method Gene rs number 
Base  
change 
Amino acid 
change 
Genotyping 
method 
RAD50 rs2706377 A>G - iPLEX TP53 rs1042522 G>C P72R TAQMAN 
 rs3187395 G>A E925K iPLEX XPC rs2228000 C>T A499V iPLEX 
RAD51 rs1801320 G>C - TAQMAN  rs2227999 G>A R492H iPLEX 
 rs1801321 G>T - TAQMAN XRCC1 rs1799782 C>T R194W RFLP 
RAD51C rs28363317 A>G T287A iPLEX  rs25487 G>A R399Q RFLP 
RAD51L1 rs28908468 C>G P365R iPLEX  rs25489 G>A R280H RFLP 
RAD52 rs7487683 C>T G180R TAQMAN XRCC2 rs3218536 G>A R188H RFLP 
RFC1 rs2066791 A>G I598V iPLEX XRCC3 rs861539 C>T T241M RFLP 
          
 
 
4.1.5 Polymerase chain reaction (PCR) 
Briefly for screening of the 5 XRCC gene SNPs, preparation of the PCR included 30 
ng of genomic DNA in total volume of 25 μl with 0.25 mM of each appropriate 
primer, in the presence of Tris-Cl, KCl, (NH4)2SO4, 15 mM MgCl2; at pH 8.7 
(Qiagen 10X PCR buffer), 0.25 mM of dATP, dCTP, dGTP, dTTP (Invitrogen) and 
1 unit of Taq DNA polymerase (Qiagen). Amplification was carried out on an 
Applied Biosystems 9700 thermocycler. Details of the primers as well as the PCR 
conditions for each SNP can be found in table 7. All PCR reactions were carried out 
in 96-well plates. Control samples were included in each plate, representing the 3 
possible genotypes (wild type, heterozygous, homozygous mutant). Each plate also 
contained a negative (no template) control.  
 
4.1.6 Restriction enzyme DNA digestion 
On completion of the amplifications, enzyme digestions were carried out to 
determine genotypes of the 5 XRCC gene SNPs investigated. Restriction enzymes 
(New England Biolabs) were diluted with their appropriate dilutent buffers (as 
recommended by the manufacturer), down to 1 unit/μl. One unit of the appropriate 
enzyme was added directly to the plates with the PCR products.  Reactions were 
incubated for at least 2 hours at the optimal temperature for each specific enzyme 
activity to ensure complete digestion. Details of the restriction enzymes used as well 
as the digestion conditions can be found in Table 8. Table 9 provides details of the 
sizes of the expected digest products for each SNP analyzed. 
 
4.1.7 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed as described by Sambrook et al. (1989), 
in a 1x TBE buffer. 2% gels were prepared with the addition of 0.5 mg ethidium 
bromide. 5 μl of loading dye (Sambrook et al, 1989) were added to the reactions 
which were subsequently loaded onto agarose gels. Gels electrophoresis was carried 
out at 1-10 volts/cm of gel for 30 min. Following gel electrophoresis, DNA was 
visualized under short wavelength UV light and a digitalized photograph was taken 
for reference. The different genotypes were recorded by observing RFLP patterns 
and comparing each sample with the 3 controls. Overall success rate for the 
genotyping assays was 99%. For quality control, random samples were genotyped in 
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duplicate and had identical genotyping assignments. Direct sequencing was also 
used to confirm these calls.   
Table 7: XRCC SNPs screened, primer sequences used, annealing temperatures and references where they were obtained  
 
Gene / 
SNP 
Nucleotide 
change Primer F (5’-3’) Primer R (5’-3’) 
PCR 
fragment 
size 
Annealing 
Temperature 
(oC) 
Primer 
Reference 
XRCC1 
rs1799782 C/T GCCCCGTCCCAGGTA AGCCCCAAGACCCTTTCACT 491 58 Hu et al., 2001 
XRCC1  
rs25489 G/A GTCTGAGGGAGGAGGGTCTG CAGAGGAGCTGGGGAAGATC 240 65 
Loizidou et 
al., 2008 * 
XRCC1  
rs25487 A/G TCTCCCTTGGTCTCCAACCT AGTAGTCTGCTGGCTCTGG 403 60 Hu et al., 2001 
XRCC2  
rs3218536 G/A CACCCATCTCTCTGCCTTT CCTCTCGACGACTGTGTGAT 237 55 
Loizidou et 
al., 2008 * 
XRCC3  
rs861539 C/T GGTCGAGTGACAGTCCAAAC TGCAACGGCTGAGGGTCTT 456 55 Hu et al., 2001 
* Primers were designed in the department of EM / Molecular Pathology of the Cyprus Institute of Neurology and Genetics  
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Table 8: Details of the restriction enzymes used, their restriction sites as well as the 
digestion conditions 
Gene / SNP Enzyme Restriction site 
XRCC1 rs1799782 Pvu II 5'…CAG▼CTG…3' 
    3'…CTC▲GAC…5' 
   
XRCC1 rs25489 RsaI 5'…GT▼AC…3' 
    3'...CA▲TG…5' 
   
XRCC1 rs25487 Msp I 5'…C▼CGG…3' 
    3'…GGC▲C…5' 
   
XRCC2 rs3218536 SexAI 5'…A▼CCWGGT…3' 
    3'…TGGWCC▲A…5' 
   
XRCC3 rs861539 Nla III 5'…CATG▼…3' 
    3'…▲GTAC…5' 
 
 
 
Table 9: Expected sizes of PCR digest products  
Gene / SNP Restriction Fragments 
  Wild type (NN) Heterozygous (NM) Homozygous (MM) 
XRCC1 rs1799782  491 491,197,294 197,294 
XRCC1 rs25489  123,117 240,123,117 240 
XRCC1 rs25487 403 403,270,133 270,133 
XRCC2 rs3218536 237 237,146,91 146,91 
XRCC3 rs861539 456 456,246,210 246,210 
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4.1.8 Taqman SNP genotyping assays 
The 12 SNPs: BARD1 rs1048108 (Pro24Ser), BRCA2 rs1799944 (Asn991Asp), 
ERCC2 rs13181 (Lys751Gln), FANCA rs2239359 (Gly501Ser), MLH1 rs1799977 
(Ile219Val), MRE11A rs601341, MSH2 rs2059520, OGG1 rs1052134 (Ser326Cys), 
RAD51 rs1801320 and rs1801321 (135G>C-5’ UTR and 172 G>T-5’UTR), RAD52 
rs11226 (2259 C>T-3’UTR) and TP53 rs1042522 (Pro72Arg) were genotyped in all 
subjects participating in the study using Taqman SNP genotyping assays from 
Applied Biosystems. All SNPs studied had a minor allele frequency of over 0.05. 
For genotyping SNP rs1801320 the primers and probes described previously by 
Kuschel et al. (2002) were used.  
 
The TaqMan SNP Genotyping Assays are single tube PCR assays that were 
developed by Applied Biosystems. The assays include two PCR primers which are 
designed against a conserved region of the genome flanking the SNP of interest and 
two TaqMan probes designed across the locus of interest, one for each allele (refer to 
Figure 16). Each probe is labelled with a different fluorescent reporter dye at the 5’ 
end (usually VIC dye is linked to the 5’ end of allele X probe and FAM dye to the 5’ 
end of allele Y probe). Each probe also has a non-fluorescent quencher and a minor 
groove binder (MGB) at its 3’ end. MGB offers stability to the double-stranded 
probe template structure and increases the probe Tm without increasing its length. 
Hence, it allows the design of shorter probes resulting in greater differences in 
melting temperature values between matched and mismatched probes. This produces 
greater accuracy in allelic discrimination. The quencher and the fluorophore dye are 
in close proximity to each other, and this provides efficient quenching of an intact 
probe (De la Vega et al., 2005). Taqman SNP analysis utilizes the 5' exonuclease 
activity of DNA Taq polymerase and the quenching effects of specific fluorescent 
dyes to determine the relative frequency of each allele within an individual genome. 
During thermocycling, each Taqman MGB probe anneals to the locus of interest in 
an allele specific manner. As Taq DNA polymerase extends the primers, it also 
degrades the annealed probe, releasing the fluorescent dye that is not longer 
quenched and thus become detectable. The use of two probes, one specific to each 
allele of the SNP, which are labelled with two different fluorophores, allows 
detection of both alleles in a single tube. Following PCR, the fluorescent signal is 
read for each reporter dye, in each well of the reaction plate. Genotype calls for each 
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sample are made by plotting the normalized intensity of the reporter dyes in each 
well on a cluster plot (Figure 17). The analysis software uses a clustering algorithm 
and each sample (well) is allocated to one of three possible genotype clusters (De la 
Vega et al., 2005).  
 
Each assay was carried out using 10 ng genomic DNA in a 5μL reaction using 
Taqman Universal PCR Master Mix (Applied Biosystems), forward and reverse 
primers, and FAM and VIC-labelled probes purchased from Applied Biosystems 
(ABI Pre-Designed assays). All assays were carried out in 384-well plates.  The 
fluorescence profile was determined on an ABI PRISM 7900HT instrument and the 
results analyzed with Sequence Detection Software (Applied Biosystems). All the 
appropriate quality control measures were taken in order to ensure reliable 
genotyping and to avoid false positive or false negative results due to genotyping 
errors. In detail, duplicates of 48 DNA samples and water controls were genotyped 
and had identical genotyping assignments.  In addition, the placement order of DNA 
samples on the 384-well plates was randomized to ensure the same study conditions 
for samples from cases and controls. Genotype call rates ranged from 99% to 100% 
and duplicate concordance rates were higher than 99%.  
 
 
Figure 16: (A) Probe binding and primer extension in a Taqman SNP Genotyping 
Assay. (B) Allelic discrimination is achieved by the selective annealing of matching 
probe and template sequences, which generates an allele specific fluorescent signal. 
Figure taken from De la Vega et al. (2005). 
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Figure 17: Representative example of a Taqman allelic discrimination plot showing 
3 clusters of samples (wild type, heterozygous, homozygous mutant)
4.1.9 MassARRAY iPLEX Gold assay  
The remaining 62 SNPs were genotyped using MassARRAY iPLEX Gold 
technology (Sequenom).  This technology combines the benefits of allele-specific 
single-base primer extension biochemistry and the sensitivity and accuracy of 
MALDI-TOF MS detection (Figure 18).  
 
Briefly, this technology involves amplifying a region containing the SNP of interest 
by PCR, followed by extension of an oligonucleotide probe over the SNP site in this 
PCR product, with a mixture of deoxynucleotides and dideoxynucleotides, to 
generate allele-specific DNA products. Extended PCR products are subsequently 
separated and analyzed using chip-based MALDI-TOF MS. The time-of-flight is 
proportional to mass, permitting precise determination of the size of products 
generated, which can be converted into genotype information. Because the mass 
resolution of this method is very high, one can routinely perform multiplexed assays 
to permit analysis of up to 40 SNPs in one PCR reaction/tube. The entire process 
permits complete automation including assay development, PCR setup, post-PCR 
treatment, nanoliter transfer of products onto silicon chips, serial reading of chip 
positions in the mass spectrometer, and final analytical interpretation. This approach 
is very reliable since allele calling, depends on mass, and spurious associations due 
to genotyping errors are far less likely, compared to other commonly used 
genotyping methods (van den Boom and Ehrich, 2007). 
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 Figure 18: Schematic representation of amplification, SAP digestion, primer 
extension and analyte detection using iPLEX chemistry and MALDI-TOF MS 
(taken from Medigenomix website: http://www.medigenomix.de/en/) 
 
 111
 112
Sixty-two SNPs in ATF1, ATM, ATR, BARD1, BLM, BRIP1, CHEK1, CHEK2, 
DDB2, DMC1, EME1, FANCA, FANCC, FANCD2, FANCE, MLH1, MRE11A, 
MSH2, MSH6, MUS81, NBS1, PALB2, PCNA, RFC1, RAD50, RAD51C, RAD51L1, 
RAD52 and XPC genes were genotyped using this method. Assay design was based 
on published sequences retrieved from the National Center of Biotechnology 
Information (NCBI) databases. A 34-plex and a 28-plex multiplex assay (table 10) 
were designed using the Sequenom MassARRAY Assay Design software (version 
3.0).  SNPs were genotyped using Sequenom iPLEX chemistry on a MALDI-TOF 
Compact Mass Spectrometer (Sequenom). 
 
Briefly, PCR reactions were carried out in a final volume of 5 μl in standard 384-
well plates. PCR was performed with 5 ng of genomic DNA, 1 unit of HotStarTaq 
DNA polymerase (Qiagen), 500 μmol of each dNTP and 100 nmol of each PCR 
primer. PCR thermal cycling was carried out in an ABI-9700 instrument (Applied 
Biosystems) for 15 min at 94°C, followed by 44 cycles of 20 s at 94°C, 30 s at 56°C 
and 60 s at 72°C. Next, PCR products were treated with 0.5 units of shrimp alkaline 
phosphatase for 40 minutes at 37oC to dephosphorylate unincorporated dNTPs, 
followed by enzyme inactivation for 5 min at 85oC. After adjusting the 
concentrations of the extension primers to equilibrate signal-to-noise ratios, the post-
PCR primer extension reaction of the iPLEX gold assay was performed in a final 10 
μl volume extension reaction containing 0.2 μl of termination mix, 0.0041 μl of 
iPLEX enzyme (Sequenom) and 700–1400 nM of extension primers. A two-step 200 
short cycles program was used for the iPLEX reaction: initial denaturation was for 
30 s at 94°C followed by five cycles of 5 s at 52°C and 5 s at 80°C. An additional 40 
annealing and extension cycles were then looped back to 5 s at 94°C, 5 s at 52°C and 
5 s at 80°C. Final extension was carried out at 72°C for 3 min. The iPLEX reaction 
products were desalted by diluting samples with 16 μl of water and adding 6 mg of 
clean resin. Following a quick centrifugation (3200 g for 5 minutes), reaction 
products were spotted on a 384-format SpectroChip (Sequenom). SpectroCHIPs 
were processed in a MassARRAY Compact Analyzer (Bruker Daltonics) by 
MassARRAY Workstation (version 3.3) software (Sequenom). Acquisition data 
were analysed using MassARRAY TYPER 3.4 software (Sequenom). Genotypes 
were differentiated on the basis on the mass of each allele (Figures 19 and 20).
Table 10: PCR and extension primers for the 34- and the 28-plex assays designed for SNP genotyping  
SNP  Forward Primer (5’-3’) Reverse Primer (5’-3’) Extension Primer (5’-3’) Assay  
rs2308317  ACGTTGGATGTCGACATACCGACTAACAGC ACGTTGGATGGTTAGGACACTACCCAATGC CCCAATGCCTCAACC 34 plex 
rs1800935  ACGTTGGATGACAAACTGCCAATTCAAGCC ACGTTGGATGATACTGAGAGCAATGCAACG AATGCAACGTGCAGA 34 plex 
rs7487683  ACGTTGGATGTCCTGTACTCTCTCTTCTCC ACGTTGGATGTGTCTGTGCACTCGCAGTAG GAGTGGGAAGGCCTC 34 plex 
rs28908468  ACGTTGGATGTGGGTATGGTGGCACATCTG ACGTTGGATGACTGAACTGGGCTCCAGAAA GCTCCAGAAATCCTCC 34 plex 
rs2227999  ACGTTGGATGTCCAAGAGTGCCTCCAGGAC ACGTTGGATGTGAAGAGCTTGAGGATGCCG GCAAGCTTGGGTCCTTA 34 plex 
rs2303428  ACGTTGGATGTATTAGTAGCAGAAAGAAG ACGTTGGATGGTTGATTTACCTCCCATATTG gCATATTGGGGCCTACA 34 plex 
rs45551636 ACGTTGGATGTGGGACCCTTTCTGATCAAC ACGTTGGATGAAAATCAATCAATGCTTTTC CAATGCTTTTCTTACCCT 34 plex 
rs1042821  ACGTTGGATGAGCCTCGCTCCAGGCCGCAT ACGTTGGATGTCACGCGAAGGCGGCCGT acGCCGCCGCTGCCCCCG 34 plex 
rs506504  ACGTTGGATGCCTGAAGATTAAAGGGAAGC ACGTTGGATGATGGTCCGATCATGTGGCAG ATGTGGCAGGAAGCCAAA 34 plex 
rs2070094  ACGTTGGATGCTCACCACTTCACGATGCAG ACGTTGGATGCATTTCTGGAGGCTCCATAG AACAGCTTGACTATATCCA 34 plex 
rs2020872  ACGTTGGATGACTCCCTCCGTACCAGTTCT ACGTTGGATGAAGTTATCCAGCGGCCAGC tcatCGGCCAGCTAATGCT 34 plex 
rs1805787  ACGTTGGATGTACTCTGTGCATGTATGTTG ACGTTGGATGTTCAGCCAGATGGCAGACTC tGCAGACTCGAGAATAGAA 34 plex 
rs7167216  ACGTTGGATGAAGAAGTGCCGCTGAGGAG ACGTTGGATGTTTACTTGCAAAGTAGTGGG GCAAAGTAGTGGGAAGATA 34 plex 
rs1800282  ACGTTGGATGCCTGGGTCCTGGCCCGAG ACGTTGGATGTGTAGGCGCCAAGGCCATGT ggggATGTCCGACTCGTGGG 34 plex 
rs7190823  ACGTTGGATGTTACCAAGATGGTAACTCAC ACGTTGGATGTCAGCATTCTCTGCAGTACA ctctaTGCAGTACATCAACCG 34 plex 
rs12450550  ACGTTGGATGAAGGGAAGGAAACGCTTCAG ACGTTGGATGACAATCACCAGTGACAGAGC ggaaCTGCTGTCTTTGCTGTG 34 plex 
rs6413508  ACGTTGGATGTTAGTTGACCATAATCATC ACGTTGGATGGACTGAATTTAGATCACTGG cAAAACTCTACTTCCAGAAATC 34 plex 
rs2272125  ACGTTGGATGAGAGTGAGCATAGCTTTGAC ACGTTGGATGACTCACCCAACATGTGCCTC ggagCAAAAAGACCCTGGAACT 34 plex 
rs3218688  ACGTTGGATGCTTCATTTAACGTAACTCACC ACGTTGGATGGATTCTAGCACGCTAGAACC tCACGCTAGAACCTACCAAATCC 34 plex 
rs2229571  ACGTTGGATGCGTAAAGTTGGTGGTACATC ACGTTGGATGTGGTGTACCTGGTGAAAGAC gCATCGGACATGTTACTGTTTTT 34 plex 
rs45494092  ACGTTGGATGTCTCTGTTTGATTTTGTTC ACGTTGGATGGTTCTCTAAATGAACTCACC tcccTGAACTCACCTACAATAACT 34 plex 
rs556477  ACGTTGGATGGTCATTGAATAGTTCACGCC ACGTTGGATGGATGAACTGACATAATGTGTG ggggTGTGTGAGAAAGTCACTGA 34 plex 
rs3218695  ACGTTGGATGTAGCAAAACAGGAAGCATAC ACGTTGGATGGCGATTGTTAACATCAAAGC tTTAACATCAAAGCTAATGAATGA 34 plex 
rs28363317  ACGTTGGATGCCACCTAATGCAGGAACAAG ACGTTGGATGTTGTAGGTAATTTTAACCAA gAGGTAATTTTAACCAATCAGATG 34 plex 
rs2522406  ACGTTGGATGATGACCCAAAGTAGCATAAG ACGTTGGATGGGGTACTTCATGCTAAGACC cctcCTTCATGCTAAGACCAGAGAC 34 plex 
rs1009456  ACGTTGGATGAATCTGGAGCTCCAGATGTG ACGTTGGATGTGAAAATAGCCAGGTTTGGG gggcAGAGTGGCTGCCACCGCGAGA 34 plex 
rs1800057  ACGTTGGATGTTACAGGAAAGTCTTTTCCC ACGTTGGATGCCACAGTTCTTTTCCCGTAG cacatTTCTTTTCCCGTAGGCTGATC 34 plex 
rs3626  ACGTTGGATGGTTTTCTGTAAATAACCTAT ACGTTGGATGGACCAGATCTGACTTTGGAC TTGGACTTTATTCTTTAAACAAATTG 34 plex 
rs4987945  ACGTTGGATGCCTGCAGTATGCTGTTTGAC ACGTTGGATGGCTCTATTCCCATTTTTACCG ggggCCTGGAACTATACTGGTGGTCA 34 plex 
rs9462088  ACGTTGGATGACCACCTCCATGGCCTATG ACGTTGGATGCCAAGGCCCTATCAATACTC ggAAGGCCCTATCAATACTCACGTTAG 34 plex 
rs1800734 ACGTTGGATGATCAATAGCTGCCGCTGAAG ACGTTGGATGAGTGCCTCGTGCTCACGTTC acatTGCCTCGTGCTCACGTTCTTCCTT 34 plex 
rs11852361  ACGTTGGATGCTAGGCAATCAAATGCCACC ACGTTGGATGTAGCATGAGCTTTAACAGAC cGACATAATCTGAAATACTATGTATTAC 34 plex 
rs13312840 ACGTTGGATGCCATGATCTGATAAAGGAC ACGTTGGATGGATGTCATGGGGAAATGTTC aaacgTTACCTTAAGTATAACGTAAACT 34 plex 
rs2227928  ACGTTGGATGGCAGTTGATGAGTATGCAAA ACGTTGGATGCACAATTGCAATAATACGAG gaaAATTGCAATAATACGAGTAAGAACC 34 plex 
rs1805794  ACGTTGGATGGGACGTCCAATTGTAAAGCC ACGTTGGATGTCAATTTGTGGAGGCTGCTT GCTGCTTCTTGGACT 28 plex 
rs2228000  ACGTTGGATGAGCCATCGTAAGGACCCAAG ACGTTGGATGTCGCTGCACATTTTCTTGCC GAGCTTGAGGATGCC 28 plex 
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SNP  Forward Primer (5’-3’) Reverse Primer (5’-3’) Extension Primer (5’-3’) Assay  
rs1800364  ACGTTGGATGACAGATGAGGAGAGCCTCCA ACGTTGGATGCGTCCCTGTCACGAGTTTGT ACGAGTTTGTGTCCCA 28 plex 
rs545500  ACGTTGGATGTTCTGATCCACAGGTAGCCC ACGTTGGATGGAGGACCAGGTTCCTGTGAA aAGGGCTGGCCAGGGT 28 plex 
rs1800149  ACGTTGGATGAGGTTAGCAAGCTGCAGGAT ACGTTGGATGGTCTATAAAGCCTTGCGCTC CCTTGCGCTCACACATT 28 plex 
rs830083  ACGTTGGATGCAACGTGACAAAACCCCATC ACGTTGGATGTCAGCCTCCCAAGTGCGTG CATGCCCAGCTAATTTTT 28 plex 
rs2299015  ACGTTGGATGAGAGGAATCCACAAATAGGG ACGTTGGATGCTGAATCCCCACACTATTCC gcttGCGTGGACACTCTGC 28 plex 
rs2230674  ACGTTGGATGTTGTCTGAGAGGTGAGAGTC ACGTTGGATGGATCCGAACTACACCTTCAG ccCCTTCAGCTACTTCTCTG 28 plex 
rs769420  ACGTTGGATGGCTAGGTTGATAACAGAAGAG ACGTTGGATGTTCCTGTATCAACAACACAC tataAACAACACACGTTCCC 28 plex 
rs6927706  ACGTTGGATGGTCAAAAGGCAACAGAGTTC ACGTTGGATGTGTGTCTGCAAGGGTGTGAG ggtCATGGTGTGACTGTTCT 28 plex 
rs3738888  ACGTTGGATGGTGAACAGGAAGAAAAGTATG ACGTTGGATGACCAGCTGTTCTCTGTTGAG ctccGTTGAGCCTGCTTCTGC 28 plex 
rs2234997  ACGTTGGATGGCTAAAATGTCAAGAACTC ACGTTGGATGATCAGCTCCGTAAATAGCAC ATTAGATGAATCTTTCACTGT 28 plex 
rs3218708  ACGTTGGATGTTAGGGCAGCTGATATTCGG ACGTTGGATGCAGGTGGAGGGATTTGGTAG atGGATTTGGTAGGTTCTAGC 28 plex 
rs45478192 ACGTTGGATGGCCTGATGTGTATAATCTCG ACGTTGGATGCCTTGGGAATTACATACCTG ccaTCTGATTTCCAAATTTCCC 28 plex 
rs2066791  ACGTTGGATGGTAGGAGTTTGTTGGCACAG ACGTTGGATGAATATAAGCCAACCTCGCTC ctaatCCAACCTCGCTCAAGACC 28 plex 
rs2229032  ACGTTGGATGAGGATGCCTGGGCAGGAGA ACGTTGGATGGCCAGTGTATGCTACCAAAG ccCTGAAAAACTCAAAGTATTCC 28 plex 
rs17879961  ACGTTGGATGCAAAGGTTCCATTGCCACTG ACGTTGGATGAGGAAGTGGGTCCTAAAAAC AGTGGGTCCTAAAAACTCTTACA 28 plex 
rs10831234  ACGTTGGATGAACCTCTGCCACAAAGCATC ACGTTGGATGCGTGACAACAGGATCTTGAG aGCTTTAGTTTATGTTGTGATCT 28 plex 
rs2241261  ACGTTGGATGTAACCTCTGGTCATTAGGTC ACGTTGGATGTCCAGGAAAACGCTGGTTAG gaAGCTAACCTGAAACAAAGGTAG 28 plex 
rs2227914  ACGTTGGATGTGCCAGCTTCTTCATGGAAC ACGTTGGATGACTGCATTTCCCATCAGGTG cccTTTCCCATCAGGTGAACATCAG 28 plex 
rs769416  ACGTTGGATGGATGAACCATCTATTGGAAG ACGTTGGATGGTTTTCCCTTTGAAGATTTG aCTTTGAAGATTTGTTTTCTTTCCT 28 plex 
rs45532440 ACGTTGGATGACTGAGTCCTAAACGCATGG ACGTTGGATGGGATGTGATTTTCCTGGTAG gcgGGTAGAACAATAAGGTCCTCTT 28 plex 
rs2235000  ACGTTGGATGTGGCTTACTTGGAGCCATAA ACGTTGGATGAGGCTGACCCAGTAAATAAC ccctTCTGTCAACCTCAACTAAACTA 28 plex 
rs2706377  ACGTTGGATGTTTATCCTATTAAACTTTGC ACGTTGGATGGCTCTTATCATTTATTTTTT TTTAAATCTAAACTTATAAACCATTTC 28 plex 
rs3187395  ACGTTGGATGCCCTTTGGAAACAACATTGG ACGTTGGATGCCTGTGCTATTTTGTTGCTTG gTTTTTTGTTGATTAATTCTTCTTTTT 28 plex 
rs9282681  ACGTTGGATGGTAAAAAGCGAAAGGCAGCA ACGTTGGATGTGTTGCAGACCTCAGGCTGG ggggTCCGTGTGGCCCCGGATCAGCAC 28 plex 
rs12677527 ACGTTGGATGGCTAATATTGTGCTTAGGAG ACGTTGGATGAAAAAGGCTGGTTTACCAA gggagAAAGGCTGGTTTACCAATCTCTT 28 plex 
rs4986764  ACGTTGGATGAGTCTACACTTGAAGTGACC ACGTTGGATGTCTGGTGATAGATGACTTGC ggaagTGCTGCTTCCAGTAAATAAGGTG 28 plex 
 
 
 
 
For quality control, 48 random samples were genotyped in duplicate. Furthermore, 
ten samples were sequenced to confirm genotype calls from the MALDI-TOF 
platform. The genotype concordance rate between platforms was 99%. The order of 
the DNA samples on 384-well plates was randomized in order to ensure the same 
study conditions for samples from cases and controls. Genotyping call rates ranged 
from 95% to 99% and duplicate concordance rates were higher than 99%. The SNP 
that had 20% missing data was excluded from further analysis. 
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Figure 19: Examples of a 28-plex (top) and a 34-plex (bottom) reaction . The 
positions of all probes and possible analyte peaks are labelled. Mass is in daltons 
(Da). 
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 Figure 20: Typical raw data output from the multiplex MassARRAY spectrometry 
iPLEX assay (rs1805794). Graphs on the left show clusters of all samples on the 
chip, with non-template controls at the bottom left (in red). The sample spectrum is 
shown on the right, with the unextended primer marked on the left with the dotted 
red line, and the three potential products marked right with dotted yellow lines. A 
homozygote wild type is shown in (a), while the heterozygote rs1805794 is shown in 
(b) and the homozygote mutant in (c). 
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4.1.10 Statistical Analysis 
Statistical analysis was performed using SNPStats, a web-based application designed 
for analysis of association studies. SNPStats has a user-friendly interface and utilizes 
PHP (Personal Home Page) server programming language for building input forms, 
uploading data, calling the statistical analysis procedures and processing the output. 
Statistical analyses are performed using the R genetics package (R Development 
Core Team, 2005, http://www.R-project.org) as well as the haplo.stats package 
(http://mayoresearch. mayo.edu/mayo/research/biostat/schaid.cfm) (Sole et al., 
2006). 
 
The validity of genetic association studies depends considerably on the use of 
appropriate controls. In theory, a control sample from a homogeneous randomly 
mating population should follow Hardy–Weinberg equilibrium (HWE). HWE for a 
locus depends on a number of assumptions about the tested population. Conformity 
with HWE suggests that these assumptions are met including, for example, absence 
of recent mutations, no selective survivorship among genotypes, conformance with 
Mendelian segregation and random mating. Testing for HWE is used primarily as a 
data quality check. Departures from HWE, may point to genotyping error or other 
biases. Loci which deviate from HWE among controls are usually discarded 
(Khoury et al., 1993). All SNPs that were genotyped in this study, were assessed for 
conformance with HWE in the control samples, by applying an exact test.  
 
The effect of each SNP on breast cancer risk, was assessed by applying a number of 
statistical tests. The primary tests of association were the univariate analyses 
between each SNP and breast cancer. Genotype frequencies in cases and controls 
were compared using the Χ2 test. The association between breast cancer and each 
SNP was examined using logistic regression with the SNP genotype tested, under 
models of complete dominance and recessive inheritance, as well as under the log-
additive model. Associations between the different genotypes and the risk of breast 
cancer were estimated by computing odds ratios (ORs) and their 95% confidence 
intervals (CIs) from logistic regression analyses with and without adjustment for age 
(under or over 55 years), menopause status (pre- or post-menopausal), family history 
of breast cancer (first degree relative with breast cancer) and use of hormone 
replacement therapy. The significance level was set at P<0.05. 
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Associations between breast cancer and common haplotypes of the ATM, MRE11A, 
NBS1 and XRCC1 genes were also investigated using SNPStats, which allows the 
estimation of maximum likelihood estimates of haplotype frequencies using the 
Expectation-Maximization (EM) algorithm. Logistic regression was performed to 
test the association between haplotypes and breast cancer risk. Haplotypes with a 
frequency of less than 1% were not considered further for analysis since they are 
likely to be a result of rare recombination events. 
 
4.2 Results 
4.2.1 Association analysis of SNPs and breast cancer 
The characteristics of the cases and controls enrolled in this study are summarized in 
Table 11. The mean ± SD age of cases and controls were 51.6±9.2 and 56.4±9.2 
years respectively with a median age of 56 years for both groups. There were no 
statistically significant differences, between cases and controls in terms of level of 
education and marital status. It is noted that the numbers of cases and controls were 
also representative of the geographical distribution of the Cypriot population. 
 
As shown in Table 11, there was a substantial, statistically significant difference in 
the frequency of cases and controls reporting a first-degree relative with breast 
cancer. Women who had a first degree relative with breast cancer were at a higher 
risk for breast cancer (OR=1.64, 95% CI 1.26 to 2.12), compared to women without 
a family history of the disease.  
 
Breast cancer risk was significantly greater in obese women (BMI >30) (OR 1.29, 
95% CI 1.03 to 1.60) when compared with women with a BMI<25 respectively.    
 
A statistically significant trend with age at menarche and breast cancer risk was 
observed. Women who started menstruating earlier than the age of 11 had ~50% 
increased risk for breast cancer, compared to women who started menstruating after 
the age of 15 years (OR=1.56, 95% CI 1.14 to2.13). Furthermore women with an age 
of menarche between 12-14 years were also at an increased risk for breast cancer 
compared to women who started menstruating after the age of 15 years (OR 1.27, 
95% [CI] 1.01-1.6). 
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Some associations of reproductive factors with breast cancer were observed in the 
study sample. In detail, cases were more likely than controls to have never been 
pregnant. This difference is statistically significant (OR 0.69, 95% [CI] 0.50-0.96). 
Furthermore, women with three or more children and women who had breastfed for 
more than 1 year had significantly reduced ORs compared with women who had 
never had a child and never breastfed respectively (Table 11). There were no notable 
case-control differences in the age at first pregnancy. 
 
Equal percentages of cases (25.32%) and controls (25.13%) had ever used birth 
control pills. However, significantly more controls than cases had ever taken HRT 
and were at a reduced risk for breast cancer (OR =0.45, 95% CI= 0.37-0.55). 
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Table 11: Demographic and risk factor characteristics in the Cypriot population 
Number  Variables 
Cases Controls  
OR (95% CI) P 
Age (years)     
 Mean ± SD 51.6±9.2 56.4±9.2   
     Median 56 56   
Education     
 Primary School 419 463 1.00 (ref.)  
 High School 412 434 1.05 (0.87-1.3) 0.62 
 College or other post HS 131 147 0.98 (0.75-1.29) 0.91 
 Bachelor’s 135 122 1.22 (0.93-1.62) 0.16 
Marital status     
 Married 924 1012 1.00 (ref.)  
 Widowed / divorced 130 117 1.22 (0.93-1.59) 0.15 
 Never married 57 42 1.49 (0.99-2.24) 0.06 
Family history of breast cancer      
 No 952 1068 1.00 (ref.)  
 Yes 156 107 1.64 (1.26-2.12) 0.0001 
Age at menarche (years)     
 ≤11 157 134 1.56 (1.14-2.13) 0.005 
 12-14 798 838 1.27 (1.01-1.6) 0.043 
 15 or more 154 205 1.00 (ref.)  
Pregnancy     
 No 88 66 1.00 (ref.)  
 Yes 1023 1110 0.69 (0.50-0.96) 0.028 
Number of children     
 None 103 88 1.00 (ref.)  
 One 90 82 0.94 (0.62-1.42) 0.76 
 Two 480 492 0.83 (0.61-1.14) 0.25 
 Three or more 436 515 0.72 (0.53-0.99) 0.04 
Age at 1st pregnancy     
 Before 30 877 991 1.00 (ref.)  
 Over 30 119 103 1.30 (0.99-1.73) 0.06 
Breast feeding     
 Never 393 346 1.00 (ref.)  
 6 months or less 331 381 0.76 (0.62-0.94) 0.01 
 7-12 months 166 181 0.81 (0.63-1.04) 0.10 
 More than 1 year 222 267 0.73 (0.58-0.92) 0.0075 
Oral contraceptive use     
 No 826 876 1.00 (ref.)  
 Yes 280 294 1.01 (0.87-1.16) 0.92 
HRT use     
 No 926 815 1.00 (ref.)  
 Yes 174 341 0.45 (0.37-0.55) <0.00001 
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A total of 79 SNPs were studied in relation to breast cancer risk in the Cypriot 
population. Of these 79 SNPs, 78 were genotyped successfully whereas one had 
more than 20% missing data and was excluded from further analysis.  
 
Table 12 summarizes the distribution of genotypes in cases and controls, as well as 
the allele frequencies, for the 79 SNPs, of which the 78 were successfully 
genotyped. Seven SNPs (rs1800149, rs1801320, rs2706377, rs1800282, rs7487683, 
rs3626, rs28908468) deviated significantly from HWE in controls (p<0.01) and were 
excluded from further analysis. SNPs which deviated slightly from HWE, 
(0.01<HWE p<0.05) were tested for association with breast cancer risk despite not 
conforming to the HWE condition. The deviations observed are likely to be chance 
results rather than genotyping errors, since the homozygotes for these SNPs are very 
rare in the Cypriot population. It is notable that the frequencies of these SNPs are 
similar to those reported by the HapMap Project. These small deviations may also be 
due to hidden population structures that specifically affect the genes of interest. Of 
the remaining 71 SNPs, 8 were monomorphic in both groups.  
 
Significant differences in genotype frequencies between breast cancer patients and 
controls were observed in 8 of the 71 SNPs analyzed. The associations of SNPs and 
breast cancer risk in Cypriot women are shown in Table 13.  Eight of the 71 SNPs 
were associated at a p value of less than 0.05. Three SNPs were protective for breast 
cancer while the remaining five, were associated with an increased risk for the 
disease.  
 
The NBS1 gene SNPs rs13312840 and rs769416 and the MRE11A SNP rs556477 
were associated with a reduced risk for breast cancer. In detail, the variant allele of 
NBS1 rs13312840 (924 T>C) was associated with a reduced risk of disease (OR TT 
vs. TC/CC = 0.58; 95% CI, 0.37 to 0.92; p = 0.019). Carriers of the NBS1 rs769416 
rare allele also had a reduced risk of breast cancer (OR GG vs. GT/TT = 0.23, 95% 
CI 0.06–0.85, P = 0.017). Furthermore, the variant allele of MRE11A rs556477 was 
associated with a reduced risk of developing the disease (OR AA vs. AG/GG = 0.76; 
95% CI, 0.64 to 0.91; p = 0.0022).  
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The variant alleles of MUS81 rs545500, PBOV1 rs6927706, XRCC1 rs25489, 
BRCA2 rs1799944 and MRE11A rs601381 were associated with an increased risk of 
breast cancer. In detail, the variant allele of MUS81 rs545500 was associated with an 
increased risk of developing breast cancer (OR GG vs. GC/CC= 1.21, 95% CI, 1.02 
to 1.45; p = 0.031). In addition, the rare allele of PBOV1 rs6927706 was also 
associated with an increased risk of developing breast cancer (OR AA vs. AG/GG = 
1.53, 95% CI, 1.07 to 2.18; p = 0.019). The rare allele of XRCC1 rs25489 was 
associated with an increased risk for breast cancer. Homozygous carriers of XRCC1 
A allele were found to have an increased risk of breast cancer (OR AA vs. GG/GA = 
4.41, 95% CI 0.93–20.99, P = 0.035). Significant associations with breast cancer risk 
were also found for the variant alleles of BRCA2 rs1799944 and MRE11A rs601341. 
Carriers of BRCA2 rs1799944 G allele were found to have an increased risk of breast 
cancer (OR AA vs. AG/GG = 1.58, 95% CI 1.19–2.09, P = 0.0013) with Ptrend = 
0.0012. Homozygous carriers of the MRE11A rs601341 A allele had an increased 
risk of breast cancer (OR AA/GA vs. GG = 1.39, 95% CI 1.09–1.77, P = 0.0081) 
with Ptrend = 0.027.  
 
No significant associations with breast cancer were observed for the other 55 SNPs 
studied. 
Table 12: Genotype frequencies in cases and controls for the 79 SNPs studied 
Gene   Controls Cases  MAF   HWE 
  rs number   AA Aa aa Total   AA Aa aa Total   Controls Cases Controls 
ATF1 rs2230674  1071 86 2 1159  1021 81 1 1103  0.04 0.04 0.69 
ATM rs1800057  1087 85 2 1174  1015 85 0 1100  0.04 0.04 0.68 
 rs2234997  1153 4 1 1158  1093 10 0 1103  0 0 0.01 
 rs2235000  1160 1 0 1161  1102 2 0 1104  0 0 1 
 rs3218688  979 2 0 981  926 0 0 926  0 0 1 
 rs3218695  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
 rs3218708  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
 rs4987945  1169 1 0 1170  1100 1 0 1101  0 0 1 
ATR rs2227928  401 520 229 1150  344 517 218 1079  0.43 0.44 0.011 
 rs2229032  899 242 17 1158  833 253 16 1102  0.12 0.13 0.89 
BARD1 rs1048108  514 520 138 1172  515 445 138 1098  0.33 0.34 0.7 
 rs2070094  466 551 156 1173  461 485 159 1105  0.37 0.36 0.75 
 rs2229571  341 580 249 1170  316 540 241 1097  0.46 0.47 0.95 
 rs3738888  1150 7 0 1157  1099 4 0 1103  0 0 1 
BLM rs11852361  1123 46 2 1171  1046 52 2 1100  0.02 0.03 0.094 
 rs7167216  1127 44 2 1173  1055 47 2 1104  0.02 0.02 0.081 
BRCA2 rs1799944  1058 108 4 1170  945 133 8 1086  0.05 0.07 0.52 
BRIP1 rs4986764  475 534 161 1170  465 502 141 1108  0.37 0.35 0.57 
CHEK1 rs506504  1064 105 5 1174  986 116 2 1104  0.05 0.05 0.19 
CHEK2 rs17879961  1158 0 0 1158  1101 1 0 1102  0 0 1 
DBC2 rs2241261  342 560 252 1154  288 546 264 1098  0.46 0.49 0.26 
DDB2 rs830083  871 271 15 1157  803 277 21 1101  0.13 0.14 0.3 
DMC1 rs2227914  1146 3 0 1149  1099 1 1 1101  0 0 1 
EME1 rs12450550  918 221 24 1163  838 239 23 1100  0.12 0.13 0.021 
ERCC2 rs13181  383 585 208 1176  331 603 171 1105  0.43 0.43 0.59 
FANCA rs1800282  978 149 19 1146  883 189 16 1088  0.08 0.1 <0.0001 
 rs2239359  433 543 186 1162  387 524 190 1101  0.39 0.41 0.46 
 rs7190823  573 476 113 1162  541 462 98 1101  0.3 0.3 0.33 
 rs9282681  1096 51 0 1147  1065 42 2 1109  0.02 0.02 1 
FANCC rs1800364  1159 1 0 1160  1104 1 0 1105  0 0 1 
FANCD2 rs2272125  787 346 38 1171  710 346 43 1099  0.18 0.2 1 
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Gene   Controls Cases  MAF   HWE 
  rs number   AA Aa aa Total   AA Aa aa Total   Controls Cases Controls 
FANCE rs9462088  1051 115 4 1170  990 106 4 1100  0.05 0.05 0.56 
MLH1 rs1800149  1156 0 1 1157  1101 0 2 1103  0 0 0.00043 
 rs2020872  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
 rs2308317  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
 rs1800734  494 496 137 1127  446 505 136 1087  0.34 0.36 0.47 
 rs1799977  568 497 110 1175  543 449 98 1090  0.31 0.3 0.95 
MRE11A rs1009456  1040 105 0 1145  992 89 5 1086  0.05 0.05 0.17 
 rs10831234  949 190 12 1151  899 193 6 1098  0.09 0.09 0.48 
 rs556477  444 550 167 1161  494 473 130 1097  0.38 0.33 0.9 
 rs601341  452 566 156 1174  385 530 190 1105  0.37 0.41 0.32 
MSH2 rs205920  562 489 119 1170  512 471 108 1091  0.31 0.31 0.41 
 rs2303428  929 217 18 1164  870 211 16 1097  0.11 0.11 0.22 
MSH6 rs1042821  653 451 64 1168  646 388 70 1104  0.25 0.24 0.24 
 rs1800935  655 428 90 1173  608 413 83 1104  0.26 0.26 0.094 
MUS81 rs545500  673 430 55 1158  589 435 77 1101  0.23 0.27 0.22 
NBS1 rs1805787  548 483 104 1135  549 447 103 1099  0.3 0.3 0.94 
 rs1805794  543 502 109 1154  511 497 96 1104  0.31 0.31 0.68 
 rs6413508  1167 6 1 1174  1097 4 0 1101  0 0 0.012 
 rs769416  1141 10 0 1151  1098 3 0 1101  0 0 1 
 rs769420  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
 rs12677527  546 505 115 1166  512 497 96 1105  0.32 0.31 0.95 
 rs13312840  1096 55 0 1151  1063 32 1 1096  0.02 0.02 1 
OGG1 rs1052134  647 455 72 1174  615 422 71 1108  0.26 0.25 0.54 
PALB2 L337S  1170 1 0 1171  1097 4 0 1101  0 0 1 
 E672Q  1035 120 4 1159  972 126 4 1102  0.06 0.06 0.77 
 L939W  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
 G998E  1076 92 2 1170  1010 92 2 1104  0.04 0.04 1 
PBOV1 rs6927706  1083 63 1 1147  1017 83 2 1102  0.03 0.04 0.61 
PCNA rs3626  827 242 36 1105  838 196 34 1068  0.14 0.12 0.0012 
RAD50 rs2299015  742 370 45 1157  743 323 37 1103  0.2 0.18 1 
 rs2522406  1064 41 1 1106  1044 31 0 1075  0.02 0.01 0.34 
 rs2706377  1052 66 21 1139  1046 37 14 1097  0.05 0.03 <0.0001 
 rs3187395  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
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Gene   Controls Cases  MAF   HWE 
  rs number   AA Aa aa Total   AA Aa aa Total   Controls Cases Controls 
RAD51 rs1801320  952 216 0 1168  915 193 0 1108  0.09 0.09 <0.0001 
 rs1801321  400 530 236 1166  340 522 236 1098  0.43 0.45 0.014 
RAD51C rs28363317  1164 6 0 1170  1095 6 0 1101  0 0 1 
RAD51L1 rs28908468  572 201 0 773  979 75 0 1054  0.13 0.04 <0.0001 
RAD52 rs11226  568 494 108 1170  561 448 92 1101  0.3 0.29 1 
 rs7487683  1135 35 3 1173  1072 33 0 1105  0.02 0.01 0.0043 
RFC1 rs2066791  1177 0 0 1177  1109 0 0 1109  0 0 Monomorphic 
TP53 rs1042522  638 438 97 1173  555 463 85 1103  0.27 0.29 0.088 
XRCC1 rs1799782  973 182 9 1164  914 175 8 1097  0.09 0.09 0.88 
 rs25487  520 516 140 1176  506 479 122 1107  0.34 0.33 0.49 
 rs25489  959 207 2 1168  923 177 9 1109  0.09 0.09 0.01 
XRCC2 rs3218536  999 177 1 1177  972 135 1 1108  0.08 0.06 0.02 
XRCC3 rs861539  351 600 226 1177  312 560 220 1092  0.45 0.46 0.32 
XPC rs2228000  673 402 64 1139  653 379 65 1097  0.23 0.23 0.68 
 rs2227999  1040 128 4 1172  963 138 4 1105  0.06 0.07 1 
AA, common homozygote; Aa, heterozygote; aa, rare homozygote.  
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Table 13: Genotypic specific risk (OR and 95% CI) 
Gene Rs number Dominant OR (95%CI)a ;  p valuea Recessive OR (95%CI)a ; p valuea Log-additive OR (95%CI)a ; p valuea 
ATF1 rs2230674 1.02 (0.74-1.42); 0.89 0.60 (0.05-7.34); 0.68 1.01 (0.73-1.40); 0.94 
ATM rs1800057 1.10 (0.79-1.52); 0.57 - 1.07 (0.78-1.47); 0.69 
 rs2234997 2.31 (0.75-7.12); 0.13 - 1.83 (0.68-4.91); 0.23 
 rs4987945 1.27 (0.07-21.89); 0.87 - - 
ATR rs2227928 1.14 (0.95-1.38); 0.15 1.04 (0.84-1.30); 0.71 1.07 (0.95-1.21); 0.25 
 rs2229032 1.09 (0.89-1.34); 0.42 1.01 (0.48-2.15); 0.97 1.07 (0.89-1.30); 0.45 
BARD1 rs1048108 0.92 (0.78-1.10); 0.37 1.07 (0.82-1.40); 0.6 0.97 (0.86-1.11); 0.68 
 rs2070094 0.98 (0.82-1.17); 0.8 1.07 (0.83-1.37); 0.6 1.01 (0.89-1.14); 0.93 
 rs2229571 0.99 (0.82-1.20); 0.93 0.96 (0.78-1.18);0.69 0.98 (0.87-1.11); 0.77 
 rs3738888 0.46 (0.13-1.66); 0.23 - - 
BLM rs11852361 1.28 (0.85-1.95); 0.24 0.95 (0.13-7.12); 0.96 1.25 (0.84-1.85); 0.27 
 rs7167216 1.26 (0.82-1.94); 0.3 0.95 (0.13-7.14); 0.96 1.22 (0.81-1.84); 0.34 
BRCA2 rs1799944 1.57 (1.19-2.07); 0.015 1.95 (0.56-6.76); 0.28 1.53 (1.17-1.99); 0.014 
BRIP1 rs4986764 0.94 (0.79-1.12);0.49 0.96 (0.75-1.25);0.78 0.96 (0.85-1.09); 0.53 
CHEK1 rs506504 1.19 (0.89-1.59); 0.24 0.48 (0.09-2.59); 0.37 1.15 (0.87-1.51); 0.34 
DBC2 rs2241261 1.18 (0.97-1.43); 0.095 1.16 (0.94-1.43); 0.17 1.12 (0.99-1.27); 0.061 
DDB2 rs830083 1.14(0.93-1.39);0.2 1.51 (0.74-3.07);0.25 1.14 (0.95-1.37); 0.15 
DMC1 rs2227914 0.63 (0.09-4.39);0.64 - 1.10 (0.25-4.73); 0.9 
EME1 rs12450550 1.15 (0.94-1.42); 0.18 0.94 (0.52-1.72); 0.85 1.11 (0.92-1.33); 0.27 
ERCC2 rs13181 1.08 (0.89-1.30); 0.43 0.80 (0.63-1.00); 0.054 0.97 (0.85-1.10); 0.61 
FANCA rs7190823 1.02 (0.86-1.22); 0.8 0.91 (0.68-1.23); 0.56 1.00 (0.87-1.14); 0.95 
 rs9282681 0.84 (0.54-1.30);0.44 - 0.89 (0.58-1.35); 0.57 
 rs2239359 1.13 (0.94-1.35); 0.2 1.05 (0.83-1.33); 0.67 1.07 (0.95-1.22); 0.26 
FANCC rs1800364 1.25 (0.07-21.55); 0.88 - - 
FANCD2 rs2272125 1.12 (0.93-1.34); 0.24 1.08 (0.68-1.72); 0.74 1.09 (0.93-1.28); 0.27 
FANCE rs9462088 0.95 (0.71-1.26); 0.71 0.73 (0.15-3.53); 0.7 0.94 (0.71-1.24); 0.67 
MLH1 rs1799977 0.97 (0.81-1.15); 0.73 1.02 (0.76-1.38); 0.88 0.99 (0.86-1.13); 0.81 
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Gene Rs number Dominant OR (95%CI)a ;  p valuea Recessive OR (95%CI)a ; p valuea Log-additive OR (95%CI)a ; p valuea 
 rs1800734 1.09 (0.91-1.31); 0.33 1.01 (0.77-1.31); 0.96 1.05 (0.92-1.20); 0.46 
MRE11A rs1009456 0.93 (0.68-1.26);0.63 - 0.98 (0.73-1.32); 0.9 
 rs10831234 1.04 (0.83-1.31);0.72 0.69 (0.25-1.93);0.47 1.02 (0.82-1.26); 0.85 
 rs556477 0.76 (0.64-0.91); 0.0022 0.81 (0.62-1.05); 0.11 0.82 (0.72-0.93); 0.0027 
 rs601341 1.12 (0.93-1.34); 0.23 1.38 (1.08-1.76); 0.0089 1.15 (1.02-1.31); 0.027 
MSH2 rs2059520 0.98 (0.82-1.17); 0.83 0.93 (0.70-1.25); 0.64 0.98 (0.85-1.11); 0.71 
 rs2303428 1.02 (0.82-1.26); 0.89 0.93 (0.45-1.89); 0.83 1.01 (0.83-1.22); 0.94 
MSH6 rs1042821 0.85 (0.71-1.01); 0.066 1.23 (0.84-1.79); 0.29 0.92 (0.80-1.07); 0.27 
 rs1800935 1.09 (0.91-1.30); 0.34 1.07 (0.77-1.48); 0.69 1.07 (0.93-1.22); 0.36 
MUS81 rs545500 1.21 (1.02-1.45); 0.031 1.43(0.98-2.08);0.06 1.21(1.04-1.39); 0.012 
NBS1 rs1805787 0.92 (0.77-1.10); 0.36 0.97 (0.72-1.31); 0.84 0.95 (0.83-1.08); 0.43 
 rs1805794 1.08 (0.91-1.28); 0.4 0.93 (0.69-1.26);0.65 1.03 (0.90-1.18); 0.65 
 rs6413508 0.46 (0.13-1.66); 0.23 - 0.46 (0.14-1.50); 0.18 
 rs769416 0.23 (0.06-0.85); 0.017 - - 
 rs12677527 1.04 (0.88-1.24); 0.64 0.88 (0.65-1.19); 0.4 1.00 (0.87-1.14); 0.98 
 rs13312840 0.58 (0.37-0.92); 0.019 - 0.61 (0.39-0.95); 0.028 
OGG1 rs1052134 0.98 (0.82-1.17); 0.82 1.15 (0.80-1.64); 0.45 1.01 (0.88-1.16); 0.91 
PALB2 L337S 3.75 (0.40-35.04); 0.2 - - 
 E672Q 1.06 (0.81-1.40); 0.66 0.73 (0.18-3.04);0.67 1.05 (0.80-1.36); 0.74 
 G998E 1.04 (0.76-1.43); 0.8 0.67 (0.09-4.89); 0.69 1.03 (0.76-1.4); 0.85 
PBOV1 rs6927706 1.53 (1.07-2.18); 0.019 1.63(0.12-21.60);0.71 1.51(1.06-2.13); 0.02 
RAD50 rs2299015 0.89 (0.74-1.07); 0.21 0.90 (0.56-1.43); 0.65 0.91 (0.77-1.06); 0.22 
 rs2522406 0.80 (0.49-1.31); 0.37 - 0.78 (0.48-1.26); 0.31 
 rs3187395 0.32 (0.06-1.85); 0.19 - - 
RAD51 rs1801320 0.91 (0.73-1.14); 0.41 - - 
 rs1801321 1.12 (0.93-1.35); 0.22 1.04 (0.84-1.29); 0.69 1.07 (0.94-1.20); 0.31 
RAD51C rs28363317 0.93 (0.28-3.10); 0.91 - - 
RAD52 rs11226 0.88 (0.74-1.05); 0.16 0.91 (0.67-1.24); 0.54 0.91 (0.80-1.04); 0.18 
TP53 rs1042522 1.10 (0.93-1.31); 0.27 0.85 (0.62-1.16); 0.3 1.03 (0.90-1.18); 0.67 
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Gene Rs number Dominant OR (95%CI)a ;  p valuea Recessive OR (95%CI)a ; p valuea Log-additive OR (95%CI)a ; p valuea 
XRCC1 rs1799782 1.05 (0.83-1.33); 0.66 1.03 (0.38-2.78); 0.95 1.05 (0.84-1.31); 0.67 
 rs25487 0.97 (0.82-1.16); 0.77 0.91 (0.69-1.19); 0.49 0.96 (0.85-1.21); 0.58 
 rs25489 0.97 (0.77-1.22); 0.78 4.41 (0.93-20.99); 0.035 1.01 (0.81-1.26); 0.92 
XRCC2 rs3218536 0.79 (0.61-1.02); 0.069 0.44 (0.02-8.00); 0.58 0.79 (0.61-1.01); 0.064 
XRCC3 rs861539 1.05 (0.87-1.35); 0.59 1.08 (0.87-1.35); 0.48 1.05 (0.93-1.19); 0.45 
XPC rs2228000 1.01 (0.84-1.21); 0.91 0.96 (0.66-1.40); 0.85 1.00 (0.87-1.16); 0.99 
 rs2227999 1.12 (0.86-1.46); 0.42 1.10 (0.26-4.64); 0.42 1.11 (0.86-1.43); 0.43 
 
Data in bold highlight the statically significant results; BRCA2 rs1799944 dominant model (AA vs AG/GG ), MRE11A rs556477 dominant model (AA vs AG/GG), rs601341 recessive model 
(GG/GA vs AA), MUS81 rs545500 dominant model (GG vs CG/CC), NBS1 rs769416 dominant model (GG vs GT), NBS1 rs13312840 dominant model (TT vs TC/CC), PBOV1 rs6927706 
dominant model (AA vs AG/GG) and XRCC1 rs25489 recessive model (GG/GA vs AA) 
a Adjusted for age, menopause status, family history of breast cancer and use of hormone replacement therapy (HRT) 
 
 
 
 
 
 
 
 
 
4.2.2 Haplotype analyses 
Data analysis suggests that the NBS1 haplotype GGCGCAC (rs769416, rs769420, 
rs13312840, rs1805794, rs6413508, rs12677527, rs1805787), which contains the 
NBS1 rs13312840 C allele, is associated with a reduced breast cancer risk compared 
with the most frequent haplotype GGTCCGC (OR=0.62; 95% CI= 0.39 to 0.97).  
This haplotype was found more frequently among controls (2.25%) than cases 
(1.47%) in Cypriot women (p=0.037). A reduced risk for breast cancer was also 
associated with a rare haplotype in the NBS1 gene (OR=0.42; 95% CI= 0.26 to 0.66; 
p=2 x 10-4). In addition, the MRE11A haplotype AGCG (rs556477, rs601341, 
rs10831234, rs1009456) is associated with a significantly increased risk for breast 
cancer (OR=1.32; 95% CI= 1.13 to 1.54; p=0.0004). This haplotype was found more 
frequently among cases (27.52%) than controls (23.84%) in Cypriot women 
(p=0.037). None of the common ATM and XRCC1 haplotypes were associated with 
breast cancer (Table 14).  
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Table 14: Estimated haplotype frequencies in cases and controls and haplotypic 
specific risks 
Gene Haplotype Control freq Case freq OR [95%CI] 2 p-value Global test p-value 
ATMa CCCCCTGC 0.92 0.9225 reference  0.53 
 GCCCCTGC 0.0367 0.0349 0.96 (0.69-1.32) 0.8  
 CCCCGTGC 0.0376 0.0329 0.89 (0.34-1.23) 0.48  
 Rare 0.0057 0.0097 1.6 (0.72-3.57) 0.25  
MRE11Ab GACG 0.3702 0.326 reference  0.021 
 AGCG 0.2384 0.2752 1.32 (1.13-1.54) 4 x 10-4  
 AACG 0.2478 0.255 1.17 (1.00-1.36) 0.044  
 AGTG 0.0864 0.0891 1.16 (0.93-1.45) 0.19  
 AGCT 0.0444 0.0438 1.12 (0.84-1.51) 0.44  
 Rare 0.0128 0.0109 0.98 (0.52-1.85) 0.95  
NBS1c GGTCCGC 0.3705 0.3886 reference  0.00019 
 GGTCCGG 0.2955 0.2925 0.94 (0.82-1.09) 0.44  
 GGTGCAC 0.2786 0.2905 0.99 (0.86-1.15) 0.92  
 GGCGCAC 0.0225 0.0147 0.62 (0.39-0.97) 0.037  
 Rare 0.0329 0.0137 0.42 (0.26-0.66) 2 x 10-4  
XRCC1d CGA 0.5021 0.493 reference  0.83 
 CGG 0.3249 0.3308 0.95 (0.83-1.09) 0.48  
 CAA 0.0818 0.0839 0.97 (0.76-1.23) 0.78  
 TGA 0.0804 0.0846 0.98 (0.77-1.24) 0.84  
 Rare 0.0108 0.0077 1.57 (0.66-3.73) 0.31  
 
Data in bold highlight the statically significant results 
a ATM haplotypes are arranged in the order of  rs1800057, rs3218688, rs3218695, rs4987945, rs2230674, 
rs2234997, rs2235000, rs3218708 
b MRE11A haplotypes are arranged in the order of rs556477, rs601341, rs10831234, rs1009456 
c NBS1 haplotypes are arranged in the order of rs769416, rs769420, rs13312840, rs1805794, rs6413508, 
rs12677527, rs1805787 
d XRCC1 haplotypes are arranged in the order of rs1799782, rs25489, rs2548 
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4.3 Discussion 
Breast cancer is a complex disease, with multiple genetic and environmental factors 
involved in its aetiology. The polygenic model of breast cancer suggests that a 
proportion of the disease can be explained by multiple loci across the genome which 
contribute to susceptibility. This model has been proposed as the most likely 
explanation for the bulk of the genetic component of breast cancer (Antoniou et al., 
2002; Pharoah et al., 2002).  
 
DNA repair is essential for maintaining genomic integrity. Deficiencies in the DNA 
repair pathway lead to genetic instability, which in turn may lead to cancer 
development. Genetic polymorphisms in DNA repair genes may contribute to 
differential DNA repair capability between individuals (Mohrenweiser and Jones, 
1998). The extent to which genetic variation in the DNA repair genes contributes to 
breast cancer risk remains unclear. Given the complexity of breast cancer aetiology 
and the involvement of different DNA repair pathways in breast cancer, this study 
was designed to investigate the association between common SNPs in DNA repair 
genes and breast cancer risk.  
 
4.3.1 General considerations regarding the study design and the population 
studied  
The case-control study is the most commonly used approach to study associations 
between genetic polymorphisms and cancer. This is mainly due to the simplicity of 
the required sampling and the ease of analysis and interpretation of results. The aim 
of a case-control association study is to identify genetic components that may 
contribute to a medical condition, by comparing the distribution of polymorphic 
markers in candidate genes in groups of unrelated affected and unaffected 
individuals (Malats and Calafell, 2003).  
 
Besides the advantages of case-control studies, this approach also has some 
weaknesses. A case-control study that has low participation rates or substantially 
different ethnicity distribution between cases and controls is subject to selection bias 
(Rothman et al., 2001; Wacholder et al., 2000). Population stratification is not 
considered to have caused any bias in the present study, as Cyprus, being an island, 
presents an example of a genetic isolate. Consequently the Cypriot population is 
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very homogeneous and this makes Cyprus an ideal location for genetic association 
studies. As this was a nationwide, population-based study, the number of controls 
participating in the study was representative of the distribution of the population in 
the five districts, Nicosia, Limassol, Larnaka, Paphos and Famagusta, as per the 
official 2004 population estimates. As the results show, in terms of the basic 
demographic characteristics of the cases and controls recruited into the study, there 
were no statistically significant differences in the level of education and marital 
status between the two groups. 
 
The study was designed to be representative of the Cypriot population and towards 
this effort 1109 Cypriot women diagnosed with breast cancer between the years 
1999 and 2006, as well as 1177 age matched healthy controls were recruited. The 
incidence of breast cancer in Cypriot women is about 400 cases per year and 
therefore the number of 1109 recruited into this study represents about 40% of the 
cases diagnosed between the years 1999-2006. Mortality data are not currently 
available for the Cypriot population. This is mainly due to the fact that until recently, 
physicians were not obliged to inform the National Cancer Registry on the disease 
progression and survival of the cases registered into the database. Assuming that the 
estimated age-adjusted survival from breast cancer for Western Europe, which sums 
up to 74% of the diagnosed patients (Parkin et al., 2005), also applies for Cyprus, it 
is estimated that of the approximately 2800 newly diagnosed breast cancer cases 
between the years 1999 and 2006, around 70 died, before or during the period that 
the cases were ascertained for the study. This is a relatively small number and the 
estimation that the present study represents 40% of the cases diagnosed with breast 
cancer in Cyprus between 1999 and 2006 is greatly not affected. 
 
The participation rate of cases and controls was very high covering around 98% of 
eligible cases and controls. It has been observed that healthy volunteers who want to 
participate in an epidemiological study tend to have a higher educational level 
compared to the remaining population (dos Santos Silva 1999). The present study 
does not confirm this observation, since the level of education was not significantly 
different between cases and controls.  
 
The control population consisted of women who were participating in the National 
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breast cancer-screening program with the use of mammography. All Cypriot women 
over the age of 50 receive an invitation from the Department of Medical and Public 
Health Services to attend for a mammogram at their local breast-screening unit, free 
of charge. Based on the fact that healthy controls were ascertained at the five district 
breast screening units, the majority of controls participating in the study were 
postmenopausal women, over the age of 50, who had accepted the invitation for a 
free mammogram. A smaller proportion of women, under the age of 50, also visit the 
mammography screening units and hence the study includes a number of 
premenopausal healthy controls aged below 50 years old. The criteria for 
ascertaining breast cancer cases were a histologically confirmed diagnosis of breast 
cancer between the years 1999 and 2006 and an age of diagnosis greater than 40 
years. Inevitably, the cases participating in the study were younger than the controls.  
 
Breast cancer is largely viewed as a disease which is predominantly influenced by 
lifestyle risk factors since only approximately 15% of all breast cancer cases can be 
attributed to familial and genetic influences (Martin and Weber, 2000). The majority 
of known risk factors for breast cancer are linked to the hazardous effects of 
hormonal exposures (ESHRE Capri Workshop Group, 2004). This is also confirmed 
in the present study. Early age at menarche, small number of children, nulliparity 
and little or no breastfeeding are all associated with an increased risk of developing 
breast cancer in the Cypriot population. 
 
Epidemiological studies have demonstrated that use of hormone replacement therapy 
is associated with an increased risk of breast cancer (Beral, 2003). However, in 
contrast to current knowledge, a tendency of decreased risk of breast cancer was 
found among women who received HRT in this study population. This might at least 
partly be due to the participation of older women in the control population, since 
HRT is more common among older women. 
 
Another possible source of bias in case-control studies is recall bias. In the current 
study, breast cancer cases were more likely and more motivated to recall and report 
exposure to risk factors than the disease-free controls. In addition, the fact that 
patients are usually more familiar with the study hypothesis than healthy controls 
could also lead to recall bias. Case-control studies are also vulnerable to information 
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biases. It is possible that study subjects are misclassified with respect to disease or 
exposure status. In the current study, cases were verified by reviewing histological 
reports and controls were women with a negative mammography result hence the 
possibility of the study being affected by information bias is limited. Furthermore, 
since the same 5 well-trained scientists conducted the interviews for all the cases and 
controls, the possibility of information bias is considered to minimal. 
 
However, since genotypes are not modifiable and cannot be affected by recall, 
information or selection biases, these potential causes of bias are not anticipated to 
have had any significant effect in the outcomes of the present study.  
 
4.3.2 Genetic variation in the DNA repair genes XRCC1,  XRCC2 and   XRCC3 
and risk of breast cancer in the Cypriot population 
The XRCC genes constitute one of the most well studied groups of genes, in relation 
to breast cancer risk. These genes were initially discovered through their role in 
DNA damage response caused by ionizing radiation. XRCC genes are important 
components of various DNA repair pathways contributing to DNA-damage 
processing and genetic stability (Thacker and Zdzienicka, 2004).  
 
The XRCC1 gene is an important component of the BER pathway acting as a 
scaffold for other BER enzymes (Caldecott, 2003). Although many SNPs in the 
XRCC1 gene have been documented, three common (variant allele frequency > 0.05) 
non-synonymous coding SNPs, which are located at codons 194, 280 and 399, have 
been studied extensively in relation to breast cancer risk (Hu et al., 2005; Saadat and 
Ansari-Lari, 2008). These SNPs have been shown to alter DNA repair capacity in 
phenotypic studies and have hence received considerable attention. In detail, 
rs1799782 (R194W) polymorphism has been associated with an increased BER 
capacity (Wang et al., 2003) whereas rs25489 (R280H) and rs25487 (R399Q) 
polymorphisms have been associated with reduced DNA repair capacity (Lunn et al., 
1999; Duell et al., 2000; Hu et al., 2001; Matullo et al., 2001; Lei et al., 2002; 
Takanami et al., 2005;  Pachkowski et al., 2006). 
 
The XRCC2 and XRCC3 genes are necessary for HR repair and are required for 
RAD51 focus formation (Bishop et al., 1998; O'Regan et al., 2001). Rs3218536, a 
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non-synonymous coding variant in the XRCC2 gene which changes amino acid 188 
from an arginine to a histidine, has been studied extensively in relation to cancer risk 
but its functional role still remains to be elucidated (Auranen et al., 2005; Danoy et 
al., 2007; Garcia-Closas et al., 2006; Popanda et al., 2006). Rs861539, a common 
XRCC3 variant, comprising a threonine to methionine substitution at amino acid 
position 241, has been associated with less efficient DNA repair (Matullo et al., 
2001) and an increase in the number of centrosomes and binucleated cells (Lindh et 
al., 2006). This variant has been proposed as a low-penetrance cancer allele for 
breast and lung cancer (Kuschel et al., 2002 ; Jacobsen et al., 2004) as well as for 
acute myeloid leukaemia (Seedhouse et al., 2004). However, it has also been 
demonstrated that the XRCC3 codon 241 wild type and variant alleles are 
functionally equivalent in the DSB repair pathway (Araujo et al., 2002) and a 
number of reports did not find a link between this variant and cancer (Thacker, 
2005). 
 
Genetic association studies on breast cancer risk have extensively studied the effects 
of the above-mentioned, potentially functional, SNPs in the X-Ray cross-
complementing genes XRCC1, XRCC2 and XRCC3 in relation to breast cancer risk.  
However, the results of these studies have been contradictory and inconsistent 
(Garcia-Closas et al., 2006; Hu et al., 2005; Saadat and Ansari-Lari, 2008), 
necessitating the organization of additional case-control studies, for evaluating these 
variants. In this context, the aim of the present study was to test the association of 
these common XRCC variants and breast cancer in the Cypriot population.  
 
Comparison of the XRCC1 R280H genotypes between breast cancer cases and 
healthy controls, revealed that the XRCC1 280H allele is associated with an 
increased risk of breast cancer. In detail, women homozygous for the histidine allele 
had a 4- to 5-fold increased risk for breast cancer compared to those homozygous for 
the arginine allele. The association between XRCC1 R280H SNP and breast cancer 
is biologically plausible.  This SNP is located between the N-terminal and the BRCT 
I domains of XRCC1, in the linker region that separates DNA polymerase b 
interacting domain, from PARP (poly-ADP-ribose polymerase) interacting domain 
(Kubota et al., 1996; Takanami et al., 2005). There is evidence that this 
nonconservative amino acid alteration may influence DNA repair capability by 
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altering the protein-protein interactions between XRCC1 and other BER proteins. 
Two recently published functional studies, which investigated the role of the XRCC1 
R280H variant in altering DNA repair capacity, have shown that relative to the wild-
type protein, the 280H variant decreases the DNA repair capacity (base excision 
repair / single strand break repair capacity) of mammalian cells exposed to chemical 
stresses (Pachkowski et al., 2006; Takanami et al., 2005). In addition, a meta-
analysis by Hu et al. (2005) concluded that the 280H variant is associated with an 
increased cancer risk. These studies support the finding reported here, i.e., the 
statistically significant association of the 280H allele with breast cancer.  
 
The study by Pachkpwski et al. (2005) has also reported a positive association 
between the XRCC1 R280H genotype, breast cancer and smoking. Cells with a 
reduced DNA repair capacity may not be able to handle DNA damage caused by 
continuous exposure to genotoxic insults such as smoking. In the current study, three 
out of the nine women homozygous for the 280His allele were smokers who started 
smoking at a young age. It is possible that the rest of the women who are 
homozygous for the 280His allele, were exposed for prolonged durations to passive 
smoking and that the combination of this exposure with the XRCC1 280His 
genotype, increased their breast cancer risk. Unfortunately information on passive 
smoking exposure was not collected and this hypothesis cannot be confirmed.  
 
In the current study, there was also some evidence of a dominant protective effect 
for the XRCC2 188His allele carriers. However, the effect of this SNP after adjusting 
for covariates such as age, menopause status, family history of breast cancer and use 
of HRT, did not remain statistically significant. There are contradictory reports 
regarding the role of this rare XRCC2 variant in breast cancer, with some studies 
showing an association with increased risk of breast cancer whereas others did not. 
A recent meta-analysis conducted by the Breast Cancer Association Consortium, 
concluded that this variant is not associated with breast cancer (Breast Cancer 
Association Consortium, 2006). Furthermore, a second meta-analysis by Garcia-
Closas et al. (2006) in Caucasian populations reached the same conclusion.  
 
This study did not show a statistically significant association between the XRCC1 
R194W, R399Q and XRCC3 T241M SNPs and breast cancer risk in the Cypriot 
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population. These results are comparable with those reported from the Breast Cancer 
Association Consortium (2006) where variants XRCC1 R399Q and XRCC3 T241M 
did not modify breast cancer risk. In addition, a recent meta-analysis supported lack 
of association between  XRCC1 R194W SNP and breast cancer risk in Caucasian 
populations (Zhang et al., 2006).  
 
In conclusion the results of this study, suggest that XRCC1 R280H SNP is associated 
with breast cancer risk in Cypriot women. Taking into account the important role of 
XRCC1 in BER, the statistically significant difference in breast cancer risk in 
Cypriot women associated with this variant may indicate a true association. 
 
4.3.2 Genetic variation in genes interacting with BRCA1/2 risk of breast cancer 
in the Cypriot population Cyprus 
Ten different genes, which are involved in pathways critical for the maintenance of 
genomic integrity, have been implicated in inherited predisposition to breast cancer, 
including BRCA1, BRCA2, p53, PTEN, CHEK2, ATM, NBS1, RAD50, BRIP1 and 
PALB2. The association of germline mutations in DNA repair genes with an 
increased susceptibility to breast cancer, highlights the importance of these pathways 
in the development of breast cancer (Walsh and King, 2007).  
 
The DNA repair pathway is clearly involved in familial breast cancer. Thus, it was 
hypothesized that common SNPs of genes involved in the DNA repair pathway, may 
influence breast cancer risk. In this context numerous studies have investigated the 
role of SNPs in DNA repair genes in relation to breast cancer and have reported 
associations with breast cancer risk (Goode et al., 2002; Kuschel et al., 2002; Garcia-
Closas et al., 2006; Haiman et al., 2008). 
 
Analysis of members of the DNA repair pathway appears to be a good rationale for 
identifying novel susceptibility loci. In particular, genes which have a direct 
interaction with the BRCA1 and BRCA2 genes are very good candidates. Recently, 
two additional susceptibility genes, namely BRIP1/FANCJ and PALB2/FANCN, 
which interact with BRCA1 and BRCA2 genes respectively, have been identified 
(Seal et al., 2006; Rahman et al., 2007). 
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The primary aim of this study was to investigate the association between SNPs in 
genes that interact with BRCA1 and BRCA2 and breast cancer risk in the Cypriot 
population. Genetic variation in 72 SNPs in 35 genes, which interact with BRCA1 
and/or BRCA2 genes and their association with breast cancer, was investigated in a 
case-control study of Cypriot women. Furthermore, the role of 2 additional SNPs in 
the PBOV1 (UROC28) and DBC2 genes which are both upregulated in breast cancer 
was also assessed (An et al., 2000; Hamaguchi et al., 2002).  
 
Significant associations with breast cancer risk were observed for eight of the 72 
SNPs investigated. Five of these eight SNPs were associated with an increased 
breast cancer risk, while the remaining three were associated with a reduced risk for 
breast cancer.  
 
In the current study, there was evidence for an increased breast cancer risk for 
women carrying the BRCA2 rs1799944 SNP. The additive model showed a 
significant trend (P = 0.014) towards increased risk of breast cancer with the number 
of aspartic acid allele copies among Cypriot women. The N991D variant is located 
in the conserved BRC repeat region of the BRCA2 gene, in exon 11 (Rapakko et al., 
2006) and many individuals with a family history of breast cancer are carriers of this 
variant. It has been classified as a variant of no clinical significance in the BIC 
database. On the other hand, in silico prediction methods suggest that this is a non 
tolerated amino acid substitution within the limits of confidence in the alignments 
(Fackenthal et al., 2005). Therefore, until functional data become available, the 
pathogenicity of this variant cannot be excluded, and it may be a variant that 
increases risk moderately, but is indeed, not highly penetrant. In this study there was 
no association between the presence of the BRCA2 991Asp allele and family history 
of breast cancer.   
 
A moderately strong association of this BRCA2 polymorphism with malignant 
melanoma has been reported. The presence of this common BRCA2 variant was 
associated with malignant melanoma risk (P = 0.002 after Bonferroni correction), in 
over 9% of the cases studied. The authors suggested that this variant is not a neutral 
missense mutation and that follow-up studies should be undertaken in melanoma and 
breast cancer populations to precisely define its pathogenicity (Debniak et al., 2008). 
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The role of this SNP in breast cancer risk has been investigated in the Multiethnic 
Cohort study and no association was found (Freedman et al., 2004).  
 
Previous studies that were performed in the Cypriot population revealed a different 
spectrum of mutations in the BRCA1 and BRCA2 genes compared to other 
populations (Hadjisavvas et al., 2004). In addition, the study of early onset breast 
cancer cases described in Chapter 3 of this thesis further confirms this finding. The 
over-representation of the BRCA2 N991D polymorphism in the breast cancer group 
supports the notion that this variant is associated with an increased breast cancer risk 
among Cypriot women and it is possible that this association is characteristic only 
for the Cypriot population. 
 
The study data also support the notion that MUS81 rs545500 C allele carriers are at 
an increased risk for breast cancer. Rs545500 is a non-synonymous SNP located in 
the coding region of MUS81, a structure-specific DNA nuclease which plays an 
important role in DNA repair by homologous recombination (Osman and Whitby, 
2007). This polymorphism results in an amino acid change from a positively charged 
hydrophilic arginine to an uncharged hydrophobic proline residue, which may have 
an effect on the 3D structure or a protein-protein binding interface of the MUS81 
protein (Nakken et al., 2007). The role of the MUS81 gene in breast cancer has not 
been investigated. However, it was demonstrated that MUS81 homozygote and 
heterozygote knockout mice, have a predisposition to develop cancer. Proper 
bialellic expression of MUS81 is critical for the maintenance of genomic integrity 
and tumour suppression (McPherson et al., 2004). Therefore, the rs545500 SNP 
could predispose individuals to breast cancer, but functional studies need to be 
performed in order to identify the actual role of this variant in carcinogenesis. 
 
The results of the  statistical analysis  also suggest that the PBOV1 rs6927706 
polymorphism may be a risk factor for breast cancer. Rs56927706 is a non-
synonymous SNP located in the coding region of PBOV1, a gene which is up-
regulated in prostate, breast, and bladder cancers (An et al., 2000). This 
polymorphism results in an amino acid change at codon 73 from a hydrophobic 
isoleucine to a hydrophilic threonine residue. Bioinformatics analysis indicates that 
this SNP could be involved in splicing regulation (Lee and Shatkay, 2008). However 
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further work is warranted since the exact roles of the PBOV1 protein as well as its 
functional domains are not well known at present. 
 
Analysis of genotyping results revealed that Cypriot women who carry the NBS1 
rs13312840 C and rs769416 T alleles have a reduced risk of breast cancer. The 
NBS1 protein is involved in NHEJ pathway that repairs DSBs. The first step of this 
pathway consists of the recognition of DSBs by the MRN complex whose core 
contains the MRE11, RAD50 and NBS1 proteins. NBS1 is the key regulator of this 
protein complex (Jazayeri and Jackson, 2002; Kobayashi et al., 2004). 
 
The NBS1 rs13312840 T>C SNP is located in the 5’ UTR (-1120) that is the 
transcription factor GATA-1 binding site. The activation domains of GATA-1 are 
capable of activating transcription in mammalian cells through GATA motifs 
(Merika and Orkin, 1993). The results of the Cypriot study are in contrast to those of 
a recent study by Lu et al. (2006), who found an increased risk for breast cancer in 
non-Hispanic Caucasian women aged 55 years or younger, who were carriers of the 
rs13312840 C allele. Conflicting evidence for association may be due to population-
specific and/or age-specific differences. The protective effect of the NBS1 
rs13312440 SNP observed in this study could be attributed to the SNP itself or to 
linkage disequilibrium with another variant. 
 
To the best of the author’s knowledge this is the first study investigating the role of 
NBS1 rs769416 SNP and breast cancer risk. The rs769416 SNP causes an amino 
acid change (Gly to Lys) at codon 216 of the NBS1 gene. This SNP is not located 
within one of the three functional regions of the NBS1 protein but it may have an 
alternative splicing regulatory effect, based on the Functional Single Nucleotide 
Polymorphism (F-SNP - http://compbio.cs.queensu.ca/F-SNP/) database (Lee and 
Shatkay, 2008). The association of rs769416 SNP and breast cancer needs to be 
interpreted with caution, since this is a rare SNP in the Cypriot population and the 
most likely explanation for this association is chance. 
 
Several studies have investigated NBS1 E185Q SNP (rs1805794) in relation to breast 
cancer risk (Forsti et al., 2004; Hsu et al., 2007; Kuschel et al., 2002; Lu et al., 2006; 
Millikan et al., 2005; Zhang et al., 2005). The allele-dose association of this SNP 
 140
with breast cancer reported by Lu et al. (2006) was not replicated in this study. A 
recent large US study of 894 African–American breast cancer cases and 788 controls 
and 1417 whites breast cancer cases and 1234 controls, reported that rs1805794 is 
not associated with breast cancer risk (Millikan et al., 2005). In addition, a large-
scale case-control study in Europe reported a similar result (Kuschel et al., 2002). 
Based on the results of these two large scale studies, which are also confirmed by the 
Cypriot study, it can be concluded that rs1805794 SNP is not associated with breast 
cancer risk.   
 
Haplotype analysis with the combination of the seven NBS1 SNPs showed that the 
frequency of the GGCGCAC haplotype (rs769416, rs769420, rs13312840, 
rs1805794, rs6413508, rs12677527, rs1805787) was lower in cases than in controls 
(0.0147 versus 0.0225; p=0.035) suggesting a protective effect. There was also 
evidence for a protective effect of the rare pooled NBS1 haplotypes. This protective 
effect is driven by the difference in frequencies of the pooled rare haplotypes which 
conferred a low risk (OR=0.42) and had a combined frequency of 3.29% in controls 
and 1.37% in cases. It is possible that this haplotype is a marker for a single, rare, 
protective mutation in the Cypriot population. There may be value in sequencing this 
region, in order to help identify the protective variant(s). Both these findings need to 
be replicated in independent studies in order to confirm or refute this effect. 
 
The data of the Cypriot breast cancer case-control study suggest that the MRE11A 
rs556477 G allele may be associated with a reduced breast cancer risk. Furthermore, 
there is evidence for an increased breast cancer risk for women homozygous for the 
MRE11A rs601341 A allele. The MRE11A gene forms a complex with RAD50 and 
NBS1 genes which is involved in the cellular response to DNA double strand breaks. 
Defects in the members of this tri-complex are linked to increased chromosomal 
instability which leads to cancer (van den Bosch et al., 2003).  
 
The rs556477 common variant is located in intron 15 of the MRE11A gene. The 
rs556477 MAF is 40% in Caucasians as reported in NCBI's dbSNP database; the 
same as that observed in our population. The functionality of this SNP is not clear. 
TFSEARCH webtool (http://www.cbrc.jp/research/db/TFSEARCH.html) was used 
to search for potential transcription factors binding sites at this position. The 
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rs556477 SNP is located in a region that is a potential transcription factor binding 
site of activator protein 1 (AP-1), which plays a critical role in signal transduction 
pathways in many cells. A recent study has shown that inhibition of AP-1 
transcription factors suppresses breast cancer growth. Inhibitors which are capable of 
blocking AP-1 activation may be promising agents for the treatment and prevention 
of breast cancer (Liu et al., 2002). The reduced risk of breast cancer for carriers of 
rs556477 SNP found in this study is in contrast with the above finding since it is 
expected that the creation of an AP-1 binding site will result in an increased breast 
cancer risk. However it must be taken into account that the prediction that rs556477 
A to G substitution results in a gain of an AP-1 binding site is based on in silico 
analysis and this remains to be proven by in vitro data. Furthermore, the MRE11A 
rs556477 polymorphism may not be causal, but could be in linkage disequilibrium 
with a true protective variant. 
 
The rs601341 A to G substitution results in potential binding of ubiquitous 
transcription factor Ying Yang 1 (YY1) that has a fundamental role in normal 
biologic processes such as differentiation, replication and cell proliferation. YY1 
overexpression and/or activation results in uncontrolled cellular proliferation, 
resistance to apoptotic stimuli and tumorigenesis (Gordon et al., 2006). To our 
knowledge, the role of rs601341 in breast cancer has not been investigated but a 
protective effect of this SNP against follicular lymphoma has been reported 
(Rollinson et al., 2006). The increased breast cancer risk associated with 
homozygous MRE11A rs601341 G allele carriers observed in this study could be 
attributed to the SNP itself or to linkage disequilibrium with another variant in the 
region. Functional studies will need to be performed in the future to identify the 
actual causal variant. 
 
The present study presents evidence for an increased breast cancer risk for women 
carrying the MRE11A AGCG (rs556477, rs601341, rs10831234, rs1009456) 
haplotype. The set of SNPs in the MRE11A gene that were genotyped in the present 
study, were characterized by Allen-Brady and Camp (2005) as the most informative 
group of SNPs (tagging SNPs) in this gene, which can capture >90% of the 
intragenetic variation. It has been suggested that haplotype based designs are more 
powerful compared to single-allele approach studies for association studies (Johnson 
 142
et al., 2001). Hence a haplotype based approach where the SNPs being analyzed 
represent the entire genetic variation of the gene of interest should provide more 
accurate and definitive findings. It is noteworthy that the effect observed for the 
MRE11A AGCG haplotype in the Cypriot study was stronger than for any individual 
SNP. This observation suggests that the association is likely to be due to another 
functional variant or variants, in linkage disequilibrium with the SNPs tested. There 
may be value in sequencing this region, in order to help identify the causative 
variant(s). This finding needs to be replicated in independent studies in order to 
confirm or refute this effect. 
 
There was no evidence of association with breast cancer risk for the rest of the SNPs 
assessed in the present study. The group of genes evaluated in this study has been 
analyzed extensively in relation to breast cancer risk and studies have produced 
contradictory results. However, none of the SNPs for which no association was 
observed in the Cypriot population, have been marked as major targets which 
modify breast cancer risk. Furthermore a recent meta-analysis by Vineis et al. 
(2009), which summarizes the data from genetic association studies for genes 
involved in DNA repair, has failed to identify associations between a number of 
SNPs included in the present study (rs4987945, rs2227928, rs2229032, rs4986764, 
rs13181, rs1052134, rs1801320, rs1801321, rs1042522) and breast cancer risk. The 
lack of evidence of association indicates that these SNPs are not susceptibility 
variants for breast cancer. However, there is always the possibility that one or more 
SNPs could be associated with the disease, but this study does not have sufficient 
statistical power to detect the association.  
 
It should be noted that the scope of this study was not to comprehensively examine 
all common genetic variation across these genes for association with breast cancer 
risk. This study was restricted to a number of SNPs, which are either functional or 
have been reported by other groups, to modify cancer risk and are located within 
genes which interact with either BRCA1 and/or BRCA2.  The possibility that other 
variants in these genes are associated with breast cancer risk cannot be excluded. 
Future large-scale comprehensive candidate gene studies are warranted, to 
systematically tag all known common variants in these genes and to test the tagging 
SNPs associations with breast cancer susceptibility.  
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This study was well powered to detect alleles with modest to high effects at stringent 
levels of significance. For example, the study has over 80% power to detect a variant 
with a MAF of  5% conferring a risk of 1.6 under a dominant model. The study had 
very limited power to detect recessive alleles. The SNP selection for this study was 
based solely on functionality and their position in genes interacting with BRCA1/2 
rather than allele frequency. As a result of this, a number of monomorphic/low-
polymorphic SNPs were included in the study. It is noted that this is the first time 
that these SNPs were studied in the Cypriot population, and their allele frequencies 
were a priori unknown. Rare SNPs can also contribute to disease risk (Gorlov et al., 
2008). However, our study did not have sufficient power to detect such associations, 
and the possibility that some of the low-polymorphic SNPs studied contribute to 
breast cancer risk cannot be ruled out. 
 
Since the design of this study knowledge about the BRCA1 and BRCA2 genes and 
their interactions has increased and a similar study starting now would have 
undoubtedly included more candidate genes and SNPs. In addition, with the 
completion of Phase III of the HapMap project there is now an unprecedented 
reference panel for tagging SNP selection which could be studied in addition to the 
functional SNPs evaluated in the present study. Despite living in the era of 
genomewide association studies, it is plausible to assume that an expansion of the 
current candidate gene approach, to more genes and SNPs interacting with BRCA1 
and BRCA2, would reveal additional important information regarding breast cancer 
susceptibility in the Cypriot population. Well-designed candidate genes methods can 
still achieve higher capture of target genetic variation in candidates genes compared 
to commercially available SNP arrays. However, this gap is quickly narrowing since 
it is expected that the new generation of SNP arrays will include a greater number of 
tagging SNPs, which will provide better coverage as well as significantly increased 
overall genetic power. 
 
One of the limitations of this study is that the analysis did not consider the 
possibility of gene-gene interactions. The available data on breast cancer suggest that 
many cases are likely to be due to co-existence of multiple low penetrance breast 
cancer susceptibility alleles (Pharoah et al., 2002; Antoniou and Easton, 2006). 
However, very little is known on how these multiple susceptibility alleles interact 
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with each other. Since the proteins encoded by the genes selected as candidate 
susceptibility loci in this study lie in the same pathway, it is possible that the risks 
observed are the result of interactions which lead to partial abrogation of the DNA 
repair function. This study has not attempted to assess such effects since the estimate 
of an interaction effect will be unreliable because of small numbers. For this type of 
analysis a very large sample size is essential. A review of the literature indicates that 
this type of analysis is still at its infancy and it is expected that data regarding the 
interactions of common breast cancer susceptibility alleles, as well as on the 
interactions among these risk alleles and non-genetic factors will emerge in the near 
future (Stratton and Rahman, 2008).  
 
It is also possible that while some SNPs displayed marginal or no association with 
breast cancer risk when studied on an individual basis, they can show evidence of an 
association with breast cancer risk when combined with other SNPs in other genes. 
There are examples which point towards this direction. Three studies have observed 
significant trends in breast cancer risk with increasing numbers of risk genotypes 
and have suggested that combined SNPs in multiple DNA repair pathways may 
contribute to breast cancer risk (Smith et al., 2003a; Fu et al., 2003; Smith et al., 
2008). Recently, novel high-throughput methods have been established which can 
determine synthetic gene interactions in multicellular organisms by genome-wide 
RNA interference (van Haaften et al., 2004). This method was successful in 
identifying previously unassociated genes with a double-strand-break response that 
may play a role in human carcinogenesis. The results of such studies can provide 
useful information on interactions of known DNA repair and related genes, which 
can be investigated further in genetic association studies.  
 
Gene-environment interactions were also not interrogated in this study. Many DNA 
repair genes are environmentally-responsive genes and it would be interesting to 
study the biological implications of genetic variation, in response to an 
environmental stimulus. However, there are analytic challenges of testing for 
multiple genetic and environmental risk factors using traditional analytic tools 
(Thornton-Wells et al., 2004). In genetic studies of complex traits, gene-environment 
interactions are common but the likelihood of false positive results occurring by 
chance because of the large number of comparisons being carried out, is a possible 
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problem which could lead to false positive associations occurring by chance (Bird et 
al., 2001).   
 
In conclusion, this study provides support for the hypothesis that genetic variants in 
DNA repair genes influence breast cancer risk and provides further evidence for the 
polygenic model of breast cancer. However, large-scale genetic epidemiologic 
studies are warranted to further examine and corroborate the associations observed, 
between polymorphisms and breast cancer in multi-ethnic groups. In addition, 
elucidation of the functional impact of the breast cancer associated SNPs is needed, 
in order to provide further insights into their mechanistic effects on risk.  
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5. General Discussion, Conclusions and Future work 
Breast cancer is a major public health problem throughout the world. It is by far the 
most commonly occurring cancer among women, accounting for 23% of all female 
cancers. Despite its common occurrence, and numerous epidemiological and 
research studies, the exact aetiology of breast cancer is still unknown. It is believed 
that breast cancer is a multifactorial disease which is a result of interactions between 
genetic and environmental factors (Ponder, 2001). Over the past decade, significant 
progress has been made, in defining risk factors that help us to identify individuals 
who are highly susceptible to developing breast cancer, as well as understanding 
some of the genetic factors that contribute to this risk. However, the major part of 
the breast cancer burden is still unexplained, so a lot needs to be done. 
 
The genetic basis of inherited predisposition to breast cancer has been investigated 
thoroughly during the past two decades and significant discoveries were made. As a 
result of several years of research, it is now widely accepted that three major groups 
of breast cancer susceptibility alleles exist, each conferring different levels of risk in 
the population. These three groups are: the rare high penetrance alleles, the rare 
moderate penetrance alleles and the common low penetrance alleles (Oldenburg et 
al., 2007; Pharoah et al., 2008; Stratton and Rahman, 2008).   
 
The two most important components of the high risk breast cancer susceptibility 
group are BRCA1 and BRCA2. The occurrence of early-onset breast cancer has been 
associated with mutations in these two genes (Langston et al., 1996; Krainer et al., 
1997). Several studies have shown that the genetics of BRCA1 and BRCA2 are 
population specific. A wide spectrum of recurrent and founder mutations have been 
found in different parts of the world, especially in ethnically defined or isolated 
populations (Neuhausen, 1999). In this context and based on the fact that Cyprus is 
an island, in which there has been little population movement, a founder mutation in 
exon 22 of the BRCA2 has been identified (Hadjisavvas et al., 2004). 
 
Family studies have proved invaluable for understanding the significance and 
contribution of BRCA1 and BRCA2 genes in breast cancer among Greek Cypriot 
women. However, observations in such families regarding the nature and penetrance 
of BRCA1 and BRCA2 mutations may not reflect the full spectrum of alterations 
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present in the general population. It is currently accepted that a variable proportion 
of early-onset breast cancer is associated with mutations in the BRCA1 and BRCA2 
genes and that the proportion may be higher in populations harbouring founder 
mutations (Robson et al., 1998). In Cyprus, the prevalence of BRCA1 and BRCA2 
mutations in breast cancer patients who were unselected for a family history of the 
disease was unknown. One of the aims, of this study was to evaluate the frequency 
and distribution of mutations in the BRCA1 and BRCA2 genes, in a group of Greek 
Cypriot women with early-onset breast cancer.  
 
The findings of the present study support a strong correlation between the early 
onset breast cancer phenotype and the presence of pathogenic BRCA1/2 mutations. 
The prevalence of these mutations in the young Cypriot patients (23%), is higher 
than most countries and compares favourably with data from the Icelandic and the 
Ashkenazic Jews populations, which display strong founder effects (Johannesdottir 
et al., 1996; Abeliovich et al., 1997; Thorlacius et al., 1997). It is of interest that 
pathogenic mutations were detected in patients without a family history of the 
disease. Based on these results, we recommend that BRCA1/2 screening, should be 
offered to patients with a diagnosis of early-onset breast cancer irrespective of their 
family history. 
 
The Department of EM/ Molecular Pathology of the Cyprus Institute of Neurology 
and Genetics has offered routine genetic testing for the BRCA1 and BRCA2 genes in 
Cyprus since January 2005. Based on the results of this study, the Department offers 
genetic testing of the BRCA1 and BRCA2 genes to all women with an a diagnosis of 
early onset age of breast cancer (less than 40 years) even in the absence of a family 
history of breast / ovarian cancer. The experience so far, confirms the results of this 
study. Genetic testing data from this group of women support the position that early-
onset of breast cancer is a sufficient criterion that can be used to identify candidates 
for BRCA1 and BRCA2 mutation screening.  
 
In view of the interesting results obtained from the early onset breast cancer study, 
my intention is to continue working with this group of breast cancer patients, 
especially those who were tested negative for BRCA1/2 mutations. Diagnosis of  
early onset of breast cancer is a strong indicator that the disease has an inherited 
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genetic component and studying this group of patients may help identify new genes 
that may be associated with the disease. It would also be worthwhile to participate in 
a large collaborative genome-wide association study of early-onset female breast 
cancer, to identify new genes responsible for young cases that are negative for 
BRCA1 and BRCA2 gene mutations.       
 
Mutations in the BRCA1 and BRCA2 genes predispose individuals to familial early 
onset breast cancer and together with other known genes account for no more than 
25% of the familial risk of breast cancer (Easton, 1999; Antoniou and Easton, 2006). 
In the years which followed the identification of the BRCA1 and BRCA2 genes, 
extensive initiatives were undertaken, in order to localize additional highly penetrant 
breast cancer susceptibility genes, but without any success (Smith et al., 2006). The 
failure to localize new high penetrance breast cancer susceptibility alleles, has led to 
the proposal that the remaining breast cancer susceptibility results from the 
combined effects of many loci each of which confers a small increase in risk 
(Antoniou et al., 2002). 
 
The most powerful approach to identify these low risk breast cancer variants is 
through association studies. Association studies are based on the “common disease- 
common variant” hypothesis (Chakravarti, 1999). These studies compare the 
frequency of genetic variants in diseased individuals (breast cancer cases) and 
individuals without the disease (controls) (Risch, 2000; Cardon and Bell, 2001). If 
the variant under study is over- or under-represented in the cases group, this 
provides evidence that the locus under study, or a neighbouring locus, is related to 
disease susceptibility. 
 
In the present thesis, this classical association approach, was followed to assess 
whether alterations in DNA repair genes modify breast cancer risk in the Cypriot 
population. The DNA repair pathway is clearly involved in familial breast cancer 
and thus analysis of members of this pathway and in particular genes which have a 
direct interaction with BRCA1 and BRCA2, appeared to be a good rationale for 
identifying novel susceptibility loci.  
 
 151
A number of SNPs were found to be associated with an increased risk for breast 
cancer in the Cypriot population, whereas others were protective for this disease. 
The results of this study provide support for the hypothesis that genetic variants in 
DNA repair genes, influence breast cancer risk and provide further evidence for the 
existence of common low penetrance variants. However, large-scale genetic 
epidemiologic studies are warranted to further examine and corroborate the 
associations observed, between these SNPs and breast cancer in multi-ethnic groups. 
The scope of this study was to examine a pre-defined set of SNPs in genes that 
participate in DNA repair and also closely associate with the BRCA1 and BRCA2 
genes. As both BRCA1 and BRCA2 are involved in a multitude of cellular functions, 
there is still a need to perform a more comprehensive investigation of all common 
genetic variation across genes which interact with BRCA1 and/or BRCA2.  The 
possibility that other variants in these genes are associated with breast cancer risk 
cannot be excluded. In the future, it would be worthwhile conducting a 
comprehensive candidate gene study focusing in this group of genes in order to get a 
more complete picture of their contribution to breast cancer susceptibility.  
 
The task(s) of validating the biological and functional significance, of the SNPs 
which were associated with breast cancer risk in the Cypriot population, is a 
challenging and long-term endeavour. Functional genomics approaches, such as the 
development of mouse models which harbour these SNPs and subjected to extensive 
phenotypic analysis, could assist us in understanding the function of these SNPs. 
Another approach to exploiting the functional significance of these promising SNPs 
is by using high-throughput tests such as yeast or cell culture systems to look at 
different aspects of variant function(s), so as to gain further insights into their role(s) 
and mechanistic effects on disease risk. 
 
The limited success of candidate gene approaches in identifying the genetic 
background of breast cancer and the recent promising results of GWAS has led 
many scientists to apply this approach in order to explore further and gain a better 
insight into breast cancer susceptibility. Currently, GWAS are considered as the 
most powerful tool to identify common low penetrance disease alleles (Easton and 
Eeles, 2008). The majority of GWAS on breast cancer conducted to-date, had a 
strong bias towards North European origin (McCarthy et al., 2008). An extended 
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analysis with samples from genetically isolated populations with different mutational 
backgrounds would be advantageous for genome-wide association mapping (Service 
et al., 2006). In this context, I had the opportunity as part of a fellowship, to receive 
training in genotyping DNA samples, using SNP arrays and with the aim of 
conducting a GWAS. A total of 25 samples from Cypriot women were genotyped 
using the Affymetrix 5.0 chip. My intention is to continue working in this field and 
provided that the necessary funds are secured by the Department, to conduct a 
genome-wide association study of breast cancer in the Cypriot population. This 
GWA approach could possibly identify additional susceptibility loci, as our 
population is a genetic isolate, and could harbour unique variants not yet disclosed in 
studies in other populations.  
 
All scientists with an interest in understanding the polygenic basis of breast cancer 
recognize the necessity of establishing multicenter collaborations, which will enable 
recruitment of large sample sizes, which will provide more reliable assessments of 
the risks associated with genetic variation across the genome. Thus the study 
population of this thesis will be used, for confirmation of associations observed 
worldwide at genome-wide levels of significance, as well as for the identification of 
novel susceptibility loci, taking advantage of the sample homogeneity as well as the 
genetic isolation of the island.  
 
In the last five years major advances in understanding breast cancer susceptibility 
have been made. Despite this remarkable progress, the majority of inherited breast 
cancer risk remains unexplained. Pharoah et al. (2002) predicted that, based on the 
polygenic model of breast cancer, half of breast cancers occur in the 12% of women 
who are at the highest genetic risk. This highlights the importance of identifying 
additional susceptibility alleles. Thus more intense research in the field of genetic 
epidemiology of breast cancer in diverse ethnic groups is still very much needed, in 
order to shed light on the complex genetic mechanisms, which underlie this common 
malignancy. To facilitate these endeavours, the study of genetic variation in relation 
to breast cancer risk in the Cypriot population should continue and be strengthened 
and expanded. It is expected that in the future, the combination of the effects of 
multiple low risk breast cancer loci will be useful for risk prediction and 
subsequently for targeted screening and preventive interventions (Easton and Eeles, 
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2008). A major challenge for molecular genetics and genetic epidemiology is to 
continue to identify new breast cancer risk alleles.  
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Abstract Inability to correctly repair DNA damage is
known to play a role in the development of breast cancer.
Single nucleotide polymorphisms (SNPs) of DNA repair
genes have been identified, which modify the DNA repair
capacity, which in turn may affect the risk of developing
breast cancer. To assess whether alterations in DNA repair
genes contribute to breast cancer, we genotyped 62 SNPs in
29 genes in 1,109 Cypriot women with breast cancer and
1,177 age-matched healthy controls. Five SNPs were
associated with breast cancer. SNPs rs13312840 and
rs769416 in the NBS1 gene were associated with a decrease
in breast cancer risk (OR TT vs. TC/CC = 0.58; 95% CI,
0.37–0.92; P = 0.019 and OR GG vs. GT/TT = 0.23, 95%
CI 0.06–0.85, P = 0.017, respectively). The variant allele
of MRE11A rs556477 was also associated with a reduced
risk of developing the disease (OR AA vs. AG/GG = 0.76;
95% CI, 0.64–0.91; P = 0.0022). MUS81 rs545500 and
PBOV1 rs6927706 SNPs were associated with an increased
risk of developing breast cancer (OR GG vs. GC/
CC = 1.21, 95% CI, 1.02–1.45; P = 0.031; OR AA vs.
AG/GG = 1.53, 95% CI, 1.07–2.18; P = 0.019, respec-
tively). Finally, haplotype-based tests identified significant
associations between specific haplotypes in MRE11A and
NBS1 genes and breast cancer risk. Further large-scale
studies are needed to confirm these results.
Keywords Breast cancer  Case–control study 
Cyprus  BRCA1/2 interacting genes 
Genetic epidemiology  SNP
Introduction
Breast cancer is the most common malignancy affecting
women worldwide, and it is the leading cancer in females
in Cyprus, with approximately 400 new cases diagnosed
annually [1]. In vitro studies have shown variability in
inter-individual DNA repair capacity and have demon-
strated that reduced ability to repair DNA is associated
with an increased risk for breast cancer [2–4]. It has also
been suggested that deficient DNA repair capacity predis-
poses to both familial and sporadic forms of breast cancer
[5–7].
Ten different genes that are involved in pathways crit-
ical to genomic integrity have been implicated in inherited
predisposition to breast cancer, including BRCA1, BRCA2,
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p53, PTEN, CHEK2, ATM, NBS1, RAD50, BRIP1 and
PALB2. The association of germline mutations in DNA
repair genes with an increased susceptibility to breast
cancer highlights the importance of these pathways in the
development of breast cancer [8].
The DNA repair pathway is clearly involved in familial
breast cancer. Thus, it was hypothesized that common
single nucleotide polymorphisms (SNPs) of genes involved
in the DNA repair pathway may influence breast cancer
risk. Many studies have investigated the role of SNPs in
DNA repair genes in relation to breast cancer and have
reported associations with breast cancer risk [9–12].
Analysis of members of the DNA repair pathway appears
to be a good rationale for identifying novel susceptibility loci.
In particular, genes which have a direct interaction with the
BRCA1 and BRCA2 genes are very good candidates.
Recently, two more susceptibility genes, namely BRIP1/
FANCJ and PALB2/FANCN, which interact with BRCA1 and
BRCA2 genes, respectively, have been identified [13, 14].
BRCA1 and BRCA2 participate in the biological response
to DNA damage that includes the activation of cell cycle
checkpoints and the recruitment of the DNA damage repair
machinery. Both BRCA1 and BRCA2 are implicated in
DNA repair by homologous recombination, and their pro-
teins have distinct roles in double-strand break repair [15].
Despite the progress that has been made in improving
our understanding of the functions of the BRCA1 protein, a
complete picture has not yet been attained. It has been
hypothesized that BRCA1 acts as a coordinator of the
various functions of DNA damage, recognition, response
and repair, and double-strand break repair. BRCA1 inter-
acts with many DNA repair proteins and protein complexes
including the RAD50-MRE11A-NBS1 (MRN) complex.
The proteins associated with BRCA1 are involved in
response to and in the repair of DNA damage in several
ways by acting as DNA damage sensors, signal transducers
and repair effectors. Hence, these proteins are instrumental
in the repair of DNA breakages and in the maintenance of
genomic integrity [16–18]. The exact role(s) of the BRCA2
protein also still remain(s) elusive. It has been demon-
strated that BRCA2 plays an important role in homologous
recombination, both in meiosis and in the repair of double-
strand breaks. Fewer proteins are known to interact with
BRCA2 compared to BRCA1 [19]. These include RAD51,
which mediates DNA repair via homologous recombina-
tion (HR) [15], and PALB2, which is required for BRCA2
nuclear localization and stability as well as for some of its
functions in HR and double-strand break repair [20].
Overall, BRCA1 and BRCA2 act in response to DNA
damage and participate in multi-protein complexes that are
involved in tumor suppression processes [17].
In this study, we hypothesized that germline variations in
genes encoding proteins that interact with BRCA1/2, are
potential candidates for modifying breast cancer risk in the
Cypriot population. Consequently, disturbances in the
interactions with BRCA1 and BRCA2 may prevent their
tumor suppression function(s) and consequently modify
inter-individual DNA repair capacity. As part of an ongoing
study we assessed genetic variation in 60 SNPs in 29 genes,
which interact with BRCA1 or BRCA2 genes and their
association with breast cancer in a case–control study of
Cypriot women. Furthermore, we investigated the role of
two additional SNPs in the PBOV1 (UROC28) and DBC2
genes that are both upregulated in breast cancer [21, 22].
Materials and methods
Study population
To investigate the associations between genetic factors and
breast cancer risk in the Cypriot population, we conducted
a population-based case–control study, with the acronym
MASTOS (Greek word for breast). The population of this
study are women participating in the MASTOS study.
Blood samples were collected between 2004 and 2006
from 1,109 female breast cancer patients diagnosed
between 40 and 70 years old and 1,177 age-matched
healthy controls. Participants were women who were pre-
viously diagnosed with breast cancer between January
1999 and December 2006. The majority of patients were
ascertained from the Bank of Cyprus Oncology Centre
which operates as a referral centre and offers treatment and
follow-up for 80–90% of all breast cancer cases diagnosed
in Cyprus. The rest of the patients were recruited at the
Oncology Departments of the Nicosia, Limassol, Larnaca
and Paphos district hospitals. The control group consisted
of healthy women who were participating in the National
program for breast cancer screening with the use of
mammography. Volunteers were enrolled in the study
during the same calendar period as the cases, from the four
district mammography screening centers that operate in
Cyprus. Eligible controls were women with no previous
history of breast cancer and who had a negative mam-
mography result. All study participants, both patients and
controls, were of Greek Cypriot Caucasian origin, thus
reducing any potential bias due to population stratification.
In addition, the study population was representative of the
whole island population and thus consisted of women, who
resided in all five districts of the country, minimizing
potential selection bias. The participation rate of cases and
controls was very high covering around 98% of eligible
cases and controls. In addition to blood samples, a risk
factor questionnaire, which included extensive demo-
graphic, epidemiologic and pathologic data, was obtained
from each participant through a standardized interview.
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Breast cancer cases were verified by reviewing histological
reports. The study was reviewed and approved by the
National Bioethics Committee of Cyprus. All participants
provided written informed consent.
Gene and SNP selection
Sixty-two SNPs in the ATF1, ATM, ATR, BARD1, BLM,
BRIP1, CHEK1, CHEK2, DDB2, DMC1, EME1, FANCA,
FANCC, FANCD2, FANCE, MLH1, MRE11A, MSH2,
MSH6, MUS81, NBS1, PALB2, PCNA, RFC1, RAD50,
RAD51C, RAD51L1, RAD52 and XPC genes were geno-
typed. The genetic variants were selected based on three
main criteria: (1) all SNPs chosen belong to genes that
interact with either BRCA1 or BRCA2; (2) the SNPs chosen
are either functional SNPs (based on potential protein
changes, evolutionary conservation and location in putative
functional regions [23–25] or (3) SNPs which were
reported by other groups to modify cancer risk [14, 26–32].
For MRE11A and RAD50, we genotyped the tagging SNPs
in Allen-Brady et al. [33], and for NBS1, we genotyped the
tagging SNPs in Lu et al. [32]. SNPs in the PBOV1 and
DBC2 genes were selected based on their minor allele
frequency (MAF) [0.05.
Genotyping
DNA was isolated from blood samples using standard
procedures (phenol–chloroform method). SNPs were gen-
otyped by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) of allele-
specific primer extension products (Mass Array, Sequenom
Inc., San Diego, CA, USA). Assay design was based on
published sequences retrieved from the National Center of
Biotechnology Information (NCBI) databases. A 34-plex
and a 28-plex multiplex assay were designed using the
Sequenom MassARRAY Assay Design software (version
3.0). SNPs were genotyped using Sequenom iPLEX
chemistry on a MALDI-TOF Compact Mass Spectrometer
(Sequenom Inc., San Diego, CA, USA).
Briefly, PCR reactions were carried out in a final volume
of 5 ll in standard 384-well plates. PCR was performed
with 5 ng of genomic DNA, 1 U of HotStarTaq DNA
polymerase (Qiagen, Hilden, Germany), 500 lmol of each
dNTP and 100 nmol of each PCR primer. PCR thermal
cycling was carried out in an ABI-9700 instrument
(Applied Biosystems, Foster City, CA, USA) for 15 min at
94C, followed by 44 cycles of 20 s at 94C, 30 s at 56C
and 60 s at 72C. Next, PCR products were treated with
0.5 U of shrimp alkaline phosphatase for 40 min at 37C to
dephosphorylate unincorporated dNTPs, followed by
enzyme inactivation for 5 min at 85C. After adjusting the
concentrations of the extension primers to equilibrate
signal-to-noise ratios, the post-PCR primer extension
reaction of the iPLEX gold assay was performed in a final
10 ll volume extension reaction containing 0.2 ul of ter-
mination mix, 0.0041 ll of iPLEX enzyme (Sequenom
Inc., San Diego, CA, USA) and 700–1,400 nM of exten-
sion primers. A two-step 200 short cycles program was
used for the iPLEX reaction: initial denaturation was for 30
s at 94C followed by five cycles of 5 s at 52C and 5 s at
80C. An additional 40 annealing and extension cycles
were then looped back to 5 s at 94C, 5 s at 52C and 5 s at
80C. Final extension was carried out at 72C for 3 min.
The iPLEX reaction products were desalted by diluting
samples with 16 ll of water and adding 6 mg of clean
resin. Following a quick centrifugation (3,200 g for 5 min),
reaction products were spotted on a 384-format Spectro-
Chip (Sequenom Inc., San Diego, CA, USA). Spectro-
CHIPs were processed in a MassARRAY Compact
Analyzer (Bruker Daltonics, Bremen, Germany) by Mass-
ARRAY Workstation (version 3.3) software (Sequenom
Inc., San Diego, CA, USA). Acquisition data were ana-
lyzed using MassARRAY TYPER 3.4 software (Sequenom
Inc., San Diego, CA, USA).
For quality control, 48 random samples were genotyped
in duplicate. Furthermore, ten samples were sequenced to
confirm genotype calls from the MALDI-TOF platform.
The genotype concordance rate between platforms was
99%. The order of the DNA samples on 384-well plates
was randomized in order to ensure the same study condi-
tions for samples from cases and controls. Genotyping call
rates ranged from 95 to 99%, and duplicate concordance
rates were higher than 99%. The SNP that had 20% missing
data was excluded from further analysis.
Data analysis
Hardy Weinberg equilibrium (HWE) was assessed in the
control samples by applying an exact test. The primary
tests of association were the univariate analyses between
each SNP and breast cancer. Genotype frequencies in cases
and controls were compared using the v2 test. The associ-
ation between breast cancer and each SNP was examined
using logistic regression with the SNP genotype tested
under models of complete dominance and recessive
inheritance as well as under the log-additive model after
adjusting for breast cancer risk factors including age (under
or over 55 years), menopause status (pre- or post-meno-
pausal), family history of breast cancer (first degree relative
with breast cancer) and use of hormone replacement ther-
apy. Statistical analysis was carried out using SNPStats, a
web-based application designed for analysis of association
studies [34].
Associations between breast cancer and common hap-
lotypes of the ATM, MRE11A and NBS1 genes were also
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investigated using SNPStats, which allows the estimation
of maximum likelihood estimates of haplotype frequencies
using the Expectation-Maximization (EM) algorithm.
Logistic regression was performed to test the association
between haplotypes and breast cancer risk. For assessing
the contribution of the MRE11A haplotypes in breast can-
cer risk, a haplotype tagging SNP genotyped previously
was also included in haplotype reconstruction [35]. Hap-
lotypes with a frequency of less than 1% were not con-
sidered further for analysis since they are likely to be a
result of rare recombination events.
Results
Table 1 shows the genotype frequency in cases and con-
trols for the 62 SNPs, of which the 61 were successfully
genotyped. Six SNPs (rs1800149, rs2706377, rs1800282,
rs7487683, rs3626, rs28908468) deviated from HWE in
controls (P \ 0.01) and were excluded from further anal-
ysis. Of the remaining 55 SNPs, 8 were monomorphic in
both groups. Significant differences in genotype frequen-
cies between breast cancer patients and controls were
observed in 5 of the 55 SNPs analyzed.
The associations of SNPs and breast cancer risk in
Cypriot women are shown in Table 2. Five of the 55 SNPs
were associated at a P value of less than 0.05. Three SNPs
were associated with a reduced risk for breast cancer while
the three remaining were associated with an increased
breast cancer risk. In detail, the variant allele of NBS1
rs13312840 (924 T[C) was associated with a reduced risk
of disease (OR TT vs. TC/CC = 0.58; 95% CI, 0.37 to
0.92; P = 0.019). Carriers of the NBS1 rs769416 rare allele
also had a reduced risk of breast cancer (OR GG vs. GT/
TT = 0.23, 95% CI 0.06–0.85, P = 0.017). Furthermore,
the variant allele of MRE11A rs556477 was associated with
a reduced risk of developing the disease (OR AA vs. AG/
GG = 0.76; 95% CI, 0.64–0.91; P = 0.0022). The variant
allele of MUS81 rs545500 was associated with an increased
risk of developing breast cancer (OR GG vs. GC/
CC = 1.21, 95% CI, 1.02–1.45; P = 0.031). In addition,
the rare allele of PBOV1 rs6927706 was also associated
with an increased risk of developing breast cancer (OR AA
vs. AG/GG = 1.53, 95% CI, 1.07–2.18; P = 0.019).
The NBS1 haplotype GGCGCAC (rs769416, rs769420,
rs13312840, rs1805794, rs6413508, rs12677527, rs1805
787), which contains the NBS1 rs13312840 C allele, to be
associated with a reduced breast cancer risk compared with
the most frequent haplotype GGTCCGC (OR = 0.62; 95%
CI = 0.39–0.97; P = 0.037). We also found a reduced risk
for breast cancer for a rare haplotype in NBS1 (OR = 0.42;
95% CI = 0.26–0.66; P = 2 9 10-4). In addition, the
MRE11A haplotype AGCG (rs556477, rs601341, rs1083
1234, rs1009456) is associated with a significantly increased
risk for breast cancer (OR = 1.32; 95% CI = 1.13–1.54;
P = 0.0004). None of the common ATM haplotypes were
associated with breast cancer (Table 3).
Discussion
Breast cancer is a complex polygenic disease. Published
data suggest that a proportion of breast cancer can be
explained by common low-penetrance alleles that increase
susceptibility [36]. High-penetrance mutations in genes
that are involved in DNA repair pathways such as BRCA1
and BRCA2 predispose to familial breast cancer [37, 38].
Previously our group characterized novel mutations in
these genes in Cypriot families [39, 40]. The importance of
common inherited variants in DNA repair genes in relation
to breast cancer risk is still being elucidated, but is cur-
rently receiving increased attention. Our group as part of an
ongoing investigation has studied genetic variation in DNA
repair genes in relation to breast cancer risk in the Cypriot
population and has reported a number of SNPs that modify
breast cancer risk [35, 41]. A number of large studies
which focused on the contribution of common SNPs in
DNA repair genes in breast cancer, using tagging SNP
approaches have also been completed [9, 42, 43]. In this
case–control study, we evaluated both functional as well as
tagging SNPs in DNA repair genes in relation to breast
cancer risk in Cypriot women.
We found that Cypriot women who carry NBS1
rs13312840 C and rs769416 T alleles have a reduced risk
of breast cancer. The NBS1 protein is involved in non-
homologous end-joining (NHEJ) pathway that repairs
DNA double-strand breaks (DSBs). The first step of this
pathway consists of the recognition of DSBs by the MRN
complex whose core contains the MRE11, RAD50 and
NBS1 proteins. NBS1 is the key regulator of this protein
complex [44, 45]. The NBS1 rs13312840 T[C SNP is
located on the 50 UTR (-1120) of the gene that is the
transcription factor GATA-1 binding site. The activation
domains of GATA-1 are capable of activating transcription
in mammalian cells through GATA motifs [46]. Our results
are in contrast to those of a recent study by Lu et al. who
found an increased risk for breast cancer in non-Hispanic
Caucasian women aged 55 or younger who were carriers of
the C allele [32]. Conflicting evidence for association may
be due to population-specific and/or age-specific differ-
ences. The protective effect of the NBS1 rs13312440 SNP
observed in our study could be attributed to the SNP itself
or to linkage disequilibrium with another variant.
To the best of our knowledge, this is the first study
investigating the role of NBS1 rs769416 SNP and breast
cancer risk. The rs769416 SNP causes an amino acid
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Table 1 Genotype frequencies in cases and controls for the 62 SNPs studied
Gene rs Number Controls Cases MAF HWE
AA Aa aa Total AA Aa aa Total Controls Cases Controls
ATF1 rs2230674 1,071 86 2 1,159 1,021 81 1 1,103 0.04 0.04 0.69
ATM rs1800057 1,087 85 2 1,174 1,015 85 0 1,100 0.04 0.04 0.68
rs2234997 1,153 4 1 1,158 1,093 10 0 1,103 0 0 0.01
rs2235000 1,160 1 0 1,161 1,102 2 0 1,104 0 0 1
rs3218688 979 2 0 981 926 0 0 926 0 0 1
rs3218695 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs3218708 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs4987945 1,169 1 0 1,170 1,100 1 0 1,101 0 0 1
ATR rs2227928 401 520 229 1,150 344 517 218 1,079 0.43 0.44 0.011
rs2229032 899 242 17 1,158 833 253 16 1,102 0.12 0.13 0.89
BARD1 rs2070094 466 551 156 1,173 461 485 159 1,105 0.37 0.36 0.75
rs2229571 341 580 249 1,170 316 540 241 1,097 0.46 0.47 0.95
rs3738888 1,150 7 0 1,157 1,099 4 0 1,103 0 0 1
BLM rs11852361 1,123 46 2 1,171 1,046 52 2 1,100 0.02 0.03 0.094
rs7167216 1,127 44 2 1,173 1,055 47 2 1,104 0.02 0.02 0.081
BRIP1 rs4986764 475 534 161 1,170 465 502 141 1,108 0.37 0.35 0.57
CHEK1 rs506504 1,064 105 5 1,174 986 116 2 1,104 0.05 0.05 0.19
CHEK2 rs17879961 1,158 0 0 1,158 1,101 1 0 1,102 0 0 1
DBC2 rs2241261 342 560 252 1,154 288 546 264 1,098 0.46 0.49 0.26
DDB2 rs830083 871 271 15 1,157 803 277 21 1,101 0.13 0.14 0.3
DMC1 rs2227914 1,146 3 0 1,149 1,099 1 1 1,101 0 0 1
EME1 rs12450550 918 221 24 1,163 838 239 23 1,100 0.12 0.13 0.021
FANCA rs1800282 978 149 19 1,146 883 189 16 1,088 0.08 0.1 \0.0001
rs7190823 573 476 113 1,162 541 462 98 1,101 0.3 0.3 0.33
rs9282681 1,096 51 0 1,147 1,065 42 2 1,109 0.02 0.02 1
FANCC rs1800364 1,159 1 0 1,160 1,104 1 0 1,105 0 0 1
FANCD2 rs2272125 787 346 38 1,171 710 346 43 1,099 0.18 0.2 1
FANCE rs9462088 1,051 115 4 1,170 990 106 4 1,100 0.05 0.05 0.56
MLH1 rs1800149 1,156 0 1 1,157 1,101 0 2 1,103 0 0 0.00043
rs2020872 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs2308317 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs1800734 494 496 137 1,127 446 505 136 1,087 0.34 0.36 0.47
MRE11A rs1009456 1,040 105 0 1,145 992 89 5 1,086 0.05 0.05 0.17
rs10831234 949 190 12 1151 899 193 6 1,098 0.09 0.09 0.48
rs556477 444 550 167 1,161 494 473 130 1,097 0.38 0.33 0.9
MSH2 rs2303428 929 217 18 1,164 870 211 16 1,097 0.11 0.11 0.22
MSH6 rs1042821 653 451 64 1,168 646 388 70 1,104 0.25 0.24 0.24
rs1800935 655 428 90 1,173 608 413 83 1,104 0.26 0.26 0.094
MUS81 rs545500 673 430 55 1,158 589 435 77 1,101 0.23 0.27 0.22
NBS1 rs1805787 548 483 104 1,135 549 447 103 1,099 0.3 0.3 0.94
rs1805794 543 502 109 1,154 511 497 96 1,104 0.31 0.31 0.68
rs6413508 1,167 6 1 1,174 1,097 4 0 1,101 0 0 0.012
rs769416 1,141 10 0 1,151 1,098 3 0 1,101 0 0 1
rs769420 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs12677527 546 505 115 1,166 512 497 96 1,105 0.32 0.31 0.95
rs13312840 1,122 55 0 1,177 1,075 32 1 1,108 0.02 0.02 1
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change (Gly to Lys) at codon 216 of the NBS1 gene. This
SNP is not located within one of the three functional
regions of the NBS1 protein, but it may have an alternative
splicing regulatory effect, based on the Functional Single
Nucleotide Polymorphism (F-SNP) database [47]. Our
result on the association of rs769416 SNP and breast
cancer needs to be interpreted with caution, since this is a
rare SNP in our population and the most likely explanation
for this association is chance.
Haplotype analysis with the combination of the seven
NBS1 SNPs showed that the frequency of the GGCGCAC
haplotype (rs769416, rs769420, rs13312840, rs1805794,
rs6413508, rs12677527, rs1805787) was lower in patients
than in controls (0.0147 vs. 0.0225; P = 0.035), suggesting
a protective effect. There was also evidence for a protective
effect of the rare pooled NBS1 haplotypes. This protective
effect is driven by the difference in frequencies of the
pooled rare haplotypes that conferred a low risk
(OR = 0.42) and had a combined frequency of 3.29% in
controls and 1.37% in patients. It is possible that these
pooled haplotypes are a marker for a single, rare, protective
mutation in the Cypriot population. There may be value in
sequencing this region in order to help identify the pro-
tective variant(s). Both these findings need to be replicated
in independent studies in order to confirm or refute this
effect.
Our data support the notion that MUS81 rs545500 C
allele carriers are at an increased risk for breast cancer.
Rs545500 is a non-synonymous SNP located in the coding
region of MUS81, a structure-specific DNA nuclease that
plays an important role in DNA repair by homologous
recombination [48]. This polymorphism results in an amino
acid change from a positively charged hydrophilic arginine
to an uncharged hydrophobic proline residue, which may
have an effect on the 3D structure or a protein–protein
binding interface of the MUS81 protein [25]. The role of
the MUS81 gene in breast cancer has not been investigated.
However, it was demonstrated that MUS81 homozygote
and heterozygote knockout mice have a predisposition to
develop cancer. Proper bialellic expression of MUS81 is
critical for the maintenance of genomic integrity and tumor
suppression [49]. Therefore, the rs545500 SNP could pre-
dispose individuals to breast cancer, but functional studies
need to be performed in order to identify the actual role of
this variant in carcinogenesis.
Our findings also suggest that the PBOV1 rs6927706
polymorphism may be a risk factor for breast cancer.
Rs6927706 is a non-synonymous SNP located in the cod-
ing region of PBOV1, a gene which is upregulated in
prostate, breast and bladder cancers [21]. The polymor-
phism results in an amino acid change at codon 73 from a
hydrophobic isoleucine to a hydrophilic threonine residue.
Bioinformatics analysis indicates that this SNP could be
involved in splicing regulation [47]. However, further work
is warranted since the exact roles of the PBOV1 protein as
well as its functional domains are not well known at
present.
Our current data suggest that the MRE11A rs556477 G
allele may be associated with a reduced breast cancer risk.
The MRE11A gene forms a complex with RAD50 and
NBS1 genes which is involved in the cellular response to
DNA double-strand breaks. Defects in the members of this
Table 1 continued
Gene rs Number Controls Cases MAF HWE
AA Aa aa Total AA Aa aa Total Controls Cases Controls
PALB2 rs45494092 1,170 1 0 1,171 1,097 4 0 1,101 0 0 1
rs45532440 1,035 120 4 1,159 972 126 4 1,102 0.06 0.06 0.77
rs45478192 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs45551636 1,076 92 2 1,170 1,010 92 2 1,104 0.04 0.04 1
PBOV1 rs6927706 1,083 63 1 1,147 1,017 83 2 1,102 0.03 0.04 0.61
PCNA rs3626 827 242 36 1,105 838 196 34 1,068 0.14 0.12 0.0012
RAD50 rs2299015 742 370 45 1,157 743 323 37 1,103 0.2 0.18 1
rs2522406 1,064 41 1 1,106 1,044 31 0 1,075 0.02 0.01 0.34
rs2706377 1,052 66 21 1,139 1,046 37 14 1,097 0.05 0.03 \0.0001
rs3187395 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
RAD51C rs28363317 1,164 6 0 1,170 1,095 6 0 1,101 0 0 1
RAD51L1 rs28908468 572 201 0 773 979 75 0 1,054 0.13 0.04 \0.0001
RAD52 rs7487683 1,135 35 3 1,173 1,072 33 0 1,105 0.02 0.01 0.0043
RFC1 rs2066791 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
XPC rs2228000 673 402 64 1,139 653 379 65 1,097 0.23 0.23 0.68
rs2227999 1,040 128 4 1,172 963 138 4 1,105 0.06 0.07 1
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Table 2 Genotypic specific risk (OR and 95% CI)
Gene rs number Dominant OR (95% CI); P valuea Recessive OR (95% CI); P valuea Log-additive OR (95% CI); P valuea
ATF1 rs2230674 1.02 (0.74–1.42); 0.89 0.60 (0.05–7.34); 0.68 1.01 (0.73–1.40); 0.94
ATM rs1800057 1.10 (0.79–1.52); 0.57 – 1.07 (0.78–1.47); 0.69
rs2234997 2.31 (0.75–7.12); 0.13 – 1.83 (0.68–4.91); 0.23
rs4987945 1.27 (0.07–21.89); 0.87 – –
ATR rs2227928 1.14 (0.95–1.38); 0.15 1.04 (0.84–1.30); 0.71 1.07 (0.95–1.21); 0.25
rs2229032 1.09 (0.89–1.34); 0.42 1.01 (0.48–2.15); 0.97 1.07 (0.89–1.30); 0.45
BARD1 rs2070094 0.98 (0.82–1.17); 0.8 1.07 (0.83–1.37); 0.6 1.01 (0.89–1.14); 0.93
rs2229571 0.99 (0.82–1.20); 0.93 0.96 (0.78–1.18); 0.69 0.98 (0.87–1.11); 0.77
rs3738888 0.46 (0.13–1.66); 0.23 – –
BLM rs11852361 1.28 (0.85–1.95); 0.24 0.95 (0.13–7.12); 0.96 1.25 (0.84–1.85); 0.27
rs7167216 1.26 (0.82–1.94); 0.3 0.95 (0.13–7.14); 0.96 1.22 (0.81–1.84); 0.34
BRIP1 rs4986764 0.94 (0.79–1.12); 0.49 0.96(0.75–1.25); 0.78 0.96(0.85–1.09); 0.53
CHEK1 rs506504 1.19 (0.89–1.59); 0.24 0.48 (0.09–2.59); 0.37 1.15 (0.87–1.51); 0.34
DBC2 rs2241261 1.18 (0.97–1.43); 0.095 1.16 (0.94–1.43); 0.17 1.12 (0.99–1.27); 0.061
DDB2 rs830083 1.14(0.93–1.39); 0.2 1.51(0.74–3.07); 0.25 1.14(0.95–1.37); 0.15
DMC1 rs2227914 0.63 (0.09–4.39); 0.64 – 1.10 (0.25–4.73); 0.9
EME1 rs12450550 1.15 (0.94–1.42); 0.18 0.94 (0.52–1.72); 0.85 1.11 (0.92–1.33); 0.27
FANCA rs7190823 1.02 (0.86–1.22); 0.8 0.91 (0.68–1.23); 0.56 1.00 (0.87–1.14); 0.95
rs9282681 0.84 (0.54–1.30); 0.44 – 0.89 (0.58–1.35); 0.57
FANCC rs1800364 1.25 (0.07–21.55); 0.88 – –
FANCD2 rs2272125 1.12 (0.93–1.34); 0.24 1.08(0.68–1.72); 0.74 1.09 (0.93–1.28); 0.27
FANCE rs9462088 0.95 (0.71–1.26); 0.71 0.73 (0.15–3.53); 0.7 0.94 (0.71–1.24); 0.67
MLH1 rs1800734 1.09 (0.91–1.31); 0.33 1.01 (0.77–1.31); 0.96 1.05 (0.92–1.20); 0.46
MRE11A rs1009456 0.93 (0.68–1.26); 0.63 – 0.98 (0.73–1.32); 0.9
rs10831234 1.04 (0.83–1.31); 0.72 0.69 (0.25–1.93); 0.47 1.02 (0.82–1.26); 0.85
rs556477 0.76 (0.64–0.91); 0.0022 0.81 (0.62–1.05); 0.11 0.82 (0.72–0.93); 0.0027
MSH2 rs2303428 1.02 (0.82–1.26); 0.89 0.93 (0.45–1.89); 0.83 1.01 (0.83–1.22); 0.94
MSH6 rs1042821 0.85 (0.71–1.01); 0.066 1.23 (0.84–1.79); 0.29 0.92 (0.80–1.07); 0.27
rs1800935 1.09 (0.91–1.30); 0.34 1.07 (0.77–1.48); 0.69 1.07 (0.93–1.22); 0.36
MUS81 rs545500 1.21 (1.02–1.45); 0.031 1.43(0.98–2.08); 0.06 1.21(1.04–1.39); 0.012
NBS1 rs1805787 0.92 (0.77–1.10); 0.36 0.97 (0.72–1.31); 0.84 0.95 (0.83–1.08); 0.43
rs1805794 1.08 (0.91–1.28); 0.4 0.93 (0.69–1.26); 0.65 1.03 (0.90–1.18); 0.65
rs6413508 0.46 (0.13–1.66); 0.23 – 0.46 (0.14–1.50); 0.18
rs769416 0.23 (0.06–0.85); 0.017 – –
rs12677527 1.04 (0.88–1.24); 0.64 0.88 (0.65–1.19); 0.4 1.00 (0.87–1.14); 0.98
rs13312840 0.58 (0.37–0.92); 0.019 – 0.61 (0.39–0.95); 0.028
PALB2 rs45494092 3.75 (0.40–35.04); 0.2 – –
rs45532440 1.06 (0.81–1.40); 0.66 0.73 (0.18–3.04); 0.67 1.05 (0.80–1.36); 0.74
rs45551636 1.04 (0.76–1.43); 0.8 0.67 (0.09–4.89); 0.69 1.03 (0.76–1.4); 0.85
PBOV1 rs6927706 1.53 (1.07–2.18); 0.019 1.63(0.12–21.60); 0.71 1.51(1.06–2.13); 0.02
RAD50 rs2299015 0.89 (0.74–1.07); 0.21 0.90 (0.56–1.43); 0.65 0.91 (0.77–1.06); 0.22
rs2522406 0.80 (0.49–1.31); 0.37 – 0.78 (0.48–1.26); 0.31
rs3187395 0.32 (0.06–1.85); 0.19 – –
RAD51C rs28363317 0.93 (0.28–3.10); 0.91 – –
XPC rs2228000 1.01 (0.84–1.21); 0.91 0.96 (0.66–1.40); 0.85 1.00 (0.87–1.16); 0.99
rs2227999 1.12 (0.86–1.46); 0.42 1.10 (0.26–4.64); 0.42 1.11 (0.86–1.43); 0.43
Data in bold highlight the statically significant results
a Adjusted for age, menopause status, family history of breast cancer and use of hormone replacement therapy (HRT)
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tri-complex are linked to increased chromosomal instabil-
ity which leads to cancer [50]. The rs556477 common
variant is located in intron 15 of the MRE11A gene. The
rs556477 MAF is 40% in Caucasians as reported in NCBI’s
dbSNP database; the same as that observed in our popu-
lation. The functionality of this SNP is not clear. Using
the TFSEARCH webtool (http://www.cbrc.jp/research/
db/TFSEARCH.html), we searched for potential tran-
scription factors binding sites at this position. The
rs556477 SNP is located in a region that is a potential
transcription factor-binding site of activator protein 1
(AP-1), which plays a critical role in signal transduction
pathways in many cells. A recent study has shown that
inhibition of AP-1 transcription factors suppresses breast
cancer growth. Inhibitors that are capable of blocking AP-1
activation may be promising agents for the treatment and
prevention of breast cancer [51]. The reduced risk of breast
cancer for carriers of rs556477 SNP found in our study is in
contrast with the above finding since it is expected that the
creation of an AP-1 binding site will result in an increased
breast cancer risk. However, it must be taken into account
that the prediction that rs556477 A to G substitution results
in a gain of an AP-1 binding site is based on in silico
analysis and this remains to be proven by in vitro data.
Furthermore, the MRE11A rs556477 polymorphism may
not be causal, but could be in linkage disequilibrium with a
true protective variant.
In the current study, we present evidence for an
increased breast cancer risk for women carrying the
MRE11A AGCG (rs556477, rs601341, rs10831234,
rs1009456) haplotype. It is noteworthy that in a previous
study conducted by our group there was evidence for an
increased breast cancer risk for women homozygous for the
MRE11A rs601341 A allele [35]. The rs601341 A to G
substitution results in potential binding of ubiquitous tran-
scription factor Ying Yang 1 (YY1) that has a fundamental
role in normal biologic processes such as differentiation,
replication and cell proliferation. YY1 overexpression and/
or activation results in uncontrolled cellular proliferation,
resistance to apoptotic stimuli and tumorigenesis [52].
Given the intronic position of the two associated SNPs, it is
unlikely that these SNPs in and by themselves are disease
associated. Rather, in all likelihood, they are in linkage
disequilibrium with other variants that cause the associa-
tions observed.
Our study has several strengths, including a high par-
ticipation rate of eligible cases (98%) and a population
sample from a homogeneous ethnic background (all par-
ticipants are Greek Cypriots) thus reducing any potential
bias due to population stratification. In addition, our study
population (both cases and controls) was from all over the
country minimizing potential selection bias.
However, there were limitations in our study, one of
which is the possibility of survivor bias. This is one of the
Table 3 Estimated haplotype frequencies in cases and controls and haplotypic specific risks
Gene Haplotype Control freq Case freq OR [95% CI] v2 P value Global test P value
ATMa CCCCCTGC 0.92 0.9225 1.00 0.53
GCCCCTGC 0.0367 0.0349 0.96 (0.69–1.32) 0.8
CCCCGTGC 0.0376 0.0329 0.89 (0.34–1.23) 0.48
Rare 0.0057 0.0097 1.6 (0.72–3.57) 0.25
MRE11Ab GACG 0.3702 0.326 1.00 0.021
AGCG 0.2384 0.2752 1.32 (1.13–1.54) 4 3 1024
AACG 0.2478 0.255 1.17 (1.00–1.36) 0.044
AGTG 0.0864 0.0891 1.16 (0.93–1.45) 0.19
AGCT 0.0444 0.0438 1.12 (0.84–1.51) 0.44
Rare 0.0128 0.0109 0.98 (0.52–1.85) 0.95
NBS1c GGTCCGC 0.3705 0.3886 1.00 0.00019
GGTCCGG 0.2955 0.2925 0.94 (0.82–1.09) 0.44
GGTGCAC 0.2786 0.2905 0.99 (0.86–1.15) 0.92
GGCGCAC 0.0225 0.0147 0.62 (0.39–0.97) 0.037
Rare 0.0329 0.0137 0.42 (0.26–0.66) 2 3 1024
Data in bold highlight the statically significant results
a ATM haplotypes are arranged in the order of rs1800057, rs3218688, rs3218695, rs4987945, rs2230674, rs2234997, rs2235000, rs3218708
b MRE11A haplotypes are arranged in the order of rs556477, rs601341, rs10831234, rs1009456
c NBS1 haplotypes are arranged in the order of rs769416, rs769420, rs13312840, rs1805794, rs6413508, rs12677527, rs1805787
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known disadvantages of all retrospective case–control
studies. In our study, samples from breast cancer cases
were collected between 2004 and 2006 for cases diagnosed
between 1999 and 2006. Our study may therefore have
excluded a number of women with the most aggressive
form of breast cancer, diagnosed between 1999 and 2003.
It is possible that this could lead to ‘‘survivor bias’’ if
genotypes differ between those who succumb quickly
compared with longer-term breast cancer survivors.
The SNP selection for this study was based solely on
functionality and their position in genes interacting with
BRCA1/2 rather than allele frequency. As a result of this, a
number of monomorphic/low-polymorphic SNPs were
included in the study. It is noted that this is the first time
that these SNPs were studied in the Cypriot population, and
their allele frequencies were a priori unknown. Rare SNPs
can also contribute to disease risk [53]. However, our study
did not have sufficient power to detect such associations,
and the possibility that some of the low-polymorphic SNPs
studied contribute to breast cancer risk cannot be ruled out.
Another limitation of our study is that we did not con-
sider the possibility of gene–gene interactions or gene–
environment interactions. It is possible that the risks
observed are the result of interactions, but we have not
attempted to assess such effects, since the estimate of an
interaction effect will be unreliable because of the small
numbers available. Furthermore, we did not account for
multiple testing. When multiple comparisons are being
made, statistically significant associations may be identi-
fied by chance alone. Replication in independent, well-
powered studies is the gold standard of bona fide true
associations from chance findings. A Cypriot replication
set is not available to attempt to replicate the variants
identified, and replication will need to be performed in
other populations.
In conclusion, this study provides support for the
hypothesis that genetic variants in DNA repair genes
influence breast cancer risk and provides further evidence
for the polygenic model of breast cancer. However, large-
scale genetic epidemiologic studies are warranted to further
examine and corroborate the associations observed
between polymorphisms and breast cancer in multiethnic
groups. In addition, elucidation of the functional impact of
the breast cancer associated SNPs is needed in order to
provide further insights into their mechanistic effects on
risk.
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Abstract The DNA repair pathway is known to play a
role in the etiology of breast cancer. A number of studies
have demonstrated that common germline variants in genes
involved in the DNA repair pathway influence breast
cancer risk. To assess whether alterations in DNA repair
genes contribute to breast cancer, we genotyped 12 single
nucleotide polymorphisms (SNPs) in 1,109 Cypriot women
with breast cancer and 1,177 age-matched healthy controls.
We found significant associations with breast cancer for
SNPs in the BRCA2 and MRE11A genes. Carriers of the
BRCA2 rs1799944 variant (991 Asp) were found to have an
increased risk of breast cancer (OR = 1.41, 95% CI 1.08–
1.83, P = 0.01) with Ptrend = 0.0076. Homozygous carri-
ers of the MRE11A rs601341 A allele had an increased risk
of breast cancer (OR = 1.36, 95% CI 1.08–1.71,
P = 0.009) with Ptrend = 0.0087. This study suggests that
genetic variants in BRCA2 and MRE11A are associated
with breast cancer risk.
Keywords Breast cancer  Case-control study 
Cyprus  DNA repair genes  Genetic epidemiology 
SNP
Introduction
Breast cancer is the most common malignancy affecting
women worldwide and it is the leading female cancer in
Cyprus, with approximately 350–400 new cases diagnosed
annually [1].
The DNA repair pathway is essential for maintaining
genomic stability of mammalian cells. Deficiencies in
DNA repair mechanisms lead to high penetrance genetic
syndromes such as Fanconi anemia and Bloom syndrome,
which have cancer as a predominant phenotype [2]. Ten
different genes, involved in pathways critical to genomic
integrity, have been implicated in inherited predisposition
to breast cancer. Germline mutations in these genes sig-
nificantly increase breast cancer risk and thus support a
major role of the DNA repair pathway in breast carcino-
genesis. The most important of these genes are BRCA1 and
BRCA2 [3]. There is also evidence from in vitro studies
that reduced DNA repair capacity is associated with
increased breast cancer risk [4, 5].
The known breast cancer susceptibility genes have been
estimated to explain only 5% of breast cancer cases, thus it
is likely that other breast cancer susceptibility genes exist
[6]. Based on the fact that the DNA repair pathway is
involved in familial breast cancer it was suggested that
single nucleotide polymorphisms (SNPs) in genes involved
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in DNA repair may influence DNA repair capacity and, in
turn, confer an altered susceptibility to develop breast
cancer. Several studies have investigated the role of SNPs
in DNA repair genes in relation to breast cancer and have
reported associations with breast cancer risk [7–10].
In this study, we hypothesized that genetic variation in
the DNA repair pathway may modify susceptibility to
breast cancer in Cypriot women. As part of an ongoing
study we assessed genetic variation in 12 SNPs in 11 DNA
repair-related pathway genes, specifically BARD1, BRCA2,
ERCC2, FANCA, MLH1, MRE11A, MSH2, OGG1, RAD51,
RAD52, and TP53 and their association with breast cancer
in a case-control study of Cypriot women.
Materials and methods
Subjects
The study population was women participating in the
MASTOS study, a population-based case-control study of
breast cancer in Cyprus [11]. Blood samples were collected
between 2004 and 2006 from 1,109 female breast cancer
patients diagnosed between 40 and 70 years old and 1,177
aged-matched healthy controls. Cases participating in the
study were women previously diagnosed with breast cancer
between January 1999 and December 2006. In addition to
blood samples, a risk factor questionnaire that included
extensive demographic, epidemiological, and pathological
data was obtained from each participant through a stan-
dardized interview. Breast cancer cases were verified by
reviewing histological reports. The study was approved by
the National Bioethics Committee of Cyprus, and all par-
ticipants provided signed informed consent.
Genotyping
DNA was isolated from blood samples using standard
procedures (phenol-chloroform method). The 12 single
nucleotide polymorphisms (SNPs): BARD1 rs1048108
(Pro24Ser), BRCA2 rs1799944 (Asn991Asp), ERCC2
rs13181 (Lys751Gln), FANCA rs2239359 (Gly501Ser),
MLH1 rs1799977 (Ile219Val), MRE11A rs601341, MSH2
rs2059520, OGG1 rs1052134 (Ser326Cys), RAD51
rs1801320 and rs1801321 (135G [ C-50UTR and 172
G [ T-50UTR), RAD52 rs11226 (2259 C [ T-30UTR) and
TP53 rs1042522 (Pro72Arg) were genotyped in all subjects
participating in the study. All SNPs studied had a minor
allele frequency of over 0.05. Genotyping was performed
using the Taqman SNP genotyping assays from Applied
Biosystems Inc. (ABI). For genotyping SNP rs1801320 the
primers and probes described previously by Kuschel et al.
were used [8]. Each assay was carried out using 10 ng
genomic DNA in a 5 ll reaction using Taqman Universal
PCR Master Mix (ABI), forward and reverse primers, and
FAM and VIC-labelled probes purchased from Applied
Biosystems (ABI Pre-Designed assays). All assays were
carried out in 384-well plates. The fluorescence profile was
read on an ABI PRISM 7900HT instrument and the results
analyzed with Sequence Detection Software (ABI). For
quality control, random samples were genotyped in dupli-
cate and had identical genotyping assignments. Genotype
call rates ranged from 99% to 100% and duplicate con-
cordance rates were higher than 99%.
Data analysis
We performed a chi square test (v2) to assess Hardy–Wein-
berg equilibrium (HWE) in the control samples. Genotype
frequencies were compared across groups using the v2 test
and the Mantel–Haenzel test for linear trend. The association
between breast cancer and each SNP was examined using
logistic regression with the SNP genotype tested under
models of complete dominance and recessive inheritance.
Statistical analysis was carried out using the SPSS v 13
software (SPSS Inc., Chicago, Illinois) and GraphPad InStat
v 3.06 (GraphPad Software, San Diego California).
Results
Genotype distributions of controls at each locus were
consistent with HWE. However, the RAD51 genotype
frequencies in the controls were not in HWE (P \ 0.05),
but were similar to the frequencies reported by the HapMap
Project (www.hapmap.org) [12]. This may be due to hid-
den population structures that specifically affect RAD51.
Neither of the RAD51 SNPs were associated with breast
cancer. Table 1 summarizes the distribution of genotypes
among cases and controls, as well as the allele frequencies
of the 12 SNPs under study.
The median ages of both the breast cancer cases and the
controls were 56 years. The mean age at diagnosis for the
breast cancer cases was 51.6 years (standard deviation
(SD) ± 9.2) and mean age at ascertainment for the controls
was 56.4 years ((SD) ± 9.2).
The associations of the SNPs and breast cancer risk in
Cypriot women are shown in Table 2. We found significant
associations of the BRCA2 rs1799944 (Asn991Asp) and
MRE11A rs601341 variants and breast cancer risk. Carriers
of BRCA2 991 Asp were found to have an increased risk of
breast cancer (OR = 1.41, 95% CI 1.08–1.83, P = 0.01)
with Ptrend = 0.0076. Homozygous carriers of the
MRE11A rs601341 A allele had an increased risk of breast
cancer (OR = 1.36, 95% CI 1.08–1.71, P = 0.009) with
Ptrend = 0.0087. A marginal association (P = 0.05) was
624 Breast Cancer Res Treat (2009) 115:623–627
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observed between TP53 rs1042522 (Pro72Arg) and risk of
breast cancer. No significant associations with breast can-
cer were observed for the other nine SNPs studied.
Discussion
Breast cancer is a common, polygenic, and heterogeneous
disease. Genetic epidemiology data suggest that part of
breast cancer etiology can be explained by common, low-
penetrance alleles that increase susceptibility to breast
cancer risk [13]. DNA repair is essential for maintaining
genomic integrity. Deficiencies in the DNA repair pathway
lead to genetic instability which in turn may lead to cancer
development. Genetic polymorphisms in DNA repair genes
may contribute to differential DNA repair capability
between individuals [14]. In an attempt to identify low-
penentrance breast cancer susceptibility alleles, we
Table 1 Genotypes and allele frequencies for the 12 SNPs under study
Gene/SNP Cases Controls P-valuea Gene/SNP Cases Controls P-valuea
MSH2 (rs2059520) RAD51 135G [ C (rs1801320)
A/A 512 562 0.8 G/G 915 952 0.5
A/G 471 489 G/C 193 216
G/G 108 119 C/C 0 0
MAFb 0.31 0.31 MAFb 0.09 0.09
Hardy–Weinbergc 0.41 Hardy–Weinbergc 0.0005
MLH1 Ile219Val (rs1799977) RAD51 172 G [ T (rs1801321)
Ile/Ile 543 568 0.78 G/G 340 400 0.24
Ile/Val 449 497 G/T 522 530
Val/Val 98 110 T/T 236 236
MAFb 0.3 0.31 MAFb 0.45 0.43
Hardy–Weinbergc 0.93 Hardy–Weinbergc 0.01
MRE11A (rs601341) BRCA2 Asn991Asp (rs1799944)
G/G 385 452 0.02 Asn/Asn 945 1058 0.03
G/A 530 566 Asn/Asp 133 108
A/A 190 156 Asp/Asp 8 4
MAFb 0.41 0.37 MAFb 0.07 0.05
Hardy–Weinbergc 0.31 Hardy–Weinbergc 0.49
BARD1 Pro24Ser (rs1048108) OGG1 Ser326Cys (rs1052134)
Pro/Pro 515 514 0.18 Ser/Ser 615 647 0.93
Pro/Ser 445 520 Ser/Cys 422 455
Ser/Ser 138 138 Cys/Cys 71 72
MAFb 0.33 0.34 MAFb 0.25 0.26
Hardy–Weinbergc 0.71 Hardy–Weinbergc 0.5
FANCA Gly501Ser (rs2239359) TP53 Pro72Arg (rs1042522)
Gly/Gly 387 433 0.52 Pro/Pro 555 638 0.08
Gly/Ser 524 543 Pro/Arg 463 438
Ser/Ser 190 186 Arg/Arg 85 97
MAFb 0.41 0.39 MAFb 0.29 0.27
Hardy–Weinbergc 0.47 Hardy–Weinbergc 0.08
ERCC2 Lys751Gln (rs13181) RAD52 2259C [ T (rs11226)
Lys/Lys 331 383 0.06 C/C 561 568 0.4
Lys/Gln 603 585 C/T 448 494
Gln/Gln 171 208 T/T 92 108
MAFb 0.43 0.43 MAFb 0.29 0.3
Hardy–Weinbergc 0.55 Hardy–Weinbergc 0.97
a Genotype frequency P-value
b MAF = minor allele frequency
c P-value from Chi-square test
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investigated the hypothesis that common variation in 11
DNA repair-related pathway genes modifies risk for breast
cancer. We genotyped 12 SNPs in a cohort of 2,286
Cypriot women (1,109 breast cancer patients and 1,177
healthy controls). We found that SNPs in BRCA2 and
MRE11A may be associated with breast cancer risk.
For the BRCA2 991Asp allele, the additive model
showed a significant trend (P = 0.0076) towards increased
risk of breast cancer with the number of copies of the Asp
allele among Cypriot women. It is located in the conserved
BRC repeat region of the BRCA2 gene in exon 11 [15].
This variant has been found in many individuals with a
family history of breast cancer and has been classified as a
variant of no clinical significance in the Breast Cancer
Information Core Database (BIC) [16]. On the other hand,
in silico prediction methods suggest that this is a non-
tolerated amino acid substitution within the limits of con-
fidence in the alignments [17]. Therefore, until functional
data become available, the pathogenicity of this variant
cannot be excluded, and it may be a variant that increases
risk moderately, but is indeed, not highly penetrant. There
was no association between the presence of the BRCA2
991Asp allele and family history of breast cancer. A
moderately strong association of this BRCA2 polymor-
phism with malignant melanoma has been reported. The
presence of this common BRCA2 variant was associated
with malignant melanoma risk (P = 0.002 after Bonferroni
correction), in over 9% of the cases studied. The authors
suggested that this variant is not a neutral missense muta-
tion and that follow-up studies should be undertaken in
melanoma and breast cancer populations to precisely define
its pathogenicity [18]. The role of this SNP in breast cancer
risk has been investigated in the Multiethnic Cohort study
and no association was found [19]. Previous studies that we
performed in our population revealed a different spectrum
of mutations in the BRCA1 and BRCA2 genes compared to
other populations [20, 21]. The over-representation of the
BRCA2 Asn991Asp polymorphism in the breast cancer
group supports that this variant is associated with an
increased breast cancer risk among Cypriot women and it is
possible that this association is characteristic only for the
Cypriot population.
In the current study, there was also evidence for an
increased breast cancer risk for women homozygous for the
MRE11A rs601341 A allele. The MRE11A gene forms a
complex with RAD50 and NBS1 genes which is involved in
the cellular response to DNA double strand breaks. Defects
in the members of this tri-complex are linked to increased
chromosomal instability which leads to cancer [22]. To our
knowledge, the role of rs601341 in breast cancer has not
been investigated but a protective effect of this SNP against
follicular lymphoma has been reported [23]. rs601341 may
be in LD with another variant in the region. Functional
studies will need to be performed in the future to identify
the actual causal variant.
There are contradictory reports regarding the role of the
TP53 Pro72Arg polymorphism and breast cancer. Our
results suggest a marginal increased risk for breast cancer
(P = 0.05) for carriers of the Pro allele. A meta-analysis
conducted by the Breast Cancer Association Consortium
concluded that this variant is not associated with breast
cancer [24].
Table 2 Genotype frequencies and risk estimates calculated using
the recessive and dominant inheritance models
Gene SNP Model OR 95% CI P-value
MSH2 rs2059520 Dominant 1.05 0.89–1.23 0.6
Recessive 0.97 0.74–1.28 0.83
0.76a
MLH1 rs1799977 Dominant 0.94 0.8–1.11 0.48
Recessive 0.96 0.72–1.27 0.76
0.5a
MRE11A rs601341 Dominant 1.17 0.99–1.39 0.07
Recessive 1.36 1.08–1.71 0.009
0.0087a
BARD1 rs1048108 Dominant 0.88 0.75–1.04 0.15
Recessive 1.08 0.84–1.39 0.56
0.43a
FANCA rs2239359 Dominant 1.1 0.92–1.3 0.3
Recessive 1.09 0.88–1.37 0.42
0.25a
ERCC2 rs13181 Dominant 1.13 0.95–1.35 0.18
Recessive 0.85 0.68–1.06 0.16
0.89a
RAD51 rs1801320 Dominant 0.93 0.75–1.15 0.5
Recessive
0.5a
RAD51 rs1801321 Dominant 1.16 0.98–1.39 0.09
Recessive 1.08 0.88–1.32 0.46
0.13a
BRCA2 rs1799944 Dominant 1.41 1.08–1.83 0.01
Recessive 2.16 0.65–7.2 0.2
0.0076a
OGG1 rs1052134 Dominant 0.98 0.83–1.16 0.85
Recessive 1.05 0.75–1.47 0.79
0.96a
TP53 rs1042522 Dominant 1.18 1–1.39 0.05
Recessive 0.93 0.68–1.25 0.62
0.19a
RAD52 rs11226 Dominant 0.89 0.76–1.06 0.19
Recessive 0.9 0.68–1.21 0.5
0.19a
a Ptrend
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Our study has several strengths, including a high par-
ticipation rate of eligible cases (98%) and a sample from a
homogeneous ethnic background (100% of study partici-
pants are Greek Cypriots) thus reducing the bias due to
population stratification. In addition, our study population
(both cases and controls) was from all over the country
minimizing potential selection bias. Limitations of this
study are that our analysis did not consider the possibility
of gene-gene interactions. It is possible that the risks
observed are the result of interactions but we have not
attempted to assess such effects since the estimate of an
interaction effect will be unreliable because of small
numbers. We also did not adjust for possible differences in
lifestyle factors.
In conclusion our results suggest that genetic variation in
the DNA repair pathway is associated with breast cancer risk
in Cypriot women. The associations with SNPs rs1799944
and rs601341 should be considered for replication efforts in
other larger studies to increase confidence in reported
association and to clarify whether the association is only
specific for the Cypriot population.
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Abstract Population-based studies have reported signifi-
cant associations between specific genetic polymorphisms
and breast cancer susceptibility. A number of studies have
demonstrated that common variants of genes involved in the
DNA repair pathway act as low penetrance breast cancer
susceptibility alleles. We aimed to investigate the associa-
tion of single nucleotide polymorphisms (SNPs) in the DNA
repair genes XRCC1, XRCC2 and XRCC3 and breast cancer
in MASTOS, a population-based case–control study of 1,109
Cypriot women with breast cancer diagnosed between 40
and 70 years and 1,177 age-matched healthy controls. Five
coding SNPs were genotyped including rs1799782, rs25489
and rs25487 in XRCC1, rs3218536 in XRCC2 and rs861539
in XRCC3. Homozygous XRCC1 280His carriers had an
increased risk of breast cancer (odds ratio 4.68; 95% CI
1.01–21.7; P = 0.03). The XRCC2 188His allele was
associated with a marginal protective effect for breast
cancer (odds ratio 0.79; 95% CI 0.62–1.00; P = 0.05). No
significant associations were observed between the other
three SNPs and breast cancer. This study suggests that
genetic variation in SNPs in XRCC1 and XRCC2 genes may
influence breast cancer susceptibility.
Keywords Breast cancer  Case–Control study 
Cyprus  DNA repair  Genetic epidemiology 
Polymorphisms  XRCC1  XRCC2  XRCC3
Introduction
Breast cancer is the most common malignancy affecting
women worldwide [1]. In Cyprus, it is the most frequent
type of cancer in women, with approximately 350–400 new
cases diagnosed annually. It is estimated that about 5% of
breast cancer cases are related to mutations in rare but
highly penetrant genes, such as BRCA1 and BRCA2 [2].
Previous studies that we performed in our population
revealed a different spectrum of mutations in the BRCA1/2
genes compared to other populations [3, 4]. It is likely that
low penetrant cancer susceptibility genes contribute to a
larger proportion of breast cancer cases.
The DNA repair pathway is essential for maintaining
genomic stability of mammalian cells. Deficiencies in the
DNA repair system are likely to cause chromosomal
aberrations which in turn lead to cell malfunctioning, cell
death and tumorigenesis [5]. Several studies have demon-
strated that polymorphisms in genes responsible for
maintaining genomic integrity are modifiers of disease risk
[6, 7]. Therefore, single nucleotide polymorphisms (SNPs)
of genes involved in DNA repair are good candidates for
low penetrance breast cancer susceptibility alleles.
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The XRCC (X-Ray cross-complementing) genes were
initially discovered through their role in DNA damage
response caused by ionizing radiation. They are important
components of various DNA repair pathways contributing
to DNA-damage processing and genetic stability [8].
XRCC1 gene is an important component of the base exci-
sion repair (BER) pathway acting as a scaffold for other
BER enzymes [9]. XRCC2 and XRCC3 genes are necessary
for homologous recombination repair (HRR) and are
required for RAD51 focus formation [10, 11].
The aim of this study was to test the hypothesis that
common variants in the XRCC genes modify susceptibility
to breast cancer. We focused the present investigation on
evaluating five potentially functional SNPs in the XRCC1,
XRCC2 and XRCC3 genes.
Materials and methods
Subjects
The study population was women participating in the
MASTOS (Greek word for breast) study, a population-based
case–control study of breast cancer in Cyprus. Blood
samples were collected between 2004 and 2006 from 1,109
female breast cancer patients diagnosed between 40 and
70 years old and 1,177 aged-matched healthy controls.
Cases participating in the study were women who were
previously diagnosed with breast cancer between January
1999 and December 2006. In addition to blood samples, a
risk factor questionnaire which included extensive demo-
graphic, epidemiological and pathological data was
obtained from each participant through a standardized
interview. Breast cancer cases were verified by reviewing
histological reports. The study was approved by the
National Bioethics Committee of Cyprus, and all partici-
pants provided signed informed consent.
Genotyping
DNA was isolated from blood samples using standard
procedures (phenol–chloroform method). The five single
nucleotide polymorphisms (SNPs): XRCC1 Arg194Trp
(rs1799782), XRCC1 Arg280His (rs25489), XRCC1
Arg399Gln (rs25487), XRCC2 Arg188His (rs3218536) and
XRCC3 Thr241Met (rs861539) were genotyped in all
subjects participating in the study. We used three PCR-
RFLP (restriction fragment length polymorphism) assays
for genotyping XRCC1 194 and 399 and XRCC3 241 SNPs
as described previously by Hu et al. [12]. The XRCC1 280
SNP was also identified by PCR-RFLP using GTCTGA
GGGAGGAGGGTCTG and CAGAGGAGCTGGGGAA
GATC primers. Detailed PCR conditions are available on
request. Amplified DNA was digested with RsaI enzyme
and size separated on a 2% agarose gel. A similar protocol
was followed for XRCC2 188 SNP using the primer pairs
CACCCATCTCTCTGCCTTT and CCTCTCGACGACTG
TGTGAT. Amplified DNA was digested with SexAI
enzyme and size separated on a 2% agarose gel. Overall
success rate for the genotyping assays was 99%. For
quality control, random samples were genotyped in dupli-
cate and had identical genotyping assignments. Direct
sequencing was also used to confirm these calls.
Data analysis
Using the control samples, a Chi square test (v2) was
applied to test for Hardy–Weinberg equilibrium (HWE).
Genotype frequencies were compared across groups using
the v2-test and the Mantel–Haenzel test for linear trend.
The association between breast cancer and each SNP was
examined using logistic regression with the SNP genotype
tested under models of complete dominance and recessive
inheritance. Because the XRCC2 188His alleles are
uncommon in this population, individuals with genotypes
Arg/His and His/His were combined into one group as
188His allele carriers and were compared with Arg/Arg
homozygotes as the reference. Statistical analysis was
carried out using the SPSS v 13 software (SPSS Inc.,
Chicago, IL) and GraphPad InStat v 3.06 (GraphPad
Software, San Diego, CA).
Results
The genotype frequencies in the controls were in HWE for
the two SNPs in XRCC1 (codons 194 and 399) and the SNP
in XRCC3 (codon 241). The XRCC1 280 SNP and the
XRCC2 188 SNP significantly deviated from HWE
(P \ 0.05). The deviations observed are likely to be chance
results rather than genotyping errors since the homozygotes
for these SNPs are very rare in this population. In XRCC1,
only two controls were homozygous for the 280His allele
and only one control was homozygous for the XRCC2
188His allele. Table 1 summarizes the distribution of
genotypes among cases and controls as well as the allele
frequencies of the five SNPs under study.
The median age of both the breast cancer cases and the
controls was 56 years. The mean age at diagnosis for the
breast cancer cases was 51.6 years (standard deviation
(SD) ± 9.2) and mean age at ascertainment for the controls
was 56.4 ((SD) ± 9.2).
We found significant associations of the XRCC1
Arg280His and XRCC2 Arg188His variants and breast
576 Breast Cancer Res Treat (2008) 112:575–579
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cancer risk. Homozygous carriers of XRCC1 280His were
found to have an increased risk of breast cancer (OR =
4.68, 95% CI 1.01–21.7, P = 0.03). Carriers of the XRCC2
His allele had a decreased risk of breast cancer (OR =
0.79, 95% CI 0.62–1.0, P = 0.05). No significant associ-
ations with breast cancer were observed for SNPs XRCC1
Arg194Trp, XRCC1 Arg399Gln and XRCC3 Thr241Met
(Table 2).
Discussion
Breast cancer is a polygenic disease. The polygenic model
of breast cancer suggests that there are multiple low-
penetrance alleles, each or in combination, together with
environmental interactions that have a small effect on
breast cancer risk [13]. DNA repair is essential for main-
taining genomic integrity. Deficiencies in the DNA repair
pathway lead to genetic instability which in turn may lead
to cancer development. Genetic polymorphisms in DNA
repair genes may contribute to differential DNA repair
capability between individuals [14]. In an attempt to
identify low-penentrance breast cancer susceptibility
alleles we have examined the hypothesis that common
variation in XRCC1, XRCC2 and XRCC3 modifies risk for
breast cancer. We have genotyped five SNPs in a cohort of
2,286 Cypriot women (1,109 breast cancer patients and
1,177 healthy controls). We found that SNPs in XRCC1
and XRCC2 may be associated with breast cancer risk.
Comparison of the XRCC1 Arg280His genotypes
between breast cancer cases and healthy controls revealed
that the XRCC1 280His allele is associated with an
increased risk of breast cancer. We observed a 4- to 5-fold
increased risk for breast cancer in women homozygous for
the His allele compared to those homozygous for the Arg
allele. The XRCC1 codon 280 polymorphism is located in
the linker region that separates DNA polymerase b inter-
acting domain from PARP (poly-ADP-ribose polymerase)
interacting domain [15]. A recently published functional
study, which investigated the role of XRCC1 variants in
altering DNA repair capacity, has shown that relative to the
wild-type protein, the 280His variant decreases the DNA
repair capacity of mammalian cells exposed to chemical
stresses. In the same study, a positive association was
observed between the XRCC1 Arg280His genotype, breast
cancer and smoking [16]. In our study three of the nine
women who were homozygous for the 280His variant were
smokers who started smoking at a young age. It is possible
that the additional 280His homozygous carriers were
exposed for a long duration to passive smoking and that the
combination of the exposure and the XRCC1 280His
genotype has increased their breast cancer risk. Unfortu-
nately information on passive smoking exposure was not
collected and our hypothesis cannot be confirmed.
In the current study, there was also some evidence of a
dominant protective effect for the XRCC2 188His allele
carriers. There are contradictory reports regarding the role
of this rare XRCC2 variant in breast cancer, with some
studies showing an association with increased risk of breast
cancer whereas others did not. A recent meta-analysis
conducted by the Breast Cancer Association Consortium
concluded that this variant is not associated with breast
cancer [17]. We observed a protective effect of 188His
Table 1 Genotypes and allele frequencies for the five SNPs under
study
Cases Controls P-valueb
XRCC1 Arg194Trp
Arg/Arg 914 973 0.97
Arg/Trp 175 182
Trp/Trp 8 9
Arg allele frequency 0.91 0.91
Trp allele frequency 0.09 0.09
Hardy–Weinberga 0.88
XRCC1 Arg280His
Arg/Arg 923 959 0.05
Arg/His 177 207
His/His 9 2
Arg allele frequency 0.91 0.91
His allele frequency 0.09 0.09
Hardy–Weinberga 0.01
XRCC1 Arg399Gln
Arg/Arg 506 520 0.7
Arg/Gln 479 516
Gln/Gln 122 140
Arg allele frequency 0.67 0.66
Gln allele frequncy 0.33 0.34
Hardy–Weinberga 0.49
XRCC2 Arg188His
Arg/Arg 972 999 0.14
Arg/His 135 177
His/His 1 1
Arg allele frequency 0.94 0.92
His allele frequency 0.06 0.08
Hardy–Weinberga 0.02
XRCC3 Thr241Met
Thr/Thr 312 351 0.75
Thr/Met 560 600
Met/Met 220 226
Thr allele frequency 0.54 0.55
Met allele frequency 0.46 0.45
Hardy–Weinberga 0.28
a P-value from v2-test
b Genotype frequency P-value
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variant, similar to what was observed in a previous study
[18]. In the Polish population, homozygotes for the 188His
variant showed a decreased risk for breast cancer, but the
association was only borderline significant when data were
pooled with those from a U.S. study [18]. It is interesting to
note that a moderately strong association of the XRCC2
Arg188His polymorphism with epithelial ovarian cancer
has been reported. Women carrying one His allele had a
20% reduction in risk and those carrying two His alleles
had a 50% reduction in risk of epithelial ovarian cancer
compared with those homozygous for the Arg allele [19]. It
is therefore possible that the rare XRCC2 188His allele is
associated with a decreased risk of breast cancer but its
functional effect must be determined in order to clarify its
role in breast cancer.
Our data did not support a significant association of risk
of breast cancer with the XRCC1 Arg188His, Arg399Gln
and XRCC3 Thr241Met SNPs. These results are compara-
ble with those reported from the Breast Cancer Association
Consortium where variants XRCC1 Arg399Gln and XRCC3
Thr241Met did not modify breast cancer risk [17]. In
addition, the XRCC1 Arg194Trp variant has been studied
extensively and no association with breast cancer has been
observed [20].
Conflicting evidence for association may be due to
population-specific differences. One example is the XRCC1
Arg399Gln SNP which was associated with an increased
risk of lung cancer among Asians but not among Cauca-
sians [21]. The SNPs evaluated in the present study have
been studied extensively in many population datasets and
conflicting results have been reported [17]. The Greek
Cypriots appear to be a genetic isolate, as shown by the
results obtained from our study of the genetics of familial
breast cancer [3]. It is possible that the associations
observed with the XRCC1 280 and XRCC2 188 SNPs and
breast cancer are characteristic mainly for the Cypriot
population.
Our study has several strengths, including a high par-
ticipation rate of eligible cases (98%) and a sample from a
homogeneous ethnic background (100% of study partici-
pants are Greek Cypriots) thus reducing the bias due to
population stratification. In addition, our study population
(both cases and controls) was from all over the country
minimizing potential selection bias. Limitations of this
study are that our analysis did not consider the possibility
of gene–gene interactions. It is possible that the risks
observed are the result of interactions but we have not
attempted to assess such effects since the estimate of an
interaction effect will be unreliable because of small
numbers. For this type of analysis a very large sample size
is essential. We also did not adjust for possible differences
in lifestyle factors nor account for multiple testing.
In conclusion our results suggest that genetic variation
in the DNA repair pathway is associated with breast cancer
risk in Cypriot women. Taking into account the important
roles of XRCC1 and XRCC2 genes in BER and HRR
pathways, the small but statistically significant differences
in breast cancer risk in Cypriot women associated with the
XRCC1 280His and the XRCC2 188His variants may
indicate a true association.
Table 2 Genotype frequencies
and risk estimates calculated
using the recessive and
dominant inheritance models
Gene SNP Genotypes Cases, n Controls, n OR 95% CI P-value
XRCC1 Arg194Trp Arg/Arg 914 973 1.00
Arg/Trp 175 182 1.02 0.82–1.28 0.84
Trp/Trp 8 9 0.95 0.36–2.46 0.91
Ptrend 0.89
XRCC1 Arg280His Arg/Arg 923 959 1.00
Arg/His 177 207 0.89 0.71–1.11 0.29
His/His 9 2 4.68 1.01–21.7 0.03
Ptrend 0.77
XRCC1 Arg399Gln Arg/Arg 506 520 1.00
Arg/Gln 479 516 0.95 0.8–1.14 0.6
Gln/Gln 122 140 0.9 0.68–1.18 0.43
Ptrend 0.71
XRCC2 Arg188His Arg/Arg 972 999 1.00
Arg/His and His/His 136 178 0.79 0.62–1 0.05
XRCC3 Thr241Met Thr/Thr 312 351 1.00
Thr/Met 560 600 1.05 0.87–1.27 0.62
Met/Met 220 226 1.1 0.86–1.39 0.46
Ptrend 0.45
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Short Report
Contribution of BRCA1 and BRCA2
germline mutations to the incidence of
early-onset breast cancer in Cyprus
Loizidou M, Marcou Y, Anastasiadou V, Newbold R, Hadjisavvas A,
Kyriacou K. Contribution of BRCA1 and BRCA2 germline mutations
to the incidence of early-onset breast cancer in Cyprus.
Clin Genet 2007: 71: 165–170. # Blackwell Munksgaard, 2007
In Cyprus, the prevalence of breast cancer associated with BRCA1 and
BRCA2 mutations in young women is unknown. In this study, we
present the results of mutational analysis of the BRCA1 and BRCA2
genes in 26 Cypriot women diagnosed with breast cancer by the age of 40.
The entire coding regions, including splice sites, of the BRCA1 and
BRCA2 genes were sequenced using cycle sequencing. We identified four
pathogenic mutations: two in BRCA1 [c.1840A.T (K614X), c.5310delG
(5429delG)] and two in BRCA2 [c.3531-3534delCAGC (3758del4),
c.8755delG (8984delG)] in six of 26 unrelated patients. The BRCA2
mutation c.3531-3534delCAGC (3758del4) is novel and the BRCA1
mutation c.1840A.T (K614X) is reported for the first time in Cypriot
patients. The BRCA2 Cypriot founder mutation c.8755delG (8984delG)
was detected in three unrelated patients. Additionally, we identified one
novel BRCA1 missense mutation, two novel polymorphisms and three
novel intronic variants of which BRCA1 c.418513A.G
(IVS1213A.G) may be pathogenic. Of the six BRCA1/2 mutation
carriers, only four had a family history. These results show that the
prevalence of BRCA1 and BRCA2 mutations in Cypriot women
diagnosed with early-onset breast cancer is high. We conclude that
Cypriot women with early-onset breast cancer should be offered
BRCA1/2 testing irrespective of their family history.
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Breast cancer is the commonest malignancy,
which affects women worldwide. The incidence
rates of breast cancer are increasing annually and
it is estimated that by the year 2010 there will be
1.5 million new cases worldwide (1). In Cyprus,
breast cancer is the most frequent type of cancer
in women, with approximately 350 new cases
diagnosed every year (2), with about 20–30 of
these, occurring in patients younger than 40
years of age.
Around 5–10% of breast cancer is due to
genetic predisposition, and two susceptibility
genes, namely, BRCA1 (3) (MIM 113705) and
BRCA2 (4) (MIM 600185) have been discovered,
which substantially increase the risk of breast/
ovarian cancer. Data from studies of these genes
reveal that women who carry a pathogenic
mutation tend to develop breast cancer at a
young age (5, 6).
It is currently accepted that a variable pro-
portion of early-onset breast cancer cases is
associated with mutations in these two tumour
suppressor genes (7), and that the proportion
may be higher in populations harbouring
founder mutations. The contribution of the
BRCA1 and BRCA2 mutations to the popula-
tion incidence of early-onset breast cancer
ranges from 20% in populations with strong
founder effects, such as Ashkenazi Jews (8, 9)
or Icelandic populations (10, 11) to between
5% and 10% among less isolated populations
(12–16).
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In a previous study, results from our department
revealed a different spectrum of BRCA mutations
in Cypriot families compared to other Mediterra-
nean countries. Recently, we have also described
a founder mutation in the BRCA2 gene in Cypriot
families (17). The aim of this study was to evaluate
the frequency and distribution of mutations in the
BRCA1 and BRCA2 genes, in a cohort of Cypriot
women with early-onset breast cancer.
Materials and methods
Twenty-six consecutive cases of women diag-
nosed with breast cancer, before the age of 40,
between the years 2003 and 2004, participated in
this study. These Cypriot patients were selected
on the basis of a diagnosis of early-onset breast
cancer, under age 40, irrespective of their family
history. Participating patients received genetic
counselling and information about the aims of
the study; all 26 agreed to undergo genetic
testing, gave an informed consent and provided
blood samples. Information on family history of
cancer, with emphasis on breast or ovarian
cancer incidence, was also obtained and pedi-
grees were constructed. Cancer diagnoses for
patients and their affected relatives were verified
by reviewing histological reports. In addition,
a control group that consisted of 50 DNA
samples from 50, age-matched, unrelated healthy
Cypriot women, with no history of breast or
ovarian cancer, was recruited. This was used to
estimate the frequency of the detected BRCA1
and BRCA2 variants in the general population.
Mutation detection
Genomic DNA was isolated from peripheral-
blood lymphocytes using standard extraction
protocols. Polymerase chain reaction (PCR)
was used to amplify the entire coding sequence
and intron–exon junctions of the BRCA1 and
BRCA2 genes. Following PCR amplification,
sequencing was carried out using the ABI
PRISM di-Deoxy Terminator Cycle sequencing
kit on an ABI 9700 thermal cycler and an ABI
310 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). The PCR products were
sequenced using the same primers as the ones used
for PCRamplification.When amutationwas iden-
tified, a new PCR product using a second DNA
sample was sequenced so as to confirm the result.
In order to detect large genomic rearrange-
ments in the BRCA1 and BRCA2 genes,
multiplex ligation-dependent probe amplifica-
tion (MLPA, MRC Holland, Amsterdam, The
Netherlands) using the P087 and P045 kits was
carried out following the manufacturer’s pro-
tocols. Fragment analysis was carried out on an
ABI 310 Genetic Analyzer using ROX-500 as a
size standard.
To evaluate potential alternative splicing ef-
fects, three in silico sequence analysis tools,
namely NNSPLICE (http://www.fruitfly.org/
seq_tools/splice.html), SpliceSiteFinder (http://
violin.genet.sickkids.on.ca/ali/splicesitefinder.
html) and NetGene (http://www.cbs.dtu.dk/
services/NetGene2/) were used.
Results
Our results show that of the 26 women diagnosed
with early-onset breast cancer, six had patho-
genic mutations: two in BRCA1 and four in
BRCA2. In total, mutation analysis of the two
genes revealed the presence of 20 variants in the
BRCA1 gene and 26 variants in the BRCA2
gene. In describing the individual variants, we
applied the mutation nomenclature guidelines of
the HGVS (Human Genome Variation Society)
(http://www.hgvs.org/rec.html) and the nomen-
clature used in BIC database (18), which appears
in brackets.
The 20 variants identified in the BRCA1 gene
include two truncating mutations, six missense
mutations, five polymorphisms and seven in-
tronic variants (Table 1). The two truncating
mutations are a nonsense mutation c.1840A.T
(1959A.T), at codon 614 in exon 11, a lysine to
a STOP (K614X) and a frameshift mutation at
position c.5310delG (5429delG) at codon 1770 in
exon 21, which introduces a STOP 22 amino
acids further down (p.Gly1770fs23). These muta-
tions were detected in two unrelated patients.
The six missense mutations are c.1067A.G
(Q356R), c.1984C.T (H662Y), c.2612C.T
(P871L), c.3113A.G (E1038G), c.3348A.G
(L1183K) and c.4837A.G (S1613G). It is noted
that missense mutation c.1984C.T (H662Y),
polymorphism c.1482A.G (Q494Q) and in-
tronic variants c.126-23C.A (IVS5-23C.A)
and c.418513A.G (IVS1213A.G) are novel.
The three in silico sequence analysis tools used,
predicted that the intronic variant c.418513A.G
(IVS1213A.G) may cause aberrant splicing.
Details of the results of the analysis of the 20
BRCA1 variants from 50 DNAs of the healthy
group and the frequency of the variants in the
patient group are also displayed in Table 1.
The 26 BRCA2 variants include two truncat-
ing mutations, seven missense mutations, six
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polymorphisms and 11 intronic variants (Table
2). The two truncating mutations include a
novel frameshift c.3531-3534delCAGC (p.
Asp1177fsx19) in exon 11 which introduces a
STOP codon (1196X). This mutation was de-
tected in one patient. The second frameshift
mutation is c.8755delG (8984delG) in exon 22
which introduces a STOP codon 7 amino acids
further down (p.Gly2919fsx8). This mutation
was detected in three unrelated patients. The
seven missense mutations are c.865A.C
(N289H), c.1114C.A (H372N), c.1889C.T
(T630I), c.2971A.G (N991D), c.4258G.T
(D1420Y) , c .5744C.T (T1915M) and
c.7544C.T (T2515I). It is noted that polymor-
phism c.7140T.C (H2380H) and intronic vari-
ant c.681143A.G (IVS8143A.G) are novel.
Details of the results of the analysis of the 26
BRCA2 variants from 50 DNAs of the healthy
group and the frequency of the variants in the
patient group are also displayed in Table 2.
The analysis of BRCA1 and BRCA2 genes with
MLPA resulted in no detection of gene rear-
rangements or duplications within the group of
26 DNA samples evaluated in this study.
Out of the 26 patients recruited, 15 women
reported a family history of at least one breast or
ovarian cancer, whereas 11 women had a negative
history. Furthermore, of the six BRCA1/2
mutation carriers detected, two had a negative
family history (two of 11, approximately 20%).
A summary of the family history of breast and
ovarian cancer for the six carriers of the patho-
genic mutations, as well for the one case carrying
the variant c.418513A.G (IVS1213A.G) is
presented in Table 3.
Discussion
This is the first study focusing on the contribu-
tion of BRCA1 and BRCA2 germline mutations
to the incidence of early-onset breast cancer in
Cypriot patients diagnosed under age 40, irre-
spective of their family history.
We have analysed a total of 26 DNA samples
from women diagnosed with breast cancer at age
below 40, and detected two pathogenic mutations
in BRCA1 affecting two patients and two
pathogenic mutations in BRCA2 affecting four
patients. All characterized disease-associated
mutations, were truncating mutations causing
premature stop codons and were detected in six
unrelated patients.
Table 1. Details of the 20 variants detected in the BRCA1 gene in the patient group and in the control group
Exon Sequence variant Amino acid variant
Mutation
type
Mutation
effect
Frequency
in the patient
group (%)
Frequency
in the control
group (%)
Truncating mutations
11 c.1840A.T (1959A.T) p.Lys614X N N 2 0
21 c.5310delG (5429delG) p.Gly1770fsx23 F F 2 0
Missense mutations
11 c.1067A.G (1186A.G) p.Gln356Arg (Q356R) M P 15 5
11 c.1984C.T (2103C.T) p.His662TTyr (H662Y) M UV 2 0
11 c.2612C.T (2731C.T) p.Pro871Leu (P871L) M P 29 50
11 c.3113A.G (3232A.G) p.Glu1038Gly (E1038G) M P 37 41
11 c.3348A.G (3467A.G) p.Leu1183Lys (L1183K) M P 31 42
16 c.4837A.G (4956A.G) p.Ser1613Gly (S1613G) M P 37 41
Polymorphisms
9 c.591C.T (710C.T) Synonymous (Cys197Cys) P P 2 0
11 c.1482A.G (1601A.G) Synonymous (Gln494Gln) P P 2 0
11 c.2082C.T (2201C.T) Synonymous (Ser694Ser) P P 37 39
11 c.2311 T.C (2430T.C) Synonymous (Leu771Leu) P P 37 34
13 c.4308T.C (4427T.C) Synonymous (Ser1436Ser) P P 37 47
Intronic variants
5 c.126-23C.A (IVS5-23C.A) UV UV 2 0
8 c.442-34T.C (IVS7-34T.C) UV P 60 100
9 c.548-57delT (IVS8-57delT) UV P 31 29
12 c.418513A.G (IVS1213A.G) UV UV 2 0
17 c.4987-68A.G (IVS16-68A.G) UV P 31 31
17 c.4987-94A.G (IVS16-94A.G) UV P 31 31
18 c.5152166G.A (IVS18166G.A) UV P 37 29
F, frameshift; N, nonsense; UV, unclassified variant; M, missense; P, polymorphism.
Entries in bold are novel variants.
Mutation nomenclature is according to GenBank accession number U14680 (BRCA1) with numbering starting at the A of the first
ATG. The nomenclature as used in the BIC database (18) is given in parentheses.
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As described in the materials and methods
section, the patients were consecutive cases
diagnosed with early-onset breast cancer, by
age 40, between the years 2003 and 2004. This
number represents the annual expected incidence
of this group of cases, as indicated by the
accumulated data from the Cyprus Cancer
Registry (2). Of the 26 recruited patients, 15
reported a positive family history of at least one
incidence of breast or ovarian cancer. In this
group, four patients were found to carry
BRCA1/2 pathogenic mutations. The remaining
11 patients had no relevant family history and it
is of interest that two of these were found to
carry BRCA1/2 pathogenic mutations. In addi-
tion, in this group of 11 patients, a possible
splice-site variant c.418513A.G (IVS1213A/G)
was detected in one patient raising the number of
pathogenic carriers to a possible three (three of
11, approximately 30%).
Table 2. Details of the 26 variants detected in the BRCA2 gene in the patient group and in the control group
Exon Sequence variant Amino acid variant
Mutation
type
Mutation
effect
Frequency
in the patient
group (%)
Frequency
in the control
group (%)
Truncating mutations
11 c.3531-3534delCAGC (3758del4) p.Asp1177fsx19 F F 2 0
22 c.8755delG (8984delG) p.Gly2919fsx8 F F 6 0
Missense mutations
10 c.865A.C (1093A.C) p.Asn289His (N289H) M P 12 11
10 c.1114C.A (1342C.A) p.His372Asn (H372N) M P 21 22
10 c.1889C.T (2117C.T) p.Thr630Ile (T630I) M UV 2 0
11 c.2971A.G (3199A.G) p.Asn991Asp (N991D) M P 12 7
11 c.4258G.T (4486G.T) p.Asp1420Tyr (D1420Y) M P 2 2
11 c.5744C.T (5972C.T) p.Thr1915Met (T1915M) M P 2 0
15 c.7544C.T (7772C.T) p.Thr2515Ile (T2515I) M P 2 0
Polymorphisms
10 c.1365A.G (1593A.G) Synonymous (Ser455Ser) P P 12 10
11 c.2229T.C (2457T.C) Synonymous (His743His) P P 8 10
11 c.3396A.G (3624A.G) Synonymous (Lys1132Lys) P P 27 26
11 c.3807C.T (4035C.T) Synonymous (Val1269Val) P P 54 57
14 c.7140T.C (7368T.C) Synonymous (His2380His) P P 2 1
14 c.7242A.G (7470A.G) Synonymous (Ser2414Sser) P P 23 20
Intronic variants
2 c.1-203G.A (203G.A) P P 23 25
4 c.425136A.G (IVS4136A.G) UV UV 2 0
8 c.681143A.G (IVS8143A.G) UV UV 2 0
8 c.681156C.T (IVS8156C.T) UV P 12 17
10 c.1909112delT (IVS10112delT) UV P 100 100
11 c.1910-51G.T (IVS11-51G.T) UV P 2 11
11 c.6841180del4 (IVS11180del4) UV P 29 51
14 c.7435153C.T (IVS14153C.T) UV P 2 11
17 c.7618-14T.C (IVS16-14T.C) UV P 46 51
25 c.9118-16T.C (IVS24-16T.C) UV UV 2 1
27 c.10333A.G (IVS27176A.G) UV UV 2 1
F, frameshift; N, nonsense; UV, unclassified variant; M, missense; P, polymorphism.
Entries in bold are novel variants.
Mutation nomenclature is according to GenBank accession number U43746 (BRCA2) with numbering starting at the A of the first
ATG. The nomenclature as used in the BIC database (18) is given in parentheses.
Table 3. Details of the BRCA1 and BRCA2 pathogenic mutation carriers
Gene Exon Mutation
Amino acid
variant
Age at
diagnosis
BC/OV
(family history)
BRCA1 11 c.1840A.T (1959A.T) p.Lys614X 40 1 MBC
BRCA1 21 c.5310delG (5429delG) p.Gly1710fs23 33 –
BRCA1 12 c.418513A.G (IVS1213A.G) 27 –
BRCA2 11 c.3531-3534delCAGC (3758del4) p.Asp1177fsx19 32 3 BC, 1 OC
BRCA2 22 c.8755delG (8984delG) p.Gly2919fs8 33 –
BRCA2 22 c.8755delG (8984delG) p.Gly2919fs8 34 3 BC
BRCA2 22 c.8755delG (8984delG) p.Gly2919fs8 30 9 BC
BC, breast cancer; M, male; OC, ovarian cancer.
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The detailed results of the present study are
displayed in Tables 1 and 2, which show all the
variants detected in the BRCA1 and BRCA2
genes, respectively. It is noted that five out of the
six missense mutations identified in the BRCA1
gene are polymorphisms since they were also
present in more than 5% of the control group.
Similarly, three out of the seven missense
mutations identified in the BRCA2 are poly-
morphisms. In addition, missense mutations
c.4258G.T (D1420Y), c.5744C.T (T1915M)
and c.7544C.T (T2515I) have been previously
reported as polymorphisms (19–21).
The unclassified variant c.418513A.G
(IVS1213A.G) in the BRCA1 gene identified
in this study is of particular interest. We have
applied three different theoretical splicing and
skipping prediction methods, in an attempt to
predict aberrant splicing based on the DNA
sequence. All three softwares used predicted that
this intron variant might result in deleterious
alterations at the mRNA level. Unfortunately, an
RNA sample from this patient, which would
allow us to assess the transcript that is produced
by this variant allele, is not available. The novel
missense mutation c.1984C.T (H662Y) in the
BRCA1 gene may be also pathogenic. The amino
acid 662 is located in the DNA-binding region of
the BRCA1 gene, and it contributes to the DNA-
repair-related functions of the BRCA1 (22).
Mutation c.1984C.T (H662Y) alters the amino
acid histidine from a basic polar, positively
charged molecule, to the aromatic, non-polar
amino acid tyrosine. It is well known that the
stoichiometry and the charges of the amino acids
play a role in the conformation and the function
of proteins. Therefore, based on the above, we
suggest that missense mutation c.1984C.T
(H662Y) in the BRCA1 gene may lead to the
synthesis of a dysfunctional BRCA1 protein which
in turn predisposes to the breast cancer phenotype.
In terms of tumour pathology, infiltrating
ductal carcinoma was the predominant tumour
type in both BRCA1/2 mutation carriers and
non-carriers. It is noted that two of the
infiltrating ductal carcinomas were comedo type
and were diagnosed in women with truncating
BRCA1/2 mutations.
Previous population-specific studies revealed
that the contribution of BRCA1 and BRCA2
mutations to the incidence of early-onset breast
cancer ranges between 5% and 10% (12–16). In
contrast, our findings show that 23% (six of 26)
of Cypriot early-onset breast cancer cases are
associated with a germline mutation in either the
BRCA1 or the BRCA2 genes. This figure of 23%
is higher than most studies but compares
favourably with data from two other ethnic
populations, for which a higher proportion of
BRCA-associated early-onset breast cancers
have been reported. Data show that the preva-
lence rates can be as high as 30% for Ashkenazi
Jews (9) and around 25% for Icelanders (10, 11).
This high percentage is a result of the presence of
founder mutations in these ethnic populations.
More specifically, three ancestral mutations
[BRCA1 c.68_69delAG (185delAG), c.5266insC
(5382insC) and BRCA2 c.5946delT (6174delT)]
appear in about 2% of Ashkenazi Jews (23),
while about 0.5% of Icelanders carry the
c.771delTCAAA (999del5) mutation in the
BRCA2 gene (10, 11). The high prevalence rates
of BRCA1 and BRCA2 mutations in our cohort
of patients may also be explained by the presence
of Cypriot founder mutation c.8755delG
(8984delG) in the BRCA2 gene (17). Although
the effect of this founder mutation is not as strik-
ing as the case of the Icelanders or Ashkenazi
Jews, our results show that it makes a substantial
contribution to the incidence of early-onset
breast cancer in the Cypriot population. In addi-
tion, it is likely that the contribution of these
genes to early-onset breast cancer might be even
higher given that certain unclassified variants
might be also causative.
In our group of patients, the highest proportion
of mutations was reported in the BRCA2 gene,
15% (four of 26 positive) vs 7.7% (two of 26
positive), in the BRCA1 gene. These results
indicate that BRCA2 mutations make a greater
contribution to the breast cancer phenotype, in
young Cypriot women, compared with BRCA1
mutations. This is in agreement with our pre-
vious data on familial breast/ovarian cancer
studies in Cypriot families (17, 24). It appears
that in most other populations studied, muta-
tions in the two genes make approximately equal
contributions to early-onset breast cancer (12, 13,
14, 16) with the exception of Iceland where
BRCA2 accounts for most of the early-onset
breast cancer cases, and the Ashkenazi Jews
where BRCA1 accounts for the majority of cases.
In the present study, BRCA1/2 pathogenic
mutations were detected in four of 15 patients
with a family history, as well as in three of 11
patients without a family history. Our findings
support a strong correlation between the early-
onset breast cancer phenotype and BRCA1/2
gene analysis, since the prevalence of BRCA1/2
mutations in young Cypriot patients is relatively
high. Based on these results, we recommend that
BRCA1/2 screening should be offered to patients
with a diagnosis of early-onset breast cancer
irrespective of their family history.
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Background 
Breast cancer is the commonest malignancy which affects women worldwide. 
Genetic factors are important in breast cancer but less than 20% are attributable to 
the inheritance of mutations in susceptibility genes such as BRCA1 and BRCA2. 
The polygenic model of breast cancer suggests that there are multiple low-
penetrance alleles, each or in combination, together with environmental interactions 
have a small effect on breast cancer risk. In the future, a combination of the presence 
of low-risk variants together with other breast cancer risk factors may have the 
power to predict an individual’s risk of breast cancer and may become clinically 
important. In an attempt to identify genetic variants which modify breast cancer risk 
we are contacting a case-control genetic epidemiology study using a cohort of 2286 
Cypriot women (1109 breast cancer patients and 1177 age-matched healthy controls) 
Methods 
In the present study we genotyped 11 single nucleotide polymorphisms (SNPs) in 
genes which are involved in the DNA repair pathway: BRCA2 N991D (rs1799944), 
OGG1 S326C (rs1052133), RAD51 135G/C (rs1801320) and 172G/C (rs1801321), 
p53 P72R (rs1042522), XRCC1 Arg194Trp (rs1799782), Arg280His (rs25489) and 
Arg399Gln (rs25487), XRCC2 Arg188His (rs3218536) and XRCC3 Thr241Met 
(rs861539). Genotyping was contacted using either Taqman® probes (Applied 
Biosystems) following the manufacturer’s instructions or by PCR followed by 
restriction digestions. The prevalence of the 11 SNPs was compared between cases 
and controls. Odds ratios were generated from 2x2 tables, and statistical significance 
was assessed using the Pearson Chi-Square test. 
Results 
BRCA2 N991D was found at a significantly higher frequency in the population-
based series of breast cancer patients (142/1086, 12.9%, odds ratio [OR] =1.42, 95% 
confidence interval [CI]= 1.09–1.85, p=0.01) than among population controls 
(112/1177, 9.5%). Homozygotes at XRCC1 R280H were found to be associated with 
an increased risk of breast cancer ([OR] (HH vs. RR+RH) =4.77, 95% CI (1.03–
22.13), p=0.03). Furthermore, a marginally significant association between the p53 
P72R variant and breast cancer was observed ([OR] (PP vs. PR+RR) =1.18, 95% CI 
(1.0–1.39), p=0.05). In addition, our results show that the effect of RAD51 135 C 
allele may be protective indicating that women who harbour this allele have a 
reduced risk of breast cancer compared with women who carry the G allele.   
Conclusions 
These results suggest that a proportion of the SNPs under study are modifying breast 
cancer risk, but the effects of individual SNPs are likely to be small. Large numbers 
of samples will be needed to verify our results in other populations. We are currently 
expanding our analysis to include a greater number of SNPs and to evaluate potential 
underlying gene-gene or gene-environment interactions, in order to advance our 
knowledge on the effect of genetic polymorphisms on breast cancer susceptibility in 
Cypriot women. 
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The Department of Life and Health Sciences of the School of 
Sciences, will like to invite you to a talk on: 
 
“Association studies for discovering 
new Breast Cancer Genes / the MASTOS 
study” 
 
By Ms. Maria Loizidou 
The Cyprus Institute of Neurology and 
Genetics 
 
In room A101 (1st floor, Main Bld.) at 14:00 hours 
On Friday, 12th of December, 2008 
 
 
ABSTRACT:  Breast cancer, the most common malignancy that affects women 
worldwide, has an estimated annual incidence of about one million cases.1 The 
family history of breast cancer constitutes one of the most important and well-
established risk factors with first degree relatives of patients having a two-fold 
elevated risk compared to the general population.2 In the 1990’s it was identified that 
inherited germline mutations in the two breast cancer susceptibility genes BRCA1 
and BRCA2.3,4 confer a strong lifetime risk of developing breast and ovarian 
cancer.5 In addition to these genes, other high-risk breast cancer susceptibility genes 
such as PTEN and TP53 were discovered6,7 while a number of genes including 
CHEK2, TGFβ1 and ATM comprise the “low to moderate-risk” breast cancer 
susceptibility group.8,9,10 Together, it is estimated that 5-10% of all breast cancers are 
caused by mutations in the above genes.11 However, although, to date, linkage 
analysis has failed to identify other major breast cancer genes it is believed that a 
substantial proportion, as high as 30%, of the total breast cancer incidence can be 
attributed to genetic factors.12 It is therefore highly likely that breast cancer is 
polygenic and that susceptibility is caused by a number of gene loci which 
individually or in combination, together with environmental factors contribute to the 
development of breast cancer.13  
 
Towards identifying genetic variants that modify breast cancer risk in the Cypriot 
population we are conducting a case-control genetic epidemiology study using 1109 
breast cancer patients and 1177 age-matched healthy controls. One of our aims is to 
investigate the contribution of single nucleotide polymorphisms (SNPs) in DNA 
repair and related genes to breast cancer risk in the Cypriot population. The results of 
this study will be communicated in this presentation.  
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Contact 
Ms Sytske Flores 
s.flores@erasmusmc.nl 
 
 
Dear Ms. Loizidou, 
 
It is my pleasure to inform you that you have been selected for a Nihes/ESP Fellowship 
for participation in the Erasmus Summer Programme 2006 taking place from 7 to 25 
August 2006 in Rotterdam, the Netherlands. You have been admitted to ‘Research 
Training in Genetic Epidemiology’. Congratulations! 
 
The fellowship covers the three-week tuition fee including course materials, except book, 
and lunch on weekdays (€ 2.500), and accommodation in the Erasmus International 
House of the Erasmus University Rotterdam (€ 250 instead of € 515). All other costs are 
at your expenses. 
 
A confirmation form and an accommodation reservation form have been attached, which I 
kindly ask you to sign and return by fax before Wednesday 24 May 2006. The fax 
number is: +31 10 408 9382. Please note that your room is available to you the entire 
month of August. You are welcome to arrive prior to the Erasmus Summer Programme 
and leave on the 30th (at the latest). Of course, subsistence costs during these additional 
days are at your expenses. 
 
As soon as we have received your confirmation and accommodation request, we will send 
you further details about your participation in the Erasmus Summer Programme 2006. 
Please make sure that the amount due for accommodation is the appropriate bank 
account before June 15th (see the confirmation form for details). 
 
The Nihes Staff and I look forward to welcoming you to Rotterdam this summer. 
 
With kind regards, 
 
 
 
 
 
 
 
Albert Hofman, MD PhD 
Scientific Director  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
